NZ708320B2 - Equine Rhinitis vaccine - Google Patents
Equine Rhinitis vaccine Download PDFInfo
- Publication number
- NZ708320B2 NZ708320B2 NZ708320A NZ70832012A NZ708320B2 NZ 708320 B2 NZ708320 B2 NZ 708320B2 NZ 708320 A NZ708320 A NZ 708320A NZ 70832012 A NZ70832012 A NZ 70832012A NZ 708320 B2 NZ708320 B2 NZ 708320B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- virus
- erav
- erbv
- strain
- equine
- Prior art date
Links
- 241000283073 Equus caballus Species 0.000 title claims description 168
- 229960005486 vaccines Drugs 0.000 title claims description 81
- 206010039083 Rhinitis Diseases 0.000 title description 31
- 239000000203 mixture Substances 0.000 claims abstract description 230
- 230000002163 immunogen Effects 0.000 claims abstract description 118
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 241000214054 Equine rhinitis A virus Species 0.000 claims description 359
- 241000700605 Viruses Species 0.000 claims description 176
- 102000011587 Polyproteins Human genes 0.000 claims description 102
- 108010076039 Polyproteins Proteins 0.000 claims description 102
- 241001465754 Metazoa Species 0.000 claims description 98
- 241000710886 West Nile virus Species 0.000 claims description 88
- 230000002238 attenuated Effects 0.000 claims description 87
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 84
- 230000036039 immunity Effects 0.000 claims description 79
- 241000283086 Equidae Species 0.000 claims description 72
- 239000000427 antigen Substances 0.000 claims description 67
- 102000038129 antigens Human genes 0.000 claims description 67
- 108091007172 antigens Proteins 0.000 claims description 67
- 241000230501 Equine herpesvirus sp. Species 0.000 claims description 65
- 241000712461 unidentified influenza virus Species 0.000 claims description 47
- 210000002966 Serum Anatomy 0.000 claims description 46
- 239000002609 media Substances 0.000 claims description 37
- 150000002500 ions Chemical class 0.000 claims description 35
- 244000144980 herd Species 0.000 claims description 33
- 229960000814 tetanus toxoid Drugs 0.000 claims description 32
- 230000000120 cytopathologic Effects 0.000 claims description 24
- 230000002829 reduced Effects 0.000 claims description 22
- 230000001717 pathogenic Effects 0.000 claims description 17
- 244000052769 pathogens Species 0.000 claims description 16
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 241000710951 Western equine encephalitis virus Species 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 13
- 239000001963 growth media Substances 0.000 claims description 12
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims description 11
- 208000000832 Equine Encephalomyelitis Diseases 0.000 claims description 11
- 230000002779 inactivation Effects 0.000 claims description 11
- 230000000415 inactivating Effects 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 241000193449 Clostridium tetani Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940035295 Ting Drugs 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 5
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 3
- 241001239777 Erbovirus A Species 0.000 abstract description 241
- 210000004027 cells Anatomy 0.000 description 108
- 229920001850 Nucleic acid sequence Polymers 0.000 description 75
- 201000010099 disease Diseases 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 54
- 102000004169 proteins and genes Human genes 0.000 description 54
- 108090000623 proteins and genes Proteins 0.000 description 54
- 201000009910 diseases by infectious agent Diseases 0.000 description 42
- 239000002773 nucleotide Substances 0.000 description 38
- 208000001756 Virus Disease Diseases 0.000 description 35
- 230000017613 viral reproduction Effects 0.000 description 35
- 230000003612 virological Effects 0.000 description 35
- 238000002955 isolation Methods 0.000 description 34
- 206010047461 Viral infection Diseases 0.000 description 32
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 32
- 125000003729 nucleotide group Chemical group 0.000 description 32
- 238000002255 vaccination Methods 0.000 description 29
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 27
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 27
- 239000002671 adjuvant Substances 0.000 description 27
- 230000000240 adjuvant Effects 0.000 description 27
- 230000029812 viral genome replication Effects 0.000 description 26
- 206010038683 Respiratory disease Diseases 0.000 description 25
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 25
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 206010039101 Rhinorrhoea Diseases 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- 108090001123 antibodies Proteins 0.000 description 20
- 102000004965 antibodies Human genes 0.000 description 20
- 239000012530 fluid Substances 0.000 description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 208000006572 Human Influenza Diseases 0.000 description 18
- 206010022000 Influenza Diseases 0.000 description 18
- 230000036760 body temperature Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 200000000003 influenza A Diseases 0.000 description 18
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 210000004369 Blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 229960002518 gentamicin Drugs 0.000 description 16
- 230000005591 charge neutralization Effects 0.000 description 14
- 230000002354 daily Effects 0.000 description 14
- 239000003085 diluting agent Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 230000001264 neutralization Effects 0.000 description 14
- 238000006386 neutralization reaction Methods 0.000 description 14
- 230000000241 respiratory Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 210000001519 tissues Anatomy 0.000 description 13
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 description 12
- 210000003097 Mucus Anatomy 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 229960001340 histamine Drugs 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- -1 t Species 0.000 description 12
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 10
- 210000001165 Lymph Nodes Anatomy 0.000 description 10
- 210000000416 Exudates and Transudates Anatomy 0.000 description 9
- 210000004072 Lung Anatomy 0.000 description 9
- 206010037660 Pyrexia Diseases 0.000 description 9
- 229960003942 amphotericin B Drugs 0.000 description 9
- 239000002054 inoculum Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 210000002700 Urine Anatomy 0.000 description 8
- 206010058874 Viraemia Diseases 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 230000001809 detectable Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000002663 nebulization Methods 0.000 description 8
- 230000002335 preservative Effects 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 201000002491 encephalomyelitis Diseases 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 239000006199 nebulizer Substances 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- 206010000210 Abortion Diseases 0.000 description 6
- 210000003128 Head Anatomy 0.000 description 6
- 208000008771 Lymphadenopathy Diseases 0.000 description 6
- 210000003437 Trachea Anatomy 0.000 description 6
- 231100000176 abortion Toxicity 0.000 description 6
- 235000012343 cottonseed oil Nutrition 0.000 description 6
- 239000002385 cottonseed oil Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 230000027950 fever generation Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 229920001888 polyacrylic acid Polymers 0.000 description 6
- 238000009613 pulmonary function test Methods 0.000 description 6
- 230000036387 respiratory rate Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 5
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 5
- 241000709664 Picornaviridae Species 0.000 description 5
- 206010053459 Secretion discharge Diseases 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 230000000890 antigenic Effects 0.000 description 5
- 230000002550 fecal Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 201000007100 pharyngitis Diseases 0.000 description 5
- 229920000023 polynucleotide Polymers 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000006163 transport media Substances 0.000 description 5
- 238000004450 types of analysis Methods 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- 229960001631 Carbomer Drugs 0.000 description 4
- 210000003169 Central Nervous System Anatomy 0.000 description 4
- 229920001405 Coding region Polymers 0.000 description 4
- 206010061428 Decreased appetite Diseases 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 4
- 210000003608 Feces Anatomy 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 4
- 101710023234 Segment 5 Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003247 decreasing Effects 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 230000002458 infectious Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000000644 propagated Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 102000033180 ERVK-6 Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229960002743 Glutamine Drugs 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 101710043203 P23p89 Proteins 0.000 description 3
- 210000003800 Pharynx Anatomy 0.000 description 3
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 3
- 206010057190 Respiratory tract infection Diseases 0.000 description 3
- KDPNLRQZHDJRFU-UHFFFAOYSA-N Romifidine Chemical compound FC1=CC=CC(Br)=C1NC1=NCCN1 KDPNLRQZHDJRFU-UHFFFAOYSA-N 0.000 description 3
- 229920000978 Start codon Polymers 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 229920000401 Three prime untranslated region Polymers 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000006143 cell culture media Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000001524 infective Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 230000002685 pulmonary Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 101700030147 rep Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZNAMMSOYKPMPGC-HTOAHKCRSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(2-phenylethylsulfanyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1SCCC1=CC=CC=C1 ZNAMMSOYKPMPGC-HTOAHKCRSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KMOOCZWLFBSQCW-WZVSWZHRSA-N 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(2-hydroxyethyl)-3-(methylaminomethyl)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-dimethy Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.CNC[C@H]1[C@H](O)[C@@H](O)[C@H](CCO)O[C@H]1O[C@@H]1C(C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O KMOOCZWLFBSQCW-WZVSWZHRSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101700041603 ERVB Proteins 0.000 description 2
- 101710038044 ERVK-6 Proteins 0.000 description 2
- 101710027967 ERVW-1 Proteins 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000272184 Falconiformes Species 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 241000726306 Irus Species 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- SDXVSIWCVTYYQN-UHFFFAOYSA-N N-(2-bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine;hydrochloride Chemical compound Cl.FC1=CC=CC(Br)=C1NC1=NCCN1 SDXVSIWCVTYYQN-UHFFFAOYSA-N 0.000 description 2
- 101710003000 ORF1/ORF2 Proteins 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 229960000440 Romifidine Hydrochloride Drugs 0.000 description 2
- 229940004452 Sedivet Drugs 0.000 description 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010044696 Tropical spastic paresis Diseases 0.000 description 2
- 101700028070 VPX Proteins 0.000 description 2
- 102000016350 Viral Proteins Human genes 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000001680 brushing Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002919 epithelial cells Anatomy 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 239000012526 feed media Substances 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000010871 livestock manure Substances 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000000926 neurological Effects 0.000 description 2
- 230000003472 neutralizing Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000001850 reproductive Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001624 sedative Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000000405 serological Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical class CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- UMHYVXGZRGOICM-AUYXYSRISA-N 2-[(Z)-octadec-9-enoyl]oxypropyl (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC\C=C/CCCCCCCC UMHYVXGZRGOICM-AUYXYSRISA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxystearic acid Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 240000007241 Agrostis stolonifera Species 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K Aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940009444 Amphotericin Drugs 0.000 description 1
- 238000000767 Anderson–Darling test Methods 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 241001600407 Aphis <genus> Species 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 208000007204 Brain Death Diseases 0.000 description 1
- 208000001183 Brain Injury Diseases 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 210000002318 Cardia Anatomy 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010011376 Crepitations Diseases 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N Decene Chemical compound CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 206010014599 Encephalitis Diseases 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 241000214056 Equine rhinitis B virus 1 Species 0.000 description 1
- 241001468007 Erbovirus Species 0.000 description 1
- 208000006881 Esophagitis Diseases 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 229940113296 Fortical Drugs 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 210000004392 Genitalia Anatomy 0.000 description 1
- 102100011932 HSD17B10 Human genes 0.000 description 1
- 101710036502 HSD17B10 Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010018913 Haemolysis Diseases 0.000 description 1
- 241000047428 Halter Species 0.000 description 1
- 208000006213 Herpesviridae Infection Diseases 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000000122 Hyperventilation Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 210000004731 Jugular Veins Anatomy 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 210000003141 Lower Extremity Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 238000010629 Molecular evolutionary genetics analysis Methods 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 210000003928 Nasal Cavity Anatomy 0.000 description 1
- 210000001989 Nasopharynx Anatomy 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940010310 PROPYLENE GLYCOL DIOLEATE Drugs 0.000 description 1
- 101700032218 PXDN Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000795 Polyadenylation Polymers 0.000 description 1
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
- 229960000380 Propiolactone Drugs 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- BBBFJLBPOGFECG-UHFFFAOYSA-N Salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 description 1
- 101710043165 Segment-2 Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N Squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940031439 Squalene Drugs 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 241001459538 Ute Species 0.000 description 1
- 101710015310 VI Proteins 0.000 description 1
- 210000003501 Vero Cells Anatomy 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- ZHCXFLVDHRUYCX-UHFFFAOYSA-J aluminum;hydroxide;phosphate Chemical compound [OH-].[Al].[O-]P([O-])([O-])=O ZHCXFLVDHRUYCX-UHFFFAOYSA-J 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000215 ciliated epithelial cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002380 cytological Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004475 gamma-delta T lymphocyte Anatomy 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 101710007446 het-s Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 101710026800 lyc Proteins 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 101700045377 mvp1 Proteins 0.000 description 1
- 230000004776 neurological deficiency Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001915 proofreading Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 230000017610 release of virus from host Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000036412 respiratory physiology Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000452 restraining Effects 0.000 description 1
- 229960005089 romifidine Drugs 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000000605 viral structures Anatomy 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N β-Propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Abstract
immunogenic composition comprising one or more strains of inactivated Equine Rhinitis B Virus (ERBV) and a method for producing said immunogenic composition.
Description
Eguine Rhinitis Vaccine
Seguence Listing
The instant application contains a Sequence g which has been submitted in ASCII format
via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created
on January 26, 2012, is named 10PCT-SEQ.txt and is 33,877 bytes in size.
ound of the Invention
Equine viral respiratory infections are commonly associated with movement of
horses and ly respiratory outbreaks are reported throughout the world. Equine Influenza 2
(AE2—H3N8), Equine Herpesvirus 1 and 4 (EHV1/4), and Equine is A and B Viruses
(ERAV and ERBV, tively) are among the most ant viruses isolated from the upper
respiratory tract during respiratory outbreaks.
In particular, ERAV has been reported in acute febrile respiratory disease in horses
(Li et al., J. Clin. Microbiol. 35:937—943; 1997, incorporated by reference). Similarly, a recent
study in Ontario found ERBV and ERAV to be highly prevalent in the horse population (Diaz—
Mendez et al., The an Journal of Veterinary Research 74:271—278; 2010, incorporated by
reference). Clinical signs of ERAV infection are non-specific and difficult to differentiate from
other atory viral ions, ing equine influenza and herpes virus infections. Non—
cytopathic strains of this virus have been identified in equine respiratory outbreaks (Li et al., J.
Clin. Microbiol. 35:937—943; 1997) making its diagnosis challenging. er, ERAV and
ERBV, being single stranded RNA viruses, have the potential for mutation, rendering the ability
of the immune system to protect an animal against disease caused by a given ERAV/ERBV
strain unclear.
A need exists for methods and medicaments for preventing respiratory diseases or
for reducing the incidence or lessening the severity of clinical symptoms associated with such
diseases, including those associated with Equine Rhinitis A and B Viruses.
Brief Summary of the Invention
The ors have determined that immunogenic compositions comprising one
or more strains of inactivated or live, attenuated ERAV, which when live and active and
unattenuated are virulent (i.e., at least 50%, 60%, 70%, 80%, 90% or even 100% of
seronegative horses, when purposely exposed to the virus, present with observable
respiratory disease, particularly nasal and/or ocular discharge), can be grown to high titers in
culture to yield a vaccine that is able to induce high titers of serum dies against ERAV
when administered, for example, to an equine, for example resulting in a serum titer of at
least 1:112, and preferably, at least 1:200, 1:500, 1:750 or 1:1000. In addition, the strains
grow well in culture and are highly efficient to produce, for example, to a titer of at least 106
TCID50/mL, more ably at least 107 TCID50/mL, 108 TCID50/mL, or even 109
TCID50/mL. Similarly, compositions comprising one or more strains of inactivated ERBV,
which when live and active and not attenuated are also virulent (as defined above for ERAV),
were also found to grow well in culture, to a titer of at least 106 TCID50/mL, more preferably
107 TCID50/mL, 108 TCID50/mL or even 109 TCID50/mL, to be highly efficient to produce,
and to induce high titers of serum antibodies in animals following immunization, for
e, resulting in a serum titer of at least 1:120 and preferably at least 1:200, 1:500, 1:750
or 1:1000. Both the ERAV and ERBV compositions, and combinations thereof, are e
of reducing the duration, severity, and incidence of disease in an animal such as a horse that
has been immunized with the compositions and subsequently challenged.
Accordingly, the present invention provides an immunogenic ition
comprising one or more strains of inactivated or live, attenuated ERAV or ERBV, wherein
the ERAV strain or the ERBV strain, prior to inactivation or attenuation, causes able
respiratory disease in at least 50% of gative horses exposed to the strain, or grows in
cell culture to 106 TCID50/mL or higher, or, when used as a vaccine in equines at a dose of
106 TCID50 or higher results in a serum titer of at least 1:112.
[0005a] According to a first aspect of the present invention there is provided an
immunogenic ition comprising one or more s of vated Equine Rhinitis B
Virus (ERBV).
[0005b] According to a second aspect of the present invention there is provided use of an
genic composition according to any one of claims 1 to 9 for the manufacture of a
(11178654_1):JJP
medicament for reducing the incidence or lessening the severity of clinical symptoms
associated with or caused by ERBV in an animal or a herd of s.
[0005c] According to a third aspect of the t invention there is provided a method
for reducing the incidence or lessening the severity of clinical symptoms associated with or
caused by ERBV in an animal or a herd of animals, said method comprising the step of
administering an immunogenic composition according to the first aspect to an animal in need
thereof, wherein the animal is a non-human animal.
[0005d] According to a fourth aspect of the present invention there is provided a method
for producing an immunogenic composition comprising one or more strains of inactivated
ERBV, the method comprising:
a) infecting a susceptible cell line with ERBV;
b) growing the infected cell line in growth media until a cytopathic effect (CPE) is
attained;
c) harvesting the media;
d) filtering the media to yield a filtered media; and
e) contacting the filtered media with an inactivating agent to obtain the inactivated
ERBV.
In n embodiments, the , when alive and nuated, causes
detectable respiratory disease (e.g., detectable ocular and/or nasal discharge) in at least 50%,
60%, 70%, 80%, 90% or even 100% of seronegative horses upon exposure to the strain.
(11178654_1):JJP
The strain can be grown in cell culture to a titer of at least 106 TCleo/mL, more
preferably 107 TCIDso/mL, 108 TCIDso/mL, or even 109 TCID50/mL. Administration of an
genic composition containing the strain results in a serum titer of at least 1:120 and
preferably at least 1:200, 1:500, 1:750 or 1:1000.
In the immunogenic compositions of the invention, the one or more strains of
ERAV or ERBV preferably include ERAV/ON/OS (ATCC Accession No. PTA-11828) and/or
ERBV strain 07-103042 (ATCC ion PTA-11829). In addition, the immunogenic
compositions of the invention contain at least an ERAV strain which comprises a genomic
sequence whose reverse transcript has greater than 95% identity to SEQ ID NO: 2 or encodes a
polyprotein with an amino acid sequence with greater than 95% identity to SEQ ID NO: 3,
wherein said ERAV strain, when not inactivated, is active to infect and ate in host cells.
The immunogenic composition of the ion may also include an ERAV strain which
comprises a genomic sequence whose reverse transcript has a nucleotide sequence comprising
SEQ ID NO: 2 or encodes a polyprotein with an amino acid sequence of SEQ ID NO: 3.
The immunogenic compositions of the invention may also e an ERBV strain
which comprises a genomic sequence whose reverse transcript has greater than 95% identity to
the reverse transcript of the genomic sequence of the ERBV strain having ATCC Accession no.
PTA—11829 or encodes a polyprotein with an amino acid ce with greater than 95%
ty to the polyprotein encoded by the genome of the ERBV strain having ATCC Accession
no. 829, wherein said ERBV , when not inactivated, is active to infect and replicate
in host cells. The ERBV strain may also comprise a genomic sequence that is the genomic
sequence of the ERBV strain having ATCC Accession no. PTA—11829 or encodes a polyprotein
that has the amino acid sequence of the polyprotein encoded by the genome of the ERBV strain
having ATCC Accession no. PTA-11829.
In a specific embodiment, the immunogenic composition of the invention comprises
Equine Rhinitis A Virus (ERAV) and Equine Rhinitis B Virus (ERBV), wherein the ERAV
strain is ERAV/ON/05 and the ERBV strain has ATCC Accession No. PTA—11829.
In addition, the invention further es multivalent immunogenic itions
sing inactivated or live attenuated viruses or antigens from viruses other than ERAV or
ERBV that cause disease in Equidae. In particular, the invention provides immunogenic
itions comprising, in addition to inactivated or live, attenuated ERAV and/or ERBV, at
least one antigen or one inactivated or live, attenuated strain of Equine Herpes Virus (EHV), and,
in particular ments, the EHV is ed from the group consisting of EHV—1 and EHV—4,
and a combination thereof, more specifically, the Equine Herpes Virus is selected from the group
consisting of EHV-1, EHV-4, strains deposited with the ATCC under accession Nos. 25
and PTA-9526, and a combination thereof.
The invention r provides immunogenic composition, which, in addition to the
inactivate or live, attenuated strain of ERAV and/or ERBV, at least one inactivated or live,
attenuated strain of or at least one antigen of Equine Influenza Virus. In specific embodiments,
the Equine Influenza Virus is selected from the group consisting of Clade l viruses, Clade 2
viruses, Influenza A/South Africa/2003, Influenza A/equine—Z/Ohio/03, Influenza A/equine—
2/New Market/2/93 Influenza Influenza
, A/equine—Z/Kentucky/95 , A/equine—
2/Richmond/1/2007, strains deposited with the ATCC under accession Nos. PTA—9522, PTA—
9523, and PTA—9524, and combinations f. The immunogenic compositions may include,
in addition to inactivated or live, ated ERAV and/or ERBV, at least one antigen or one
inactivated or live, attenuated strain of Equine Herpes Virus and at least one antigen or one
inactivated or live, attenuated strain of Equine Influenza Virus.
The immunogenic compositions of the invention may include, in addition to
inactivated or live, attenuated ERAV and/or ERBV, at least one inactivated or live, attenuated
Virus or at least one antigen of one or more strains selected from the group consisting of West
Nile Virus, Eastern Equine Encephalomyelitis Virus, n Equine Encephalomyelitis Virus,
Venezuelan Equine Encephalomyelitis Virus, and s Toxoid, and combinations thereof.
Alternatively, the immunogenic composition, in addition to vated or live, attenuated ERAV
and/or ERBV, comprises one or more vated or live, ated strains of or antigens of
strains of Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis, Venezuelan
Equine Encephalomyelitis Virus, and Tetanus Toxoid. In specific embodiments, the West Nile
Virus is one of the strains selected from the group consisting of Horse Origin 2005, deposited
with the ATCC under accession number PTA—9409; NAEE159, deposited at the United States
ment of Agriculture Isolate under accession number 405330; NY2002Nassau;
NY2002Clinton; NY2002Queens; GA20021; GA20022; TX20021; TX20022; IN2002;
NY2003Albany; NY2003Suffolk; NY2003Chatauqua; C020031; C020032; TX2003;
TX2003Harris4; TX2003Harris6; TX2003Harris7; Harrile; A22004; and
TX2004Harris4; and ation thereof. In immunogenic compositions comprising Western
Equine Encephalomyelitis Virus, the strain may be the strain deposited with the ATCC under
accession number PTA-9410. In compositions sing Venezuelan Equine
Encephalomyelitis Virus, the strain may be the strain deposited with the ATCC under accession
number PTA—9411. In immunogenic compositions comprising Eastern Equine
Encephalomyelitis Virus, the strain may be the strain deposited with the ATCC under accession
number 12. And, in immunogenic compositions comprising Equine Herpes Virus, the
strain may be selected from the group consisting of the strains ted with the ATCC under
accession Nos. PTA—9525 or PTA—9526, and combinations thereof.
In specific embodiments, one or more of the strains in the immunogenic
composition are t in an amount from about 102'0TCID50/mL to about 1010‘0TCID50/mL per
dose. The composition may further include a suitable pharmaceutical carrier, such as a diluent,
adjuvant, antimicrobial agent, preservative, inactivating agent, or combination thereof. In
particular embodiments, the immunogenic composition comprises an adjuvant, specifically,
HRA-S.
The invention further provides methods for reducing the incidence or lessening the
ty of al symptoms associated with or caused by Equine is A Virus or Equine
Rhinitis B Virus in an animal or a herd of animals sing the step of administering an
immunogenic composition that comprises one or more strains of inactivated or live, attenuated
ERAV or ERBV, wherein the ERAV strain or the ERBV strain, prior to inactivation or
attenuation, causes detectable atory disease in at least 50% of seronegative horses exposed
to the strain, or grows in cell culture to 106 TCIDsO/mL or higher, or, when used as a vaccine in
equines at a dose of 106 TCID50 or higher results in a serum titer of at least 1:112. In particular,
the one or more strains of ERAV or ERBV preferably include ERAV/ON/OS (ATCC Accession
No. PTA—11828) and/or ERBV strain 071103042 (ATCC Accession PTA—11829). In addition,
the ERAV strain may comprise a genomic sequence whose reverse transcript has greater than
95% identity to SEQ ID NO: 2 or encodes a polyprotein with an amino acid sequence with
greater than 95% identity to SEQ ID NO: 3, n said ERAV strain, when not inactivated or
attenuated, is active to infect and replicate in host cells, or the ERAV strain comprises a genomic
sequence whose reverse ript has a tide sequence comprising SEQ ID NO: 2 or
encodes a polyprotein with an amino acid sequence of SEQ ID NO: 3. In addition, or
alternatively, the ERBV strain may comprise a genomic sequence whose e transcript has
greater than 95% identity to the reverse transcript of the genomic ce of the ERBV strain
having ATCC Accession no. PTA—11829 or encodes a polyprotein with an amino acid sequence
with greater than 95% identity to the polyprotein encoded by the genome of the ERBV strain
having ATCC Accession no. PTA—11829, wherein said ERBV strain, when not inactivated or
attenuated, is active to infect and replicate in host cells. The ERBV strain may also comprise a
genomic sequence that is the genomic sequence of the ERBV strain having ATCC Accession no.
PTA—11829 or encodes a polyprotein that has the amino acid sequence of the otein
encoded by the genome of the ERBV strain having ATCC Accession no. PTA—11829.
In on to providing methods for reducing the incidence or lessening the
severity of clinical symptoms associated with or caused by ERAV or ERBV in an animal or a
herd of animals, the methods of the invention may further reduce the nce or lessening the
severity of clinical ms associated with or caused by one or more of the pathogens ed
from the group consisting of West Nile Virus, n Equine Encephalomyelitis Virus, Western
Equine Encephalomyelitis Virus, Venezuelan Equine Encephalomyelitis Virus, and Clostridium
tetani in an animal or a herd of animals by administering an immunogenic composition of the
invention. The methods of the invention also include methods of reducing the incidence or
lessening the severity of clinical symptoms associated with or caused by ERAV or ERBV in an
animal or a herd of animals along with reducing the incidence or lessening the severity of al
symptoms associated with or caused by one or more of the pathogens selected from the group
consisting of: Eastern Equine Encephalomyelitis Virus, Western Equine Encephalomyelitis
Virus, Venezuelan Equine Encephalomyelitis Virus, Equine Herpes Virus, and Clostridium
tetani in an animal or a herd of animals by administering an immunogenic composition of the
invention.
The invention also provides s for reducing the nce or lessening the
severity of al symptoms associated with or caused by ERAV and/or ERBV as well as one
or more of the pathogens selected from the group consisting of: West Nile Virus, Eastern Equine
Encephalomyelitis Virus, Western Equine Encephalomyelitis Virus, Venezuelan Equine
Encephalomyelitis Virus, Equine Herpes Virus, Equine Influenza Virus, and Clostridium tetani
in an animal or a herd of animals, comprising the step of administering an immunogenic
composition of the invention.
In connection with the methods of the invention, the incidence of clinical symptoms
caused by one or more of said pathogens in a herd of animals is reduced from about 10% — 50%
as compared to a herd not receiving the immunogenic composition. The s of the
invention, in particular embodiments, e a duration of immunity of at least 12 months
against one or more of the pathogens present in the genic composition. In the s of
the ion, the immunogenic composition is administered to an Equidae, preferably a horse.
The dosing scheme may include administration of the immunogenic composition in one or more
doses. The doses for the methods of the invention may be formulated in 0.5 mL to 2.5 mL
dosage forms. Preferably, the methods of the invention administer immunogenic compositions
which are safe for use in foals or horses 4 months of age or older.
The invention also es methods for producing an immunogenic composition
comprising one or more strains of inactivated Equine Rhinitis A Virus (ERAV) or Equine
Rhinitis B Virus (ERBV) as follows:
a) infecting a susceptible cell line with ERAV or ERBV;
b) growing the infected cell line in growth media until a cytopathic effect (CPE) is attained;
c) harvesting the media;
d) filtering the media to yield a ed media; and
e) contacting the filtered media with an inactivating agent to obtain the inactivated ERAV or
ERBV.
Brief Description of the Drawings
Fig. 1 is a graphical representation of the proportion of virus positive across time.
Fig. 2 is a graphical representation of the proportion of buffy coat positive across
time.
Fig. 3 is a graphical entation of the serum neutralization titers across time.
Fig. 4 is a graphical representation of the mean nasal scores across time.
Fig. 5 is a graphical representation of the mean ocular scores across time.
Fig. 6 is a ClustalW alignment of a portion of equine rhinitis A virus N/05
(5’ UTR portion, SEQ ID NO: 1) with ERAV/PERV—l sion number: DQ272578 (SEQ ID
NO: 14)). ERAV/ON/05 nucleotide insertions shown in bold and deletions in g.
Fig. 7 is a graph of total clinical score means from control, infected, and re—infected
groups from Example 4.
Fig. 8 is a graph of body temperature means from control, infected, and re—infected
groups from Example 4.
Fig. 9 is a Table showing titers to equine rhinitis A virus (ERAV) and equine
rhinitis B virus (ERBV) in control, infected, and re—infected groups of Example 4. The virus
neutralization test (VN) was used to measure antibody titers on serum samples.
ed Description of the Invention
The inventors have determined that immunogenic itions comprising one or
more strains of inactivated ERAV, which when live and active are virulent (i.e., at least 50%,
60%, 70%, 80%, 90% or even 100% of seronegative , when ely exposed to the
virus, present with observable respiratory disease, particularly nasal and/or ocular discharge), can
be grown to high titers in culture to yield a e that is able to induce high titers of serum
antibodies against ERAV when administered, for example, to an equine, for example resulting in
a serum titer of at least 1:112, and preferably, at least 1:200, 1:500, 1:750 or 1:1000. In addition,
the strains grow well in e and are highly efficient to produce, for example, to a titer of at
least 106 TCID50/mL, more preferably 107 TCID50/mL, 108 TCID50/mL, or even 109 TCID50/mL.
Similarly, compositions comprising one or more strains of inactivated ERBV, which when live
and active and not attenuated are also virulent (as defined above for ERAV), were also found to
grow well in culture, to a titer of at least 106 TCID50/mL, more preferably 107 TCleo/mL, 108
TCID50/mL or even 109 TCID50/mL, to be highly efficient to produce, and to induce high titers of
serum antibodies in animals following immunization, for example, resulting in a serum titer of at
least 1:120 and ably at least 1:200, 1:500, 1:750 or . Both the ERAV and ERBV
itions, and combinations f, are capable of reducing the duration, severity, and
incidence of disease in an animal such as a horse that has been immunized with the compositions
and subsequently nged.
In one embodiment, provided is an genic composition comprising one or
more strains of vated ERAV and/or ERBV. Alternatively, the s may be attenuated by
routine means and the live, attenuated virus used in the vaccine composition. In some
embodiments, the ERAV strain comprises a genomic sequence whose e transcript has a
’UTR comprising the nucleotide sequence of SEQ ID NO: 1. In some embodiments, the ERAV
strain comprises a genomic sequence whose reverse transcript has a nucleotide sequence with
greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater than 99%
identity to the nucleotide sequence of SEQ ID NO: 2 and, when not inactivated or attenuated, is
active to infect and replicate in host cells and/or encodes functional ERAV proteins, or which
encodes a polyprotein having an amino acid sequence with greater than 95%, greater than 96%,
greater than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of
SEQ ID NO: 3, which polyprotein contains functional ERAV proteins (i.e., active in viral
infection and replication). In some embodiments, the ERAV strain comprises a genomic
sequence which, when reverse transcribed, has a nucleotide sequence of SEQ ID NO: 2 or which
encodes a polyprotein with an amino acid sequence of SEQ ID NO: 3. In certain ments
the ERAV strain is ERAV/ON/05 having ATCC Accession No. PTA—11828, deposited with the
American Type Culture Collection on April 14, 2011, which is hereby orated by reference.
In some embodiments, the ERBV is strain 042, having ATCC Accession No:
PTA-11829, deposited with the American Type Culture Collection on April 14, 2011, which is
hereby incorporated by reference. In some embodiments, the ERBV strain comprises a genomic
sequence whose reverse transcript has a nucleotide sequence with greater than 95%, greater than
96%, greater than 97%, r than 98% or greater than 99% identity to the nucleotide sequence
of the reverse transcript of the genome of the ERBV strain having ATCC ion No. PTA—
ll829 and, when not inactivated or attenuated, is active to infect and ate in host cells
and/or encodes functional ERBV proteins, or which encodes a polyprotein having an amino acid
sequence with greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater
than 99% identity to the amino acid sequence of the polyprotein of the strain with ATCC
Accession No. PTA-11829, which polyprotein contains functional ERBV proteins (i.e., active in
viral infection and replication).
In one embodiment provided is an immunogenic composition comprising
inactivated (or, alternatively, live, attenuated) ERAV and ERBV. In some embodiments, the
ERAV strain comprises a genomic sequence whose reverse transcript has a 5’UTR comprising
the nucleotide ce of SEQ ID NO: 1. In some embodiments, the ERAV strain comprises a
genomic sequence whose e transcript has a tide sequence with greater than 95%,
greater than 96%, greater than 97%, greater than 98% or greater than 99% identity to the
nucleotide sequence of SEQ ID NO: 2 and, when not inactivated, is active to infect and replicate
in host cells and/or encodes onal ERAV proteins, or which encodes a polyprotein having
an amino acid sequence with greater than 95%, greater than 96%, greater than 97%, greater than
98% or greater than 99% identity to the amino acid sequence of SEQ ID NO: 3, which
polyprotein contains functional ERAV proteins (i.e., active in viral ion and replication). In
some embodiments, the ERAV strain comprises a genomic sequence which, when reverse
transcribed, has a nucleotide sequence of SEQ ID NO: 2 or which encodes a polyprotein with an
amino acid sequence of SEQ ID NO: 3. In some embodiments, the ERAV strain is
ERAV/ON/05 (ATCC Accession No. PTA—11828). In some embodiments, the ERBV is a strain
having ATCC Accession No: PTA-11829. In some ments, the ERBV strain comprises a
genomic ce whose reverse transcript has a nucleotide sequence with greater than 95%,
greater than 96%, greater than 97%, r than 98% or greater than 99% identity to the
nucleotide sequence of the reverse ript of the genome of the ERBV strain having ATCC
ion No. PTA—11829 and, when not inactivated, is active to infect and replicate in host
cells and/or encodes functional ERBV proteins, or which encodes a polyprotein having an amino
acid sequence with greater than 95%, greater than 96%, greater than 97%, greater than 98% or
greater than 99% identity to the amino acid sequence of the polyprotein of the strain with ATCC
Accession No.PTA—l 1829, which polyprotein contains functional ERBV proteins (i.e., active in
viral infection and replication).
In one embodiment, along with the inactivated or live, attenuated one or more
strains of ERAV and/or ERBV, the immunogenic compositions provided herein further comprise
at least one n or one additional inactivated or live, attenuated strain of Equine Herpes Virus
(EHV). In some embodiments the itions comprise at least one antigen of EHV. In some
embodiments the EHV is selected from the group consisting of EHV-l, EHV—4, strains deposited
with the ATCC under accession Nos. PTA—9525 and PTA—9526, and combinations thereof. In
some embodiments, the ERAV strain comprises a genomic sequence whose reverse ript
has a 5’UTR comprising the nucleotide sequence of SEQ ID NO: 1. In some embodiments, the
ERAV strain comprises a genomic sequence whose reverse transcript has a nucleotide sequence
with greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater than
99% identity to the tide sequence of SEQ ID NO: 2 and, when not inactivated, is active to
infect and replicate in host cells and/or encodes functional ERAV ns, or which encodes a
polyprotein having an amino acid sequence with greater than 95%, greater than 96%, greater
than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of SEQ ID
NO: 3, which polyprotein contains functional ERAV proteins (i.e., active in viral infection and
replication). In some embodiments, the ERAV strain comprises a genomic sequence which,
when reverse transcribed, has a nucleotide sequence of SEQ ID NO: 2 or which encodes a
polyprotein with an amino acid ce of SEQ ID NO: 3. In some embodiments, the ERAV
strain is ERAV/ON/05 (ATCC Accession No. PTA—11828). In some ments, the ERBV is
a strain having ATCC Accession No: PTA—11829. In some embodiments, the ERBV strain
ses a genomic sequence whose reverse transcript has a nucleotide sequence with greater
than 95%, greater than 96%, r than 97%, greater than 98% or r than 99% identity to
the nucleotide sequence of the reverse transcript of the genome of the ERBV strain having
ATCC Accession No. PTA—11829 and, when not inactivated or attenuated, is active to infect and
replicate in host cells and/or encodes functional ERBV proteins, or which encodes a polyprotein
having an amino acid sequence with greater than 95%, r than 96%, greater than 97%,
greater than 98% or greater than 99% identity to the amino acid sequence of the polyprotein of
the strain with ATCC Accession No. PTA—11829, which polyprotein contains functional ERBV
ns (i.e., active in viral infection and replication).
In one ment, along with the inactivated (or attenuated) one or more strains
of ERAV and/or ERBV, the immunogenic compositions provided herein further comprise at
least one antigen or one additional vated or attenuated strain of Equine za Virus
(EIV). In some embodiments the compositions comprise at least one antigen of EIV. In some
embodiments the EIV is selected from the group consisting of Clade 1 Viruses, Clade 2 Viruses,
Influenza A/South Africa/2003, Influenza A/equine—2/Ohio/03, Influenza A/equine—2/New
Market/2/93, Influenza A/equine—2/Kentucky/95, Influenza A/equine—2/Richmond/l/2007 and
combinations thereof. In some embodiments, the ERAV strain comprises a genomic sequence
whose reverse transcript has a 5’UTR comprising the nucleotide sequence of SEQ ID NO: 1. In
some embodiments, the ERAV strain comprises a genomic sequence whose reverse transcript
has a nucleotide sequence with r than 95%, greater than 96%, greater than 97%, greater
than 98% or r than 99% identity to the nucleotide sequence of SEQ ID NO: 2 and, when
not inactivated or ated, is active to infect and ate in host cells and/or encodes
functional ERAV proteins, or which encodes a polyprotein having an amino acid sequence with
greater than 95%, greater than 96%, greater than 97%, r than 98% or greater than 99%
identity to the amino acid sequence of SEQ ID NO: 3, which polyprotein contains functional
ERAV proteins (i.e., active in viral infection and replication). In some embodiments, the ERAV
strain comprises a genomic sequence which, when reverse transcribed, has a nucleotide sequence
of SEQ ID NO: 2 or which encodes a polyprotein with an amino acid sequence of SEQ ID NO:
3. In some embodiments, the ERAV strain is ERAV/ON/05 (ATCC Accession No.PTA—11828).
In some embodiments, the ERBV is a strain having ATCC Accession No: PTA-11829. In some
ments, the ERBV strain ses a genomic sequence whose e transcript has a
nucleotide sequence with r than 95%, greater than 96%, r than 97%, greater than
98% or greater than 99% identity to the nucleotide sequence of the reverse transcript of the
genome of the ERBV strain having ATCC Accession No. PTA—11829 and, when not inactivated
or attenuated, is active to infect and replicate in host cells and/or encodes functional ERBV
proteins, or which encodes a polyprotein having an amino acid sequence with greater than 95%,
r than 96%, greater than 97%, greater than 98% or greater than 99% identity to the amino
acid ce of the polyprotein of the strain with ATCC Accession No. PTA—11829, which
polyprotein contains functional ERBV proteins (i.e., active in viral infection and replication
In one embodiment, along with the inactivated (or live, attenuated) one or more
strains of ERAV and/or ERBV, the immunogenic compositions provided herein r comprise
at least one antigen or one additional inactivated or live, attenuated strain of Equine Influenza
Virus and at least one n or one additional inactivated or live, attenuated strain of Equine
Herpes Virus. In some embodiments the compositions comprise at least one antigen of EHV and
at least one antigen of EIV. In some embodiments the EHV is EHV—1 or EHV—4 or a
combination thereof and the EIV is selected from the group consisting of Clade 1 Viruses, Clade
2 Viruses, Influenza A/South Africa/2003, za A/equine—2/Ohio/03, Influenza A/equine—
2/New Market/2/93, Influenza ne—2/Kentucky/95, Influenza A/equine—2/Richmond/1/2007
and combinations thereof. In some embodiments, the ERAV strain comprises a genomic
sequence whose reverse ript has a 5’UTR comprising the nucleotide sequence of SEQ ID
NO: 1. In some ments, the ERAV strain comprises a genomic sequence whose reverse
ript has a nucleotide ce with greater than 95%, greater than 96%, greater than 97%,
greater than 98% or greater than 99% identity to the nucleotide sequence of SEQ ID NO: 2 and,
when not inactivated or attenuated, is active to infect and replicate in host cells and/or s
functional ERAV proteins, or which encodes a polyprotein having an amino acid sequence with
greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater than 99%
identity to the amino acid sequence of SEQ ID NO: 3, which polyprotein contains functional
ERAV proteins (i.e., active in viral infection and replication). In some embodiments, the ERAV
strain comprises a genomic sequence which, when reverse transcribed, has a tide sequence
of SEQ ID NO: 2 or which encodes a polyprotein with an amino acid sequence of SEQ ID NO:
3. In some embodiments, the ERAV strain is ERAV/ON/OS (ATCC Accession No. PTA-
11828). In some embodiments, the ERBV is a strain having ATCC Accession No: PTA—11829.
In some embodiments, the ERBV strain comprises a genomic sequence whose reverse transcript
has a tide sequence with greater than 95%, greater than 96%, r than 97%, greater
than 98% or greater than 99% identity to the nucleotide sequence of the reverse transcript of the
genome of the ERBV strain having ATCC Accession No. PTA—11829 and, when not inactivated,
is active to infect and replicate in host cells and/or encodes functional ERBV proteins, or which
encodes a polyprotein having an amino acid sequence with greater than 95%, r than 96%,
greater than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of
the polyprotein of the strain with ATCC Accession No. PTA-11829, which polyprotein contains
functional ERBV proteins (i.e., active in viral infection and replication).
In one embodiment, along with the vated (or live, ated) one or more
strains of ERAV and/or ERBV, the immunogenic compositions provided herein further se
at least one antigen or vated virus of one or more additional strains selected from the group
ting of Equine Influenza Virus, Equine Herpes Virus, West Nile Virus, Eastern Equine
Encephalomyelitis Virus, Western Equine Encephalomyelitis Virus, and Venezuelan Equine
Encephalomyelitis Virus, and/or Tetanus Toxoid, and combinations f. In some
embodiments, the ERAV strain comprises a genomic ce whose reverse transcript has a
’UTR comprising the nucleotide sequence of SEQ ID NO: 1. In some embodiments, the ERAV
strain comprises a genomic sequence whose reverse ript has a nucleotide ce with
greater than 95%, greater than 96%, greater than 97%, r than 98% or greater than 99%
identity to the nucleotide sequence of SEQ ID NO: 2 and, when not inactivated is attenuated, is
active to infect and replicate in host cells and/or encodes functional ERAV proteins, or which
encodes a polyprotein having an amino acid sequence with greater than 95%, greater than 96%,
greater than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of
SEQ ID NO: 3, which polyprotein contains functional ERAV proteins (i.e., active in viral
infection and replication). In some embodiments, the ERAV strain comprises a c
sequence which, when reverse transcribed, has a nucleotide sequence of SEQ ID NO: 2 or which
encodes a polyprotein with an amino acid sequence of SEQ ID NO: 3. In some embodiments,
the ERAV strain is N/OS (ATCC Accession No. PTA-11828). In some embodiments,
the ERBV is a strain having ATCC Accession No: PTA—11829. In some embodiments, the
ERBV strain comprises a genomic sequence whose reverse transcript has a nucleotide sequence
with greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater than
99% identity to the nucleotide sequence of the e transcript of the genome of the ERBV
strain having ATCC Accession No. PTA—11829 and, when not inactivated or attenuated, is active
to infect and replicate in host cells and/or encodes functional ERBV ns, or which encodes a
polyprotein having an amino acid sequence with greater than 95%, greater than 96%, r
than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of the
polyprotein of the strain with ATCC Accession No. PTA-11829, which polyprotein contains
functional ERBV proteins (i.e., active in viral infection and replication).
In one embodiment, along with the inactivated (or live, attenuated) one or more
strains of ERAV and/or ERBV, the immunogenic compositions provided herein further comprise
at least one additional inactivated or live, attenuated virus of a strain selected from the group
consisting of West Nile Virus, Eastern Equine Encephalomyelitis Virus, Western Equine
Encephalomyelitis Virus, and Venezuelan Equine Encephalomyelitis Virus, and/or Tetanus
Toxoid, and combinations thereof. In some embodiments, the ERAV strain comprises a genomic
sequence whose reverse transcript has a 5’UTR comprising the nucleotide sequence of SEQ ID
NO: 1. In some embodiments, the ERAV strain comprises a genomic sequence whose reverse
ript has a nucleotide sequence with r than 95%, greater than 96%, r than 97%,
greater than 98% or greater than 99% identity to the tide sequence of SEQ ID NO: 2 and,
when not inactivated or attenuated, is active to infect and replicate in host cells and/or encodes
functional ERAV proteins, or which encodes a polyprotein having an amino acid sequence with
greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater than 99%
identity to the amino acid sequence of SEQ ID NO: 3, which otein ns functional
ERAV proteins (i.e., active in viral infection and replication). In some ments, the ERAV
strain comprises a genomic sequence which, when reverse transcribed, has a nucleotide sequence
of SEQ ID NO: 2 or which s a polyprotein with an amino acid sequence of SEQ ID NO:
3. In some embodiments, the ERAV strain is ERAV/ON/OS (ATCC ion No. PTA-
11828). In some embodiments, the ERBV is a strain having ATCC Accession No: 829.
In some embodiments, the ERBV strain comprises a genomic sequence whose reverse transcript
has a nucleotide sequence with greater than 95%, greater than 96%, greater than 97%, greater
than 98% or greater than 99% identity to the nucleotide sequence of the reverse transcript of the
genome of the ERBV strain having ATCC Accession No. PTA—11829 and, when not inactivated
or attenuated, is active to infect and replicate in host cells and/or encodes functional ERBV
proteins, or which encodes a polyprotein having an amino acid sequence with greater than 95%,
greater than 96%, greater than 97%, greater than 98% or greater than 99% identity to the amino
acid sequence of the polyprotein of the strain with ATCC Accession No. PTA—11829, which
polyprotein contains functional ERBV ns (i.e., active in viral infection and replication).
In one embodiment, provided is a method of making the immunogenic composition
of the present invention. The method generally comprises the steps of combining an vated
or live, attenuated ERAV and/or ERBV and a pharmaceutically acceptable carrier. In some
embodiments, the ERAV strain comprises a genomic sequence whose reverse transcript has a
’UTR comprising the nucleotide sequence of SEQ ID NO: 1. In some embodiments, the ERAV
strain comprises a genomic sequence whose reverse transcript has a nucleotide sequence with
greater than 95%, greater than 96%, greater than 97%, r than 98% or greater than 99%
identity to the nucleotide sequence of SEQ ID NO: 2 and, when not inactivated or ated, is
active to infect and replicate in host cells and/or encodes functional ERAV ns, or which
encodes a otein having an amino acid sequence with greater than 95%, greater than 96%,
greater than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of
SEQ ID NO: 3, which polyprotein ns functional ERAV proteins (i.e., active in viral
infection and replication). In some embodiments, the ERAV strain comprises a genomic
sequence which, when reverse transcribed, has a nucleotide sequence of SEQ ID NO: 2 or which
s a polyprotein with an amino acid sequence of SEQ ID NO: 3. In some embodiments,
the ERAV strain is ERAV/ON/OS (ATCC Accession No. PTA—11828). In some embodiments,
the ERBV is a strain having ATCC ion No: PTA—11829. In some embodiments, the
ERBV strain comprises a genomic sequence whose reverse transcript has a tide sequence
with greater than 95%, greater than 96%, greater than 97%, greater than 98% or r than
99% identity to the nucleotide sequence of the reverse transcript of the genome of the ERBV
strain having ATCC Accession No. PTA—11829 and, when not inactivated or attenuated, is active
to infect and replicate in host cells and/or encodes onal ERBV proteins, or which s a
polyprotein having an amino acid sequence with greater than 95%, greater than 96%, greater
than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of the
polyprotein of the strain with ATCC Accession No. PTA—11829, which polyprotein contains
functional ERBV proteins (i.e., active in viral infection and replication). In some embodiments
the method further comprises the step of adding one or more additional equine virus antigens or
inactivated or live, attenuated equine viruses. In another embodiment, the method further
comprises the step of adding a suitable adjuvant to the composition.
In one embodiment, provided is a method for reducing the incidence of or lessening
the severity of clinical symptoms associated with or caused by ERAV or ERBV in an animal or a
herd of animals sing administering an immunogenic composition as disclosed herein to an
animal in need thereof. In some embodiments, the animal is a horse.
The entioned embodiments may further n one or more of the ing
features described below.
In one embodiment, provided is a composition comprising at least one strain of
inactivated (or, alternatively, live, attenuated) ERAV and/or ERBV and further containing many
or all relevant antigenic components and proteins of pathogenic West Nile Virus (WNV) or an
inactivated or live, attenuated strain of WNV.
In one embodiment, provided is a vaccine composition comprising one or more
strains of vated (or live, attenuated) ERAV and/or ERBV in combination with one or more
immunologically ive amounts of antigenic ents or one or more inactivated or live,
attenuated strains selected from the group consisting of West Nile Virus (WNV), Venezuelan
Equine Encephalomyelitis (VEE), Eastern Equine Encephalomyelitis (EEE), Western Equine
Encephalomyelitis (WEE), s toxoid (T), Equine herpes viruses (EHV) including types 1
and 4, Equine influenza viruses (EIV), and ations thereof, along with a pharmaceutically
able carrier. Preferably such embodiments will include an adjuvant, such as a carbomer,
and a pharmaceutically acceptable carrier. In other embodiments the adjuvant is HRA-S, a
carbomer, or mineral oil.
In some embodiments, the compositions also e inactivated or live, attenuated
ERAV and/or ERBV in combination with the following inactivated or live, attenuated viral
strains or ns and combinations of strains and ns: West Nile Virus; Eastern Equine
Encephalomyelitis; Western Equine Encephalomyelitis; Venezuelan Equine Encephalomyelitis;
Tetanus Toxoid; Eastern Equine Encephalomyelitis and Western Equine Encephalomyelitis;
Eastern Equine Encephalomyelitis and elan Equine Encephalomyelitis; Eastern Equine
Encephalomyelitis and Tetanus Toxoid; Eastern Equine alomyelitis, Western Equine
alomyelitis, and elan Equine Encephalomyelitis; Eastern Equine
Encephalomyelitis, Western Equine Encephalomyelitis, and Tetanus Toxoid; Eastern Equine
Encephalomyelitis, Western Equine Encephalomyelitis, elan Equine Encephalomyelitis
and Tetanus Toxoid; Western Equine Encephalomyelitis and elan Equine
Encephalomyelitis; Western Equine Encephalomyelitis and Tetanus Toxoid; Western Equine
Encephalomyelitis, Venezuelan Equine alomyelitis, and Tetanus Toxoid; Venezuelan
Equine Encephalomyelitis and Tetanus Toxoid; and Eastern Equine Encephalomyelitis,
Venezuelan Equine Encephalomyelitis and Tetanus Toxoid, or antigens or antigenic components
thereof. A red combination of these specified combinations es ERAV and/or ERBV
in combination with antigens or nic components of inactivated viruses of West Nile Virus,
Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis, Venezuelan Equine
alomyelitis, and Tetanus . Another preferred combination includes ERAV and/or
ERBV in combination with antigens or antigenic components of Eastern Equine
Encephalomyelitis, Western Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis,
and Tetanus Toxoid. Preferred ERAV include ERAV/ON/05(ATCC Accession No. PTA—
11828), ERAV strain which comprises a genomic sequence whose reverse transcript has a
S’UTR comprising the nucleotide sequence of SEQ ID NO: 1, which comprises a genomic
sequence whose reverse transcript has a nucleotide sequence with r than 95%, greater than
96%, greater than 97%, greater than 98% or greater than 99% identity to the tide sequence
of SEQ ID NO: 2 and, when not inactivated or attenuated, is active to infect and replicate in host
cells and/or s functional ERAV proteins, or which encodes a polyprotein having an amino
acid sequence with greater than 95%, greater than 96%, greater than 97%, greater than 98% or
greater than 99% identity to the amino acid sequence of SEQ ID NO: 3, which polyprotein
contains functional ERAV proteins (i.e., active in viral infection and replication). The ERAV
strain may also comprise a genomic sequence which, when reverse transcribed, has a nucleotide
sequence of SEQ ID NO: 2 or which encodes a otein with an amino acid sequence of SEQ
ID NO: 3. Preferred ERBV is a strain having ATCC ion No: PTA—11829, or which
comprises a genomic sequence whose reverse transcript has a nucleotide sequence with greater
than 95%, greater than 96%, greater than 97%, greater than 98% or greater than 99% identity to
the nucleotide sequence of the reverse transcript of the genome of the ERBV strain having
ATCC Accession No. PTA-11829 and, when not vated, is active to infect and replicate in
host cells and/or encodes functional ERBV ns, or which encodes a polyprotein having an
amino acid sequence with greater than 95%, greater than 96%, greater than 97%, greater than
98% or greater than 99% identity to the amino acid sequence of the polyprotein of the strain with
ATCC Accession No. PTA—11829, which otein contains functional ERBV proteins (i.e.,
active in Viral infection and replication). In each such specified combination, an adjuvant or
combination of adjuvants can be used such as, HRA—S, carbomer or with carbopol. The NJO
strain of Eastern Equine Encephalomyelitis, the Fleming strain of Western Equine
Encephalomyelitis strain, and the TC—83 strain of Venezuelan Equine Encephalomyelitis strain
are all representative strains of these e components.
Further preferred embodiments of the present invention include immunogenic
compositions made using each of the specified combination vaccines listed above and adding
ns or inactivated or attenuated viruses from Equine Herpesvirus, preferably type 1, type 4,
(EHVl and/or EHV4) or combinations thereof.
Still further variations of each of the specified combination vaccines or
immunogenic itions listed above, including those that include EHVl and/or EHV4 can be
made by adding in antigens or inactivated or attenuated viruses from Equine influenza Virus
(EIV). Preferred ments incorporating Equine influenza virus include inactivated or live,
attenuated: ERAV and/or ERBV and at least one vated or live, attenuated strain of each of
WNV, Equine za Virus, and Tetanus Toxoid; ERAV and/or ERBV and at least one
inactivated or live, attenuated strain of each of WNV, Equine Influenza Virus, Tetanus Toxoid,
and Eastern Equine Encephalomyelitis; ERAV and/or ERBV and at least one strain of each of
WNV, Equine Influenza Virus, Tetanus Toxoid, Eastern Equine Encephalomyelitis, and Western
Equine Encephalomyelitis; ERAV and/or ERBV and at least one strain of each of WNV, Equine
za Virus, Tetanus Toxoid, Eastern Equine Encephalomyelitis, Western Equine
Encephalomyelitis; and Venezuelan Equine Encephalomyelitis; ERAV and/or ERBV and at least
one strain of each of WNV, Equine Influenza Virus, and Eastern Equine Encephalomyelitis;
ERAV and/or ERBV and, at least one strain of each of WNV, Equine Influenza Virus, and
Western Equine Encephalomyelitis; ERAV and/or ERBV and at least one strain of each of
WNV, Equine za Virus, and Venezuelan Equine Encephalomyelitis; ERAV and/or ERBV
and at least one strain of each of WNV, Equine Influenza Virus, n Equine
Encephalomyelitis, and Western Equine Encephalomyelitis; ERAV and/or ERBV and at least
one strain of each of WNV, Equine Influenza Virus, Eastern Equine Encephalomyelitis, and
Venezuelan Equine Encephalomyelitis; ERAV and/or ERBV and at least one strain of each of
WNV, Equine Influenza Virus, Western Equine Encephalomyelitis, and Venezuelan Equine
Encephalomyelitis; ERAV and/or ERBV and at least one strain of each of WNV, Equine
Influenza Virus, Western Equine Encephalomyelitis, and tetanus toxoid; ERAV and/or ERBV
and at least one strain of each of WNV, Equine Influenza Virus, Venezuelan Equine
Encephalomyelitis, and tetanus toxoid; ERAV and/or ERBV and at least one strain of each of
WNV, Equine Influenza Virus, Venezuelan Equine Encephalomyelitis, Western Equine
alomyelitis, and s toxoid; and ERAV and/or ERBV and at least one strain of each
of WNV, Equine Influenza Virus, Venezuelan Equine Encephalomyelitis, Eastern Equine
Encephalomyelitis, and tetanus toxoid, wherein the aforementioned strains are inactivated or
live, attenuated. In each specified embodiment one or more inactivated or live, ated strains
of Equine Influenza Virus may be present. Preferred strains of Equine Influenza virus include
Influenza A/equine—2/Ohio/03, Influenza A/equine—2/New Market/2/93, Influenza A/equine—
2/Kentucky/95, and combinations thereof. In all of the combinations listed above, it is preferred
to use at least two inactivated or live, attenuated s of Equine Influenza Virus and still more
preferred to use at least 3 strains of Equine za Virus.
red embodiments incorporating Equine Herpes Virus include: ERAV and/or
ERBV and at least one strain of each of WNV, Equine Influenza Virus, Tetanus Toxoid, and
Equine Herpes Virus; ERAV and/or ERBV and at least one strain of each of WNV, Equine
Influenza Virus, Tetanus Toxoid, n Equine Encephalomyelitis, and Equine Herpes Virus;
ERAV and/or ERBV and at least one strain of each of WNV, Equine Influenza Virus, s
, Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis, and Equine
Herpes Virus; ERAV and/or ERBV and at least one strain of each of WNV, Equine Influenza
Virus, Tetanus Toxoid, Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis;
Venezuelan Equine Encephalomyelitis, and Equine Herpes Virus; ERAV and/or ERBV and at
least one strain of each of WNV, Equine Influenza Virus, and Eastern Equine Encephalomyelitis;
ERAV and/or ERBV and at least one strain of each of WNV, Equine za Virus, Western
Equine Encephalomyelitis and Equine Herpes Virus; ERAV and/or ERBV and at least one strain
of each of WNV, Equine Influenza Virus, Venezuelan Equine alomyelitis, and Equine
Herpes Virus; ERAV and/or ERBV and at least one strain of each of WNV, Equine za
Virus, Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis, and ERAV and/or
ERBV and at least one strain of each of WNV, Equine Influenza Virus, Eastern Equine
Encephalomyelitis, Venezuelan Equine Encephalomyelitis, and Equine Herpes Virus; ERAV
and/or ERBV and at least one strain of each of WNV, Equine Influenza Virus, Western Equine
Encephalomyelitis, Venezuelan Equine Encephalomyelitis, and Equine Herpes Virus; ERAV
and/or ERBV and at least one strain of each of WNV, Equine Influenza Virus, Western Equine
Encephalomyelitis, Tetanus Toxoid, and Equine Herpes Virus; ERAV and/or ERBV and at least
one strain of each of WNV, Equine Influenza Virus, Venezuelan Equine Encephalomyelitis,
tetanus toxoid, and Equine Herpes Virus; ERAV and/or ERBV and at least one strain of each of
WNV, Equine Influenza Virus, Venezuelan Equine Encephalomyelitis, Western Equine
Encephalomyelitis, Tetanus Toxoid, and Equine Herpes Virus; and ERAV and/or ERBV and at
least one strain of each of WNV, Equine Influenza Virus, Venezuelan Equine Encephalomyelitis,
Eastern Equine Encephalomyelitis, Tetanus Toxoid, and Equine Herpes Virus, wherein the
aforementioned strains are vated or live, ated. In all of the combinations listed above,
it is preferred to use at least two strains of vated or live, attenuated Equine Influenza Virus
and still more preferred to use at least 3 strains of inactivated or live, attenuated Equine Influenza
Virus. onally, in all combinations above, the “at least one” strain of Equine Herpes Virus
is preferred to be selected from the group consisting of inactivated EHV—l and EHV—4. In some
preferred forms, both inactivated or live, attenuated strains, EHV—l and EHV—4, will be included
in the immunogenic composition. In other preferred forms, just EHV—l will be included. In a
preferred combination, the inactivated or live, attenuated ERAV strain is ERAV/ON/05, an
ERAV strain which comprises a genomic sequence whose reverse transcript has a 5’UTR
comprising the nucleotide sequence of SEQ ID NO: 1, which comprises a genomic sequence
whose reverse transcript has a nucleotide sequence with greater than 95%, greater than 96%,
greater than 97%, greater than 98% or r than 99% identity to the nucleotide sequence of
SEQ ID NO: 2 and, when not inactivated, is active to infect and replicate in host cells and/or
encodes functional ERAV ns, or which encodes a otein having an amino acid
sequence with greater than 95%, r than 96%, greater than 97%, greater than 98% or greater
than 99% identity to the amino acid sequence of SEQ ID NO: 3, which otein contains
functional ERAV proteins (i.e., active in viral infection and replication). The ERAV strain may
also comprise a genomic sequence which, when reverse transcribed, has a nucleotide ce of
SEQ ID NO: 2 or which encodes a polyprotein with an amino acid sequence of SEQ ID NO: 3.
In other preferred ations, the ERBV is a strain having ATCC Accession No: PTA—11828,
or which comprises a genomic sequence whose reverse transcript has a nucleotide sequence with
greater than 95%, greater than 96%, r than 97%, greater than 98% or greater than 99%
identity to the tide sequence of the reverse transcript of the genome of the ERBV strain
having ATCC Accession No. PTA—11828 and, when not inactivated or attenuated, is active to
infect and replicate in host cells and/or encodes functional ERBV ns, or which encodes a
polyprotein having an amino acid sequence with greater than 95%, greater than 96%, greater
than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of the
polyprotein of the strain with ATCC Accession No. PTA—11828, which otein contains
functional ERBV proteins (i.e., active in viral infection and replication).
The immunogenic compositions as disclosed herein can be administered in any
genically effective dose. In a preferred embodiment, the immunogenic composition is
administered as a single dose. Preferably, the dose has a total volume between about 0.5 mL and
about 2.5 mL, more ably between about 0.6 mL and about 2.0 mL, even more preferably
between about 0.7 mL and about 1.75 mL, still more preferably between about 0.8 mL and about
1.5 mL, even more preferably between about 0.9 mL and about 1.25 mL, with a single dose
about 1.0 mL being the most preferred.
In r embodiment, the immunogenic composition is stered with a first
dose being administered prior to the administration of a second (booster) dose. Preferably, the
second dose is administered at least about 15 days after the first close. More preferably, the
second dose is administered between about 15 and about 28 days after the first dose. Even more
preferably, the second dose is administered at least about 17 days after the first dose. Still more
preferably, the second dose is administered n about 17 and about 25 days after the first
dose. Even more ably, the second dose is administered at least about 19 days after the first
dose. Still more preferably, the second dose is administered between about 19 and about 23 days
after the first dose. Most preferably the second dose is administered at least about 21 days after
the first dose. In a preferred embodiment, both the first and second doses of the immunogenic
composition are in the same . Preferably, each dose is in the preferred amounts specified
above, with a dose of about 1 mL for the first and second dose being most preferred. In addition
to the first and second dose n, an alternate embodiment comprises further subsequent
doses. For example, a third, fourth, or fifth dose could be administered in these embodiments.
Preferably, subsequent third, fourth, and fifth dose regimens are administered in the same
amount as the first dose, with the time frame between the doses being consistent with the timing
between the first and second doses mentioned above, although the timing may also vary.
In one embodiment the immunogenic composition is administered in three doses.
In some embodiments the three doses are administered at three week intervals.
In an embodiment that comprises ERAV, preferably ERAV/ON/OS, the amount of
ERAV in the immunogenic composition is at least about 102‘0TCID50/dose. More preferably, the
amount of ERAV is between about 102‘0TC1D50/dose to about 1010‘0TCID50/dose. Still more
preferably, the amount of ERAV is at least about 102'5TCID50/dose. Even more preferably, the
amount of ERAV is between about 102‘5TCleo/dose to about 109'5TCID50/dose. Still more
preferably, the amount of ERAV is at least about CID50/dose. Even more preferably, the
amount of ERAV is between about 103'0TClD5o/dose to about 109'0TCID50/dose. Still more
ably, the amount of ERAV is at least about ClD5o/dose. Even more preferably, the
amount of ERAV is between about CID50/dose to about 109'0TCID50/dose. Sill more
preferably, the amount of ERAV is between about 106‘5TCID50/dose and about CID50/dose.
More preferably, the amount of ERAV is between about 107‘0TCID50/dose and about
109‘0TCID50/dose. The TCID50 values of an vated or attenuated ERAV or any other
inactivated or attenuated vaccine refer in general to the viral content in the final vaccine that
however is equivalent to the viral content calculated for the vaccine composition prior to the
inactivation of its virus. Preferably, the immunogenic composition of the present invention
stimulates serum neutralizing antibodies to ERAV at a titer of at least 1:112, 1:300, 1:500, 1:700,
1:900, 1:1000, or 1:1500
In an embodiment that comprises ERBV, ably a strain having ATCC
Accession NO: PTA—11829, the amount of ERBV is at least about 102'0TCID50/dose. More
preferably, the amount of ERBV is between about 102'0TCIDso/dose to about lOlO'OTCID50/dose.
Still more preferably, the amount of ERBV is at least about 102'5TCID50/dose. Even more
preferably, the amount of ERBV is between about 102'5TCIDso/dose to about 109‘5TCID50/dose.
Still more ably, the amount of ERBV is at least about 103‘0TCID50/dose. Even more
ably, the amount of ERBV is between about 103'0TCID50/dose to about 109‘0TCID50/dose.
Still more preferably, the amount of ERBV is at least about 103‘5TCID50/dose. Even more
preferably, the amount of ERBV is between about 103‘5TCIDso/dose to about 109‘0TCID50/dose.
Sill more preferably, the amount of ERBV is between about 106‘5TCID50/dose and about
108‘5TCID50/dose. More preferably, the amount of ERBV is between about 107'0TCID50/dose
and about 109‘0TCID50/dose. The TCIDsO values of an vated ERBV or any other
inactivated vaccine refer in general to the viral t in the final vaccine that however is
equivalent to the viral content calculated for the vaccine composition prior to the inactivation of
its virus. ably, the immunogenic composition of the present invention stimulates serum
neutralizing antibodies to ERBV at a titer of at least 1:4 or higher. In some embodiments, the
titer is at least 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11; 1:12, 1:13, 1:14, or 1:15 or higher. In some
embodiments, the titer is at least 1:64, 1:256, or 1:512 or higher. In some embodiments, the titer
is at least 1:1024 or higher. In some embodiments, the titer is at least 1:2048, 1:1536, 1:3072,
1:4096, 1:6144, 1:8192, 1:12288, or 9 or higher. In some embodiments, the titer is no
more than 1:300, 1:1050, 1:32000, 1:70000, or 1:140000.
In one embodiment, in each dose of an embodiment of the t invention that
comprises one or more additional equine antigens, the amount of Eastern Equine
Encephalomyelitis or Venezuelan Equine alomyelitis in any dose is ably at least
about CID50/dose. Even more ably, the dose is between about 105'5TCID50/dose and
about 109‘5TCID50/dose. Still more preferably, the dose is at least about 106'0TCID50/dose. Still
more ably, the dose is between about 106'0TCID50/dose and about 109'0TCID50/dose. Even
more preferably, the dose is at least about 106'5TCID50/dose. Still more preferably, the dose is
between about 106‘5TCID50/dose and about 109'5TC1D50/dose. Even more preferably, the dose is
at least about 107‘0TCID50/dose. Most preferably, the dose is between about 106'7TCID50 and
about 109‘2TCID50/dose.
In an embodiment that comprises inactivated or killed WNV or antigen, the amount
of WNV or antigen is at least about 102'0TCID50/dose. More preferably, the WNV or antigen is
between about 102‘0TCID50/dose to about 1010'0TCID50/dose. Still more preferably, the WNV or
antigen is at least about 102‘5TCID50/dose. Even more preferably, the WNV or antigen is
between about CID50/dose to about 109‘5TCIDso/dose. Still more preferably, the WNV or
antigen is at least about 103‘0TCID50/dose. Even more preferably, the WNV or antigen is
between about CID50/dose to about 109‘0TCIDso/dose. Still more preferably, the WNV or
antigen is at least about 103‘5TCID50/dose. Even more preferably, the WNV or antigen is
between about 103‘5TCID50/dose to about 109‘0TCIDsO/dose. Most preferably, the WNV or
antigen is between about 107‘0TCID50/dose and about 109‘0TCID50/dose. The TCID50 values of
an inactivated WNV vaccine or any other vated vaccine refer in general to the antigen
content in the final vaccine that however is equivalent to the antigen content calculated for the
e composition prior to the inactivation of its antigen. Preferably, the immunogenic
composition of the t invention stimulates serum neutralizing antibodies to WNV at a titer
of at least 1:4 or higher. In some embodiments the titer is at least 1:5, 1:6, 1:7, 1:8, 1:9, 1:10,
1:11; 1:12, 1:13, 1:14, or 1:15 or higher. In some embodiments, the titer is no more than 1:300,
1:1050, 1:32000, 1:70000, or 1:140000. In a preferred embodiment, in each dose of an
embodiment of the present invention that comprises additional equine n, the amount of
Eastern Equine alomyelitis or elan Equine alomyelitis in any dose is
preferably at least about lOS‘STCID50/dose. Even more preferably, the dose is between about
105‘5TCID50/dose and about 109‘5TC1D50/dose. Still more preferably, the dose is at least about
106‘0TCID50/dose. Still more preferably, the dose is between about 106‘0TCIDso/dose and about
109‘0TCID50/dose. Even more ably, the dose is at least about 106‘5TCID50/dose. Still more
preferably, the dose is between about 106'5TCID50/dose and about 109‘5TCID50/dose. Even more
preferably, the dose is at least about 107'0TCID50/dose. Most preferably, the dose is between
about 106-7TC1D50 and about C1D50/dose.
Preferably, the Western Equine Encephalomyelitis antigen, when present in the
composition of the present invention, is in an amount of at least about 106'2PFU/mL. Even more
preferably, the amount is between about 106'2PFU/mL and about lOlO'ZPFU/mL. Still more
preferably, the amount is at least about 106'7PFU/mL. Even more preferably, the amount is
between about 106‘5PFU/mL and about 109'7PFU/mL. Still more preferably, the amount is at
least about 107‘2PFU/mL. Even more preferably, the amount is between about 107‘2PFU/mL and
about FU/mL. Still more preferably, the amount is at least about 107‘7PFU/mL with
between about 106‘5 PFU/dose and about 109‘OPFU/mL being the most preferred.
In another preferred embodiment, the amount of tetanus toxoid, if present in the
composition of the present ion, is in an amount of at least about 3 CPU, more preferably,
between about 3 CPU and about 20 CPU, still more preferably, at least about 4 CPU, and most
preferably, at least about 5 CPU but not more than about 20 CPU.
In an alternate embodiment, where one or more strains of Equine Influenza Virus is
present, the amount of Equine Influenza present in the composition is in an amount of at least
about 105‘0 TCIDso/mL. More ably, the Equine Influenza is in an amount of between about
105‘0 TCIDso/mL to about 109'0 TCIDso/mL, and, more preferably, at least about 106‘0 TCID50/mL.
Still more preferably, the amount is between about 106‘0 TCIDso/mL to about 108‘0 TCIDso/mL
and, more ably, the amount is at least about 106'5 TCID50/mL. Still more preferably, the
amount is between about 106‘5 TCID50/mL to about 107'5 TClD50/mL, with the most preferred
amount being between about 106‘7 TCID50/mL to about 107'3 TCID50/mL.
In an embodiment that comprises Equine Herpes Virus, the amount of Equine
Herpes Virus in each dose is at least about 106‘0 /mL. More preferably, Equine Herpes
Virus is present in the composition in an amount of between about 106‘0 TCID50/mL to about
109‘5 TCIDso/mL and, more preferably, in an amount of about 107‘0 TCleo/mL. Still more
preferably, Equine Herpes Virus is present in an amount between about 107‘5 TCIDso/mL to about
109‘0 TCIDso/mL and, more preferably, in an amount of about 108‘0 TCID50/mL. Still more
preferably, Equine Herpes Virus is present in an amount of between about 108‘0 TCIDsO/mL to
about 109‘0 TCID50/mL and, most preferably, in an amount of about 108'50 TCID50/mL.
In yet another preferred embodiment, a vaccine composition comprising the
chronologically contemporary and epidemiologically prevalent s of ERAV and/or ERBV is
provided. Preferably the composition comprises ERAV/ON/05 and/or a ERBV strain having
ATCC Accession NO: PTA—11829. In specific embodiments, the ERAV strain comprises a
genomic sequence whose e transcript has a 5’UTR comprising the nucleotide ce of
SEQ ID NO: 1. In some embodiments, the ERAV strain comprises a genomic sequence whose
reverse transcript has a nucleotide ce with greater than 95%, greater than 96%, greater
than 97%, greater than 98% or greater than 99% identity to the nucleotide sequence of SEQ ID
NO: 2 and, when not inactivated, is active to infect and ate in host cells and/or encodes
functional ERAV proteins, or which encodes a polyprotein having an amino acid sequence with
greater than 95%, r than 96%, greater than 97%, greater than 98% or greater than 99%
identity to the amino acid ce of SEQ ID NO: 3, which polyprotein contains onal
ERAV proteins (i.e., active in viral infection and replication). In some embodiments, the ERAV
strain comprises a genomic sequence which, when reverse transcribed, has a nucleotide sequence
of SEQ ID NO: 2 or which encodes a polyprotein with an amino acid ce of SEQ ID NO:
3. In some embodiments, the ERBV is a strain having ATCC Accession No: PTA-11829. In
some embodiments, the ERBV strain comprises a genomic sequence whose reverse transcript
has a nucleotide sequence with greater than 95%, greater than 96%, greater than 97%, greater
than 98% or greater than 99% identity to the nucleotide sequence of the reverse ript of the
genome of the ERBV strain having ATCC Accession No. PTA—11829 and, when not inactivated
or attenuated, is active to infect and replicate in host cells and/or encodes functional ERBV
proteins, or which encodes a polyprotein having an amino acid sequence with greater than 95%,
r than 96%, greater than 97%, greater than 98% or r than 99% identity to the amino
acid sequence of the otein of the strain with ATCC Accession No. PTA—11829, which
polyprotein contains functional ERBV proteins (i.e., active in viral infection and replication).
Such a composition will generally improve the cy of the composition.
The present invention additionally provides for a method of reduction of the
incidence of and/or severity of clinical signs associated with, ERAV and/or ERBV infection in
an animal, preferably a horse. Such methods generally se the step of administering a
vaccine composition comprising an inactivated or live, ated strain of an ERAV and/or
ERBV and a pharrnaceutically acceptable r. In particular embodiments, the ERAV is
ERAV/ON/05, or the ERAV strain comprises a genomic sequence whose reverse transcript has a
’UTR comprising SEQ ID NO: I. In some embodiments, the ERAV strain comprises a
genomic sequence whose reverse transcript has a nucleotide sequence with greater than 95%,
greater than 96%, greater than 97%, greater than 98% or greater than 99% identity to the
nucleotide sequence of SEQ ID NO: 2 and, when not inactivated, is active to infect and replicate
in host cells and/or encodes functional ERAV proteins, or which encodes a polyprotein having
an amino acid sequence with greater than 95%, greater than 96%, greater than 97%, greater than
98% or r than 99% identity to the amino acid ce of SEQ ID NO: 3, which
polyprotein ns functional ERAV proteins (i.e., active in viral infection and replication). In
some embodiments, the ERAV strain ses a c sequence which, when reverse
transcribed, has a nucleotide sequence of SEQ ID NO: 2 or which encodes a polyprotein with an
amino acid sequence of SEQ ID NO: 3. In some embodiments, the ERBV is a strain having
ATCC Accession No: PTA-11829. In some embodiments, the ERBV strain comprises a genomic
sequence whose e transcript has a nucleotide sequence with greater than 95%, greater than
96%, greater than 97%, greater than 98% or greater than 99% identity to the nucleotide sequence
of the reverse transcript of the genome of the ERBV strain having ATCC Accession No. PTA-
11829 and, when not inactivated or attenuated, is active to infect and replicate in host cells
and/or encodes onal ERBV proteins, or which encodes a polyprotein having an amino acid
sequence with greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater
than 99% identity to the amino acid sequence of the polyprotein of the strain with ATCC
Accession No. PTA—11829, which polyprotein contains functional ERBV proteins (i.e., active in
Viral infection and replication). In some preferred embodiments, an adjuvant, particularly HRA—
, is added to the composition, and in other preferred forms, no adjuvant is provided.
In an alternate preferred embodiment, the method ses administering a
vaccine composition comprising one or more inactivated or live, attenuated strains of ERAV
and/or ERBV in combination with immunologically effective amounts of antigenic components
or vated strains from other equine pathogens. Preferably, the ERAV strain is ERAV/ON/05
(ATCC Accession No. PTA—11828) and the ERBV strain has ATCC ion NO: PTA—11829.
In certain such embodiments, the ERBV strain comprises a genomic sequence whose e
ript has a 5’UTR comprising SEQ ID NO: 1. In some embodiments, the ERAV strain
comprises a genomic sequence whose reverse transcript has a tide sequence with greater
than 95%, greater than 96%, greater than 97%, greater than 98% or greater than 99% identity to
the nucleotide sequence of SEQ ID NO: 2 and, when not inactivated or live, attenuated, is active
to infect and replicate in host cells and/or encodes functional ERAV proteins, or which encodes a
polyprotein haVing an amino acid sequence with greater than 95%, greater than 96%, greater
than 97%, greater than 98% or greater than 99% identity to the amino acid sequence of SEQ ID
NO: 3, which polyprotein contains functional ERAV ns (i.e., active in Viral ion and
replication). In some embodiments, the ERAV strain ses a genomic ce which,
when reverse ribed, has a nucleotide sequence of SEQ ID NO: 2 or which encodes a
otein with an amino acid sequence of SEQ ID NO: 3. In some embodiments, the ERBV is
a strain having ATCC Accession No: PTA—11829. In some embodiments, the ERBV strain
comprises a genomic sequence whose reverse transcript has a nucleotide sequence with greater
than 95%, greater than 96%, greater than 97%, greater than 98% or greater than 99% identity to
the nucleotide sequence of the reverse transcript of the genome of the ERBV strain having
ATCC Accession No. PTA-11829 and, when not inactivated or attenuated, is active to infect and
replicate in host cells and/or s functional ERBV proteins, or which encodes a otein
having an amino acid sequence with greater than 95%, greater than 96%, greater than 97%,
greater than 98% or greater than 99% identity to the amino acid sequence of the polyprotein of
the strain with ATCC ion No. PTA—11829, which polyprotein contains functional ERBV
proteins (i.e., active in viral ion and replication).
In some embodiments of the method, the pathogens in combination with the ERAV
and/or ERBV strains, are selected from the group consisting of antigens or inactivated or
attenuated strains of EHV and EIV and combinations thereof. In some embodiments the
pathogens are antigens. In some embodiments the EHV is EHV-1 or EHV-4 or a combination
thereof. In other embodiments the EIV is selected from the group consisting of Clade 1 viruses,
Clade 2 s, za A/South Africa/2003, Influenza A/equine—2/Ohio/03, Influenza
A/equine—2/New Market/2/93, Influenza A/equine—2/Kentucky/95, Influenza A/equine—
2/Richmond/l/2007 and combinations thereof.
In still other embodiments of the method, the pathogens in combination with the
ERAV and/or ERBV strains, are selected from the group consisting of antigens or inactivated or
attenuated strains of WNV, n Equine Encephalomyelitis, Western Equine
Encephalomyelitis, and Venezuelan Equine Encephalomyelitis, and tetanus toxoid, and
combinations thereof, and more preferably being those combinations described above. In another
preferred embodiment, the vaccine of the present invention is combined with a suitable nt
and/or pharmaceutically able carrier.
The present invention provides for ion of the incidence of and/or severity of
clinical symptoms ated with, ERAV and/or ERBV infection in a herd. Preferably, the
ty and/or incidence of clinical symptoms in animals receiving the immunogenic
composition of the present invention are reduced at least 10% in comparison to animals not
receiving such an administration when both groups (animals receiving and animals not receiving
the composition) are challenged with or exposed to infection by ERAV and/or ERBV. More
preferably, the incidence or severity is reduced at least 20%, even more preferably, at least 30%,
still more ably, at least 40%, even more ably, at least 50%, still more preferably, at
least 60%, even more preferably, at least 70%, still more preferably, at least 80%, even more
preferably, at least 90%, still more preferably, at least 95%, and most preferably, at least 100%,
wherein the animals receiving the composition of the present invention exhibit no clinical
symptoms, or alternatively exhibit clinical ms of reduced severity. Advantageously, the
present invention also provides protection from heterologous strains ive to the strain used in
the composition) of pathogens.
The present invention further provides a method of stimulating serum neutralizing
or serum hemagglutination antibodies to a pathogen selected from the group consisting of
ERAV, ERBV, WNV, WEE, VEE, EEE, EHV, EIV, and combinations thereof by administering
a composition in accordance with the present invention bed herein. In particular
embodiments, the ERAV is ERAV/ON/OS, or the ERAV strain comprises a genomic sequence
whose reverse transcript has a 5’UTR comprising SEQ ID NO: 1. In some embodiments, the
ERAV strain comprises a genomic sequence whose reverse transcript has a nucleotide ce
with greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater than
99% identity to the nucleotide ce of SEQ ID NO: 2 and, when not inactivated or
attenuated, is active to infect and replicate in host cells and/or encodes functional ERAV
proteins, or which encodes a polyprotein having an amino acid ce with greater than 95%,
greater than 96%, greater than 97%, greater than 98% or greater than 99% ty to the amino
acid sequence of SEQ ID NO: 3, which polyprotein contains functional ERAV proteins (i.e.,
active in viral infection and replication). In some embodiments, the ERAV strain comprises a
genomic sequence which, when reverse transcribed, has a nucleotide sequence of SEQ ID NO: 2
or which encodes a polyprotein with an amino acid sequence of SEQ ID NO: 3. In some
embodiments, the ERBV is a strain having ATCC Accession No: PTA—11829. In some
embodiments, the ERBV strain ses a c sequence whose reverse transcript has a
nucleotide sequence with greater than 95%, greater than 96%, greater than 97%, greater than
98% or greater than 99% identity to the nucleotide sequence of the reverse transcript of the
genome of the ERBV strain having ATCC Accession No. PTA—11829 and, when not inactivated
or attenuated, is active to infect and replicate in host cells and/or encodes onal ERBV
proteins, or which encodes a polyprotein having an amino acid sequence with greater than 95%,
greater than 96%, greater than 97%, greater than 98% or greater than 99% identity to the amino
acid ce of the otein of the strain with ATCC Accession No. PTA—11829, which
polyprotein ns functional ERBV proteins (i.e., active in viral infection and replication).
Preferably the compositions of the present invention stimulate serum neutralizing dies to
ERAV and/or ERBV at a titer of at least 1:112, 1:120, 1:300, 1:500, 1:1000, or 1:1024, or higher.
The immunogenic ition of the present ion provides an extended
duration of immunity against all strains t in the vaccine. Preferably, the duration of
ty against ERAV and/or ERBV is at least 1 month, more preferably, the duration of
immunity is at least 2 months, still more ably, the duration of immunity is at least 3
months, even more ably, the duration of immunity is at least 4-24 months, still more
preferably, the duration of immunity is at least 6—24 months, even more preferably, the duration
of immunity is at least 7—24 months, still more ably, the duration of ty is at least 8—
24 months, even more preferably, the duration of immunity is at least 9—24 months, still more
preferably, the duration of immunity is at least 10—24 months, and most preferably, the duration
of immunity is at least 12—24 months.
The immunogenic composition of the t invention also provides an extended
duration of immunity against all antigens present in the vaccine. Preferably, the duration of
ty against West Nile is at least 1 month, more preferably, the duration of immunity is at
least 2 months, still more preferably, the duration of immunity is at least 3 months, even more
preferably, the duration of immunity is at least 4—24 months, still more preferably, the on of
immunity is at least 6—24 months, even more preferably, the duration of immunity is at least 7—24
months, still more preferably, the duration of immunity is at least 8—24 months, even more
preferably, the on of immunity is at least 9—24 months, still more preferably, the duration of
immunity is at least 10—24 months, and most preferably, the duration of immunity is at least 12—
24 months.
Preferably, the duration of immunity against EIV is at least 1 month, more
preferably, the duration of immunity is at least 2 months, still more preferably, the duration of
immunity is at least 3 , even more preferably, the duration of immunity is at least 4- 24
months, still more preferably, the duration of immunity is at least 6 -24 months, even more
preferably, the duration of immunity is at least 7—24 months, still more preferably, the duration of
immunity is at least 8—24 months, even more preferably, the duration of immunity is at least 9—24
months, still more ably, the duration of immunity is at least 10—24 months, and most
preferably, the duration of immunity is at least 12—24 months.
ably, the duration of immunity against EHV is at least 1 month, more
ably, the duration of immunity is at least 2 months, still more ably, the duration of
immunity is at least 3 months, even more preferably, the duration of immunity is at least 4— 24
months, still more preferably, the duration of immunity is at least 6 -24 months, even more
preferably, the duration of immunity is at least 7-24 months, still more preferably, the duration of
immunity is at least 8—24 months, even more preferably, the duration of immunity is at least 9—24
months, still more preferably, the duration of immunity is at least 10—24 months, and most
preferably, the duration of immunity is at least 12—24 months.
Preferably, the duration of ty t Western Equine Encephalomyelitis is
at least 1 month, more preferably, the duration of immunity is at least 2 months, still more
preferably, the duration of immunity is at least 3 months, even more preferably, the duration of
immunity is at least 4— 24 months, still more preferably, the duration of immunity is at least 6 —24
months, even more preferably, the on of immunity is at least 7—24 , still more
preferably, the duration of immunity is at least 8—24 months, even more preferably, the duration
of immunity is at least 9—24 months, still more preferably, the duration of immunity is at least 10—
24 months, and most preferably, the duration of immunity is at least 12—24 months.
ably, the duration of immunity against Eastern Equine Encephalomyelitis is at
least 1 month, more preferably, the duration of immunity is at least 2 months, still more
preferably, the duration of immunity is at least 3 months, even more preferably, the duration of
immunity is at least 4— 24 months, still more preferably, the duration of immunity is at least 6 —24
months, even more preferably, the duration of ty is at least 7—24 months, still more
preferably, the duration of immunity is at least 8-24 months, even more preferably, the duration
of ty is at least 9-24 months, still more preferably, the duration of ty is at least 10-
24 months, and most preferably, the duration of immunity is at least 12-24 .
Preferably, the duration of immunity against Venezuelan Equine Encephalomyelitis
is at least 1 month, more ably, the duration of immunity is at least 2 months, still more
preferably, the duration of immunity is at least 3 months, even more preferably, the duration of
immunity is at least 4— 24 months, still more preferably, the duration of immunity is at least 6 —24
, even more preferably, the duration of immunity is at least 7—24 months, still more
preferably, the duration of immunity is at least 8—24 months, even more preferably, the duration
of immunity is at least 9-24 months, still more preferably, the duration of immunity is at least 10—
24 months, and most preferably, the duration of immunity is at least 12—24 months.
Preferably, the duration of immunity against Tetanus Toxoid is at least 1 month,
more preferably, the duration of ty is at least 2 months, still more preferably, the duration
of immunity is at least 3 months, even more preferably, the duration of immunity is at least 4— 24
months, still more preferably, the on of ty is at least 6 —24 months, even more
preferably, the duration of immunity is at least 7—24 months, still more preferably, the duration of
ty is at least 8—24 months, even more preferably, the duration of immunity is at least 9—24
months, still more preferably, the duration of immunity is at least 10—24 , and most
preferably, the on of immunity is at least 12—24 months.
Preferably, the duration of immunity of at least 12 months further relates to any
combination of antigens forming the immunogenic composition of the t invention.
In one embodiment comprising an inactivated (or, alternatively live attenuated)
ERAV and/or ERBV as disclosed herein, the immunogenic composition ameliorates shedding of
infectious ERAV and/or ERBV to prevent spread of the virus to other susceptible animals. In
some embodiments the compositions prevent shedding of the virus.
In one embodiment comprising EIV and/or EHV antigen, as described above, the
immunogenic composition ameliorates shedding of infectious EIV or EHV to prevent spread of
the virus to other susceptible s.
In one embodiment, compositions in accordance with the present invention
described herein me interference from passively acquired maternal immunity and
stimulate active immunity and a reduction in the incidence of or severity of clinical signs of EIV
infection in vaccinated animals against EIV.
In one embodiment of the present invention, an immunogenic composition
comprising ERAV and/or ERBV, VEE, WEE, EEE, tetanus, WNV, equine rhinopneumonitis
and equine influenza, all as bed herein, demonstrates cy against ERAV, ERBV, VEE,
WEE, EEE, tetanus, WNV, equine rhinopneumonitis and equine za after administration in
accordance with the present invention. Preferably, such a composition will further include an
adjuvant, preferably HRA—S, mineral oil and/or a carbomer, and a pharmaceutically acceptable
carrier. In preferred forms, the composition will be stered in a single, 1 mL dose. In
some embodiments composition is administered in two doses or preferably three doses, with
each dose separated by 1, 2, 3, and 4 weeks.
Each of the immunogenic compositions described herein that include ERAV,
particularly ERAV/ON/OS (ATCC Accessions NO: PTA—11828) and other strains as bed
supra, and/or ERBV, particularly a ERBV strain having ATCC Accession NO: PTA—11829, or
others as also described supra, can be administered as described such that they reduce the
incidence of or lessen the severity of clinical symptoms associated with ERAV and/or ERBV,
such as pyrexia, elevations in temperature, increased lung sounds, lymphadenopathy, nasal
discharge, ocular discharge, pharyngitis, edema of legs, cough, and in the case of ERAV,
increased incidence of abortion in nt mares. In some aspects, the compositions lessen the
amount or length of nasal or ocular discharge or the length of time that such ms are
presented. In some aspects, animals inoculated with the compositions show no clinical
symptoms of ERAV and/or ERBV infection one week or longer after exposure to ERAV and/or
ERBV. In other aspects, animals inoculated with the compositions show no clinical symptoms
of ERAV and/or ERBV infection when d to ERAV and/or ERBV. al symptoms of
ERAV and ERBV may be scored such as according to Table 3 in e 2, Table 14 in
Example 4, or Table 17 in Example 5.
Each of the immunogenic compositions described herein that include EIV n
or inactivated EIV and can be administered as described such that they reduce the incidence of or
lessen the severity of clinical symptoms associated with Equine Influenza Virus.
The t invention also provides a method for reducing the incidence of or
lessening the severity of clinical symptoms associated with Equine Herpes Virus comprising the
step of administering any one of the immunogenic compositions described above containing
EHV antigen or inactivated or attenuated EHV to an animal.
The present invention also es a method for reducing the incidence of clinical
symptoms associated with West Nile Virus comprising the step of administering any one of the
immunogenic compositions that includes WNV antigen or inactivated or attenuated WNV, as
described herein, to an animal.
The present invention also provides a method for ng the incidence of clinical
symptoms associated with Equine Influenza Virus comprising the step of administering any one
of the immunogenic itions described above, that includes an EIV antigen or inactivated
or attenuated EIV, to an animal.
The present invention further provides a method for reducing the incidence of
clinical symptoms associated with Equine Herpes Virus comprising the step of administering any
one of the immunogenic compositions described above that es an EHV antigen or
inactivated or attenuated EHV, to an animal.
The present invention provides a method of reducing the incidence of viral infection
in a herd comprising the step of administering any one of the genic compositions
described above to an animal, wherein the reduction of nce of infection, ed to herds
not receiving the immunogenic composition, is from about 10% to about 50% reduction. In one
embodiment the compositions provided herein reduce ERAV infection by 10% to 50%. In other
embodiments the compositions provided herein reduce ERBV ion by 10% to 50%.
The present invention also provides a method of reducing the incidence of clinical
symptoms ated with Equine Influenza Virus comprising the step of administering any one
of the genic compositions described above to an animal, wherein the reduction in clinical
signs, compared to animals not receiving the immunogenic ition, is at least a 10%
reduction in clinical signs.
The t invention es a method of reducing the incidence and severity of
clinical symptoms of ERAV or ERBV in a herd, wherein the clinical symptoms are selected from
the group consisting of pyrexia, elevations in temperature, increased lung sounds,
lymphadenopathy, nasal discharge, ocular discharge, pharyngitis, cough, edema of legs, and in
the case of ERAV, increased incidence of abortion in pregnant mares.
The present invention es a method of reducing the incidence and severity of
al symptoms of EHV in a herd, wherein the al symptoms are ed from the group
consisting of respiratory disease, abortion, reproductive complications, ogical disease,
central nervous system e, and combinations thereof.
The present invention es a method for reducing the incidence of or lessening
the severity of clinical symptoms associated with Equine Herpes Virus comprising the step of
stering any one of the immunogenic compositions disclosed herein, that includes an EHV
antigen or inactivated or ated EHV, to an animal.
The present invention provides a method for reducing the incidence of or lessening
the severity of clinical ms associated with Equine Influenza Virus in a herd, comprising
the step of administering any one of the immunogenic compositions disclosed herein, that
includes an EIV antigen or inactivated or attenuated EIV, to an animal.
The present invention provides a method for reducing the incidence of or lessening
the severity of clinical symptoms associated with West Nile Virus in a herd, comprising the step
of administering any one of the immunogenic compositions sed herein, that includes a
WNV antigen or inactivated or attenuated WNV, to an animal.
The present invention provides a method for reducing the incidence of or lessening
the severity of clinical symptoms associated with Eastern Equine Encephalomyelitis in a herd,
comprising the step of administering any one of the immunogenic compositions disclosed herein
that includes an EEE virus antigen or an inactivated or attenuated EEE Virus, to an animal.
The present invention further provides a method for reducing the incidence of or
lessening the severity of clinical symptoms associated with Western Equine Encephalomyelitis
in a herd, sing the step of administering any one of the immunogenic itions
disclosed , that includes a WEE virus antigen or an inactivated or attenuated WEE virus, to
an animal.
The present invention further es a method for reducing the incidence of or
lessening the severity of clinical symptoms associated with Venezuelan Equine
Encephalomyelitis in a herd, comprising the step of administering any one of the immunogenic
compositions disclosed herein, that includes a VEE virus antigen or an inactivated attenuated
VEE virus, to an animal.
The aforementioned embodiments may be used in a combination therapy or as part
of a immunization schedule in combination with other genic agents and vaccines. In one
embodiment, the compositions provided herein are used in combination with the immunogenic
agents and vaccines bed in , which is incorporated herein by nce in
its entirety.
The present invention also provides a method of making any one of the
immunogenic composition as described above and herein, comprising the steps of combining an
inactivated or live, attenuated ERAV or ERBV with a suitable pharmaceutical carrier. In
preferred forms, this method further comprises the step of adding one or more equine antigens or
inactivated or attenuated s. A red group of equine antigens and viruses are ed
from the group consisting of West Nile Virus, Western Equine alomyelitis, Eastern
Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, EHV, and EIV, and tetanus
toxoid, and combinations thereof. In some preferred forms, the methods described herein can
further comprise a filtration step, wherein the final product is in a more pure form.
“About” refers to i10% of the specified quantity.
“Animals” as used herein includes domesticated animals including dogs and
hooved animals including equidae, and specifically, horses. In some embodiments, the term also
refers to a human.
“Adjuvants” as used , can include aluminum hydroxide and aluminum
phosphate, saponins e.g., Quil A, QS-Zl (Cambridge Biotech Inc., dge MA), GPI—OlOO
(Galenica ceuticals, Inc., Birmingham, AL), tabolizable oil, mineral and/or
plant/vegetable and/or animal oils, polymers, carbomers, tants, natural organic compounds,
plant extracts, carbohydrates, cholesterol, lipids, water-in-oil emulsion, oil-in-water emulsion,
water-in-oil-in-water emulsion, HRA-3 (acrylic acid saccharide cross-linked polymer), HRA-3
with cottonseed oil (CSO), or preferably HRA—S (acrylic acid polyol linked polymer). The
emulsion can be based in particular on light liquid paraffin oil (European copeia type);
isoprenoid oil such as squalane or squalene; oil resulting from the oligomerization of alkenes, in
ular of isobutene or decene; esters of acids or of alcohols ning a linear alkyl group,
more particularly plant oils, ethyl oleate, propylene glycol di—(caprylate/caprate), yl tri—
(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in
particular isostearic acid esters. The oil is used in combination with emulsifiers to form the
emulsion. The emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of
mannide (e.g. anhydromannitol oleate), of glycol, of polyglycerol, of propylene glycol and of
oleic, isostearic, ricinoleic or hydroxystearic acid, which are optionally ethoxylated, and
polyoxypropylene—polyoxyethylene copolymer , in particular the Pluronic products,
especially L121. See Hunter et al., The Theory and Practical Application of Adjuvants
(Ed.Stewart—Tull, D. E. S.) John Wiley and Sons, NY, 4 (1995) and Todd et al., Vaccine
:564—570 (1997). In a preferred ment the adjuvant is at a concentration of about 0.01 to
about 50%, preferably at a concentration of about 2% to 30%, more preferably at a concentration
of about 5% to about 25%, still more ably at a concentration of about 7% to about 22%,
and most preferably at a concentration of about 10% to about 20% by volume of the final
product.
As used herein, “a pharmaceutically acceptable carrier” or “pharmaceutical carrier”
includes any and all excipients, solvents, growth media, dispersion media, coatings, adjuvants,
izing , diluents, preservatives, inactivating agents, antimicrobial, antibacterial and
antifungal agents, isotonic agents, adsorption delaying agents, and the like. Such ients
include those that are safe and appropriate for use in veterinary applications. In some preferred
embodiments, and especially those that include lyophilized immunogenic compositions,
stabilizing agents for use in the present invention e stabilizers for lization or freeze—
drying.
“Diluents” can include water, saline, dextrose, ethanol, glycerol, and the like.
Isotonic agents can e sodium de, dextrose, mannitol, sorbitol, and lactose, among
others. Stabilizers include albumin and alkali salts of ethylendiamintetracetic acid, among others.
In a preferred embodiment, the immunogenic composition of the present invention
is prepared comprising a preservative and a stabilizer; and, more preferably, the immunogenic
ition of the present invention is prepared comprising Amphotericin, formaldehyde,
gentamycin, EDTA, glycerol, and combinations thereof.
An “immunogenic or immunological composition” refers to a composition of
matter that comprises at least one antigen, which elicits an immunological response in the host of
a cellular and/or antibody-mediated immune response to the composition or vaccine of interest.
Usually, an “immunological se” es but is not limited to one or more of the following
effects: the production or activation of antibodies, B cells, helper T cells, suppressor T cells,
and/or cytotoxic T cells and/or gamma—delta T cells, directed specifically to an n or
antigens included in the composition or vaccine of interest. Preferably, the host will display
either a therapeutic or protective immunological response such that ance to new infection
will be enhanced and/or the clinical severity of the disease d. Such protection will be
demonstrated by either a reduction or lack of clinical signs normally displayed by an infected
host, a quicker recovery time and/or a lowered duration or bacterial titer in the tissues or body
fluids or ions of the infected host.
The term “in need of such administration” or “in need of such administration
treatment,” as used herein means that the administration/treatment is associated with the boosting
or improvement in health or any other positive medicinal effect on health of the animals which
receive the genic composition in accordance with the present invention, such as reducing
the incidence or ty of a viral infection or disease.
“Equine rhinitis A virus (ERAV)” refers to an Aphthovims in the family
aviridae, and was previously known as Equine rhinovirus l. “ERAV” as used herein
includes inactivated forms. In one embodiment, the ERAV is strain ERAV/ON/OS having
ion number PTA-11829 deposited on April 14, 2011 with the ATCC (American Type
e Collection, PO. Box 1549 Manassas, VA 20108 USA) in accordance with the Budapest
Treaty, and that was recovered from Rabbit-kidney-13 (RK-13) cell culture from a nasal swab
from a horse in Ontario Canada in 2005. The ERAV/ON/OS when reverse transcribed and
sequenced has SEQ ID NO: 1 in its 5’ UTR region.
The reverse ribed genomic sequence of ERAV/ON/OS is SEQ ID NO:2.
The polyprotein encoded by the genomic sequence of ERAV/ON/05 is SEQ ID
NO:3.
The ERAV strains useful in the immunogenic compositions of the invention have
reverse transcribed 5’UTR nucleotide sequences that have greater than 85%, 90%, 95%, 98%,
99% or 100% sequence identity to SEQ ID NO:1. In some embodiments, the ERAV strains have
genomic ces that when reverse transcribed into DNA are greater than 85%, 90%, 95%,
98%, 99% or 100% identical to SEQ ID NO:2 or have polyprotein coding sequences that are
more than 97%, 98%, 99%, or 100% identical to the polyprotein coding sequence in SEQ ID
NO:2. In some embodiments, the ERAV have polyproteins with an amino acid sequence greater
than 95%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:3 or to the VP1 ce
within SEQ ID NO:3. In yet other embodiments, the ERAV has an L protein, VP2, VP3, VP4,
VPO, 2A, 2B, 2C, 3A, 3B, 3C or 3D, that have an amino acid sequence with r than 80%,
greater than 90%, greater than 99%, or 100% identity to the same protein found in SEQ ID
NO:3. All of the ERAV strains are, when not inactivated or attenuated, infective and able to
ate in host cells.
e rhinitis B virus (ERBV)” refers to an Erbovirus in the family
Picornaviridae, and was previously known as Equine rhinovirus 2. “ERBV” as used herein
es inactivated forms. In one embodiment, the ERBV is a strain deposited with the ATCC
that was recovered from Rabbit—kidney—l3 (RK—l3) cell culture from a nasal swab from a horse
in Ontario Canada (ATCC Accession NO: PTA—11828) that was deposited with the ATCC
(American Type Culture Collection, PO. Box 1549 Manassas, VA 20108 USA) on April 14,
2011 under the Budapest Treaty. The ERBV strains useful in the immunogenic compositions of
the invention have c sequences that when e transcribed into DNA are greater than
85%, 90%, 95%, 98%, 99% or 100% identical to the reverse transcript of the genomic sequence
of the ERBV strain having ATCC Accession No. PTA-11829, or have polyprotein coding
sequences that are more than 97%, 98%, 99%, or 100% identical to the polyprotein coding
sequence of the ERBV strain having ATCC Accession No. PTA—11829. In some embodiments,
the ERBV strains useful in the invention have polyproteins with an amino acid sequence greater
than 95%, 95%, 97%, 98%, 99%, or 100% cal to the polyprotein sequence of the ERBV
strain having ATCC Accession No. PTA—11829. In yet other embodiments, the ERBV has an L
n, VP4. VPZ. V1333, Vl’l. 2A, 2.8, ’2 T, 3A (Vpg). 38, 3Cpro, 3?le that have an amino acid
sequence with greater than 80%, greater than 90%, greater than 99%, or 100% identity to the
same protein found in the ERBV strain having ATCC Accession No. PTA—11829. All of the
ERBV strains are, when not inactivated or attenuated, infective and able to replicate in host cells.
The term “West Nile Virus” antigen means, but is not limited to the components of
the WNV virion that are genic when present in an animal, and most particularly protein
components, such as envelope and ructural proteins, of the WNV that e humoral or
cellular immune responses When present in an animal. Such antigens can include DNA, protein
subunits, modified live virus, and inactivated Virus. In preferred forms of the ion, the
WNV antigen or antigens comprise inactivated or killed, and even more preferably, North
American dominant, WNV strains.
The term “North American West Nile Virus ns)” refers to, but is not limited to
any West Nile Virus strain that has ever been discovered on the North American continent.
Preferably, a North American West Nile Virus strain has a sequence identity to the NY99 strain
(GenBank accession no. AF196835 or NCBI reference sequence NC_00942.1 of at least 97%,
even more preferably, at least 98%, still more preferably, at least 98.5%, more preferably, at least
99%, even more preferably, at least 99.2%, and, most preferably of at least 99.4%. WN02 is a
representative example of a WNV strain that can be referred to as a North American Dominant
West Nile Virus strain. Specifically, North American nt strains are those having at least
1 nucleotide change resulting in an amino acid change from the WN99 isolates. Strain NY99
(GenBank accession no. AF196835) serves as a reference strain for ining if a strain is
North American Dominant. In addition, these strains may have one or more silent amino acid
changes. In some embodiments, the nucleotide change results in an amino acid change in an
envelope protein of the strain and, more ably, the tide change results in an amino
acid change from valine to alanine. ably, this amino acid change is associated with a
greater ability to replicate in the intermediate host, , the mosquito. More preferably,
North American Dominant strains include either (and preferably both) a U to C mutation and a C
to U mutation at positions 1442 and 2466 (in comparison to a North American strain, e. g., NY
99), respectively. Still more preferably, North American Dominant strains further include a
mutation in the nucleotide sequence encoding the E n and the C to U mutation at position
9352 in the sequence encoding the NSS protein (again in comparison to a North American ,
e.g., NY 99). These preferred mutations are shown in Phylogenetic is of North American
West Nile Virus Isolates, 2001-2004: Evidence For the Emergence of a Dominant Genotype, C.
Todd Davis, et. al, Virology 342, p. 252-265 (2005), the teaching and content of which is hereby
incorporated by reference. West Nile Virus strains, for purposes of the present invention, are
not limited to horse and equine West Nile Virus strains but encompass, while not being limited
to, those West Nile Virus strains of bird origin, donkey origin, pig origin, human origin, mammal
origin, and equine origin.
“Sequence Identity” as it is known in the art refers to a onship between two or
more polypeptide sequences or two or more polynucleotide sequences, namely a reference
sequence and a given sequence to be compared with the reference sequence. Sequence identity
is determined by comparing the given sequence to the reference sequence after the sequences
have been optimally aligned to produce the highest degree of sequence similarity, as ined
by the match between strings of such sequences. Upon such ent, sequence identity is
ascertained on a position—by—position basis, e.g., the sequences are “identical” at a ular
position if at that position, the nucleotides or amino acid residues are identical. The total number
of such position ties is then divided by the total number of nucleotides or residues in the
reference sequence to give % ce identity. Sequence identity can be readily calculated by
known methods, including but not limited to, those described in Computational lar
Biology, Lesk, A. N., ed., Oxford University Press, New York (1988), Biocomputing:
Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York (1993);
er Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H. G., eds., Humana
Press, New Jersey (1994); Sequence is in Molecular Biology, von Heinge, G., Academic
Press (1987); Sequence Analysis Primer, Gribskov, M. and ux, J ., eds., M. Stockton
Press, New York (1991); and o, H., and Lipman, D., SIAM J. Applied Math., 48: 1073
(1988), the teachings of which are incorporated herein by reference. Preferred methods to
ine the ce identity are designed to give the largest match between the sequences
tested. Methods to determine sequence identity are codified in publicly available computer
programs which determine sequence identity between given sequences. Examples of such
programs include, but are not limited to, the GCG program e (Devereux, J ., et al., Nucleic
Acids Research, 12(1):387 (1984)), BLASTP, BLASTN and FASTA (Altschul, S. F. et al., J.
Molec. Biol, 215 :403-410 (1990). The BLASTX program is publicly available from NCBI and
other sources (BLAST Manual, Altschul, S. et al., NCVI NLM NIH Bethesda, MD 20894,
ul, S. F. et al., J. Molec. Biol, 215:403-410 (1990), the ngs of which are
incorporated herein by reference). These programs optimally align sequences using default gap
weights in order to produce the highest level of sequence identity between the given and
reference sequences. As an illustration, by a polynucleotide having a nucleotide sequence
having at least, for example, 85%, preferably 90%, even more preferably 95% nce
identity” to a reference nucleotide sequence, it is intended that the nucleotide sequence of the
given polynucleotide is identical to the reference sequence except that the given polynucleotide
sequence may include up to 15, preferably up to 10, even more preferably up to 5 point
ons per each 100 nucleotides of the reference nucleotide sequence. In other words, in a
polynucleotide having a nucleotide ce having at least 85%, preferably 90%, even more
preferably 95% identity relative to the reference nucleotide sequence, up to 15%, preferably
%, even more preferably 5% of the tides in the reference sequence may be deleted or
tuted with r nucleotide, or a number of tides up to 15%, preferably 10%, even
more preferably 5% of the total nucleotides in the reference sequence may be inserted into the
reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal
positions of the reference tide sequence or anywhere n those terminal positions,
interspersed either individually among nucleotides in the reference sequence or in one or more
contiguous groups within the reference ce. Analogously, by a polypeptide having a given
amino acid sequence having at least, for example, 85%, preferably 90%, even more preferably
95% sequence identity to a reference amino acid sequence, it is intended that the given amino
acid sequence of the polypeptide is identical to the nce sequence except that the given
polypeptide sequence may include up to 15, preferably up to 10, even more preferably up to 5
amino acid alterations per each 100 amino acids of the reference amino acid sequence. In other
words, to obtain a given polypeptide sequence having at least 85%, preferably 90%, even more
preferably 95% sequence identity with a reference amino acid sequence, up to 15%, ably
up to 10%, even more preferably up to 5% of the amino acid residues in the reference sequence
may be deleted or substituted with another amino acid, or a number of amino acids up to 15%,
ably up to 10%, even more ably up to 5% of the total number of amino acid residues
in the reference sequence may be inserted into the reference sequence. These alterations of the
reference sequence may occur at the amino or the carboxy al positions of the reference
amino acid sequence or anywhere between those terminal positions, interspersed either
individually among es in the reference ce or in the one or more contiguous groups
within the reference sequence. Preferably, residue positions which are not identical differ by
conservative amino acid substitutions. However, conservative substitutions are not included as a
match when determining sequence identity. In the present disclosure, it is understood that SEQ
ID NO:1 (5’ UTR) and SEQ ID NO:2 are the DNA sequences that result from reverse
transcription of the 5’ UTR and the entire genome of ERAV/ON/05, respectively. Likewise,
SEQ ID NO: 3 refers to the amino acid sequence corresponding to the polyprotein encoded by
the genomic sequence of ERAV/ON/05. Percent identity of a given ERAV strain in comparison
to SEQ ID NO:1 or SEQ ID NO:2 is thus meant to refer to the corresponding DNA ce
ing from reverse transcription and sequencing.
“TCID50” refers to tissue culture infective dose ing 50% of cells in a culture
inoculated with the virus.
For purposes of the present invention the terms “strain” and “isolate” have the same
g and are used interchangeably.
“Clinical signs” or “clinical symptoms” for ERAV and ERBV e but are not
limited to pyrexia, elevation in temperature, increased lung sounds, lymphadenopathy, nasal
rge, ocular rge, and cough, and pharyngitis. Still other signs or symptoms include
anemia, anorexia, lymphadenitis of the head and neck, edema of the legs, lethargy, and pain.
Additionally, clinical signs of ERAV and/or ERBV infections may include those associated with
Equine Herpes virus and Equine Influenza virus. In one embodiment the clinical signs for
ERAV include cough, pharyngitis, pyrexia, elevations in temperature, increased submandibular
lymph node size, nasal discharge, and ocular discharge. In n embodiments, the clinical
signs of ERAV include an increased incidence of abortion in pregnant mares. In another
ment the clinical signs to be addressed by an immunological composition disclosed
herein are those of respiratory ions, such as those cause by one or more of ERAV, ERBV,
EIV, EHV-l, and EHV-4.
“Clinical signs” or “clinical symptoms” of West Nile Virus, for purposes of this
invention, include, but are not limited to, symptoms or lesions associated with encephalitis,
Viremia, anorexia, depression, fever, weakness, abnormal gait, sis of hind limbs, impaired
vision, ataxia, aimless wandering, convulsions, inability to swallow, coma, posterior weakness,
paralysis, poor coordination, depression and related behavior, tremors, convulsions, paddling of
the limbs, neurological problems, swelling of the central nervous system, death, and
combinations f. The al signs exhibited by an infected animal vary depending on the
ty of infection.
“Clinical Signs” or “clinical symptoms” of Equine Herpes virus, for purposes of
this invention e, but are not limited to, abortion, neurological encies, respiratory
disease, reproductive system encies and failure, and symptoms relating to the central
nervous system. Additionally, clinical symptoms of EHVl include, but are not limited to, the
enon of foals infected with EHVl, exhibiting atory complications, passing the virus
to the older members of the herd who then exhibit uctive deficiencies, including abortion,
and neurological deficiencies, normally exhibited in the central nervous system.
“Clinical Signs” or “clinical symptoms” of Eastern Equine Encephalomyelitis,
Western Equine Encephalomyelitis, and Venezuelan Equine alomyelitis, for purposes of
the present invention are those symptoms normally known to be associated with
encephalomyelitis, including, but are not limited to fever, nervous signs such as sensitivity to
sound, periods of excitement, and restlessness, brain lesions, drowsiness, drooping ears, circling,
abnormal gait, paralysis, loss of appetite, depression, head pressing, lack of coordination, long-
term disability, brain damage, death, and combinations thereof. “Safety” as used herein, refers to
the absence of adverse consequences in the vaccinated animal following vaccination, including
but not limited to, potential reversion of e virus to virulence and clinically significant side
effects, such as persistent systemic illness or unacceptable inflammation at the site of vaccine
administration.
“Reduction of the incidence and/or severity of clinical signs” or “reduction in the
incidence and/or severity of clinical symptoms,” as referred to herein, means reducing the
number of infected animals in a group, reducing or eliminating the number of animals exhibiting
al signs of infection, or reducing the severity of any al signs that are present in the
animals, in comparison to ype infection. For example, such clinical signs included
Viremia, fever, dy response, ocular discharge, nasal discharge, and histopathology.
Preferably, these are reduced in animals receiving the composition of the present invention by at
least 10% in comparison to animals not receiving the vaccination which may become infected.
More preferably, clinical signs are reduced in animals receiving the composition of the present
invention by at least 20%, more ably by at least 30%, even more preferably by at least
40%, and even more preferably by at least 50%.
“Duration of Immunity,” as used herein, refers to the m number of days
during which an animal produces an immunogenic response such that the animal will be
vely immune from contracting a Virus and/or benefit from reduction of incidence and/or
severity of al signs, as described herein.
The term “inactivated” and “inactivated virus” refers to a previously virulent Virus
that has been heated or chemically treated to inactivate, kill, or otherwise modify the Virus to
substantially eliminate its virulent properties while retaining its immunogenicity. In a preferred
embodiment, the inactivated Viruses disclosed herein are inactivated by treatment with an
inactivating agent. Suitable inactivating agents include beta—propiolactone, binary
ethyleneimine, aldenyde, and formaldehyde. In some ments, the inactivating agent
is formaldehyde.
The terms ne” and ogenic composition”, when used herein, are meant
to be used interchangeably.
Any West Nile Virus strain(s) or isolate(s) can be used in accordance with the
present invention. In a preferred embodiment, the isolate is selected from one or more of the
following: New York (Northeastern North American) Isolate (WN—NY 99), Horse Origin, 1999,
New York (Northeastern North American) Isolate (WN—NY 99), Crow Origin, 1999, United
States Department of Agricultures Isolate 292206 (USDA 2004), Donkey Origin, United States
Department of Agriculture Isolate 405330 (USDA 2005), Horse Origin, North American e
(WN—Texas—2002/2003), Southeast Texas Coastal Isolate 2002, Mexico (Tabasco) Isolate 2003,
and combinations thereof, and in a more preferred embodiment the isolate is ed from one or
more of the following: United States Department of Agricultures Isolate 292206 (USDA 2004),
Donkey Origin, United States Department of Agriculture Isolate 405330 (USDA 2005), Horse
Origin, North American Isolate (WN—Texas—2002/2003), Southeast Texas Coastal Isolate 2002,
Mexico (Tabasco) Isolate 2003, and combinations thereof. In a most preferred embodiment, the
isolate is United States Department of Agriculture Isolate 405330 (USDA 2005), Horse Origin
singularly or in ation with one or more isolates as listed above. In an additionally
preferred embodiment, those isolates which are part of the North an West Nile Virus
isolates are included. In yet another preferred embodiment North American Dominant West Nile
Virus isolates are included. In on to those listed above, specific isolates include, but are
not limited to, WN02 and isolates which have at least 1, preferably at least 2, and even more
preferably at least 3 nucleotide s resulting in at least one amino acid change from the WN
NY99 isolates, and most red are s with the amino acid change from valine to alanine
at position 159 of the envelope protein. Most preferred North American Dominant strains
include, but are not limited to: NY2002Nassau, NY2002Clinton, NY2002Queens, GA20021,
GA20022, TX20021, TX20022, IN2002, NY2003Albany, NY2003Suffolk, NY2003Chatauqua,
CO20031, CO20032, , TX2003Harris4, TX2003Harris6, TX2003Harris7,
TX2003Harris10, AZ2004, and TX2004Harris4, and combinations thereof. The strains of West
Nile Virus useful in the vaccine or immunogenic composition of the present invention can be any
strain or isolate. In a red embodiment, the North American Dominant West Nile Virus
strain used is either E-159 (Horse Origin) or E-159 (Donkey Origin). A representative strain of
such a North American Dominant WNV strain includes the Horse Origin 2005 strain ted
with the ATCC (ATCC Accession NO: PTA—9409), located at 10801 University Boulevard,
Manassas, VA, 20110—2209, on August 14, 2008, under the provisions of the Budapest Treaty.
Equine Influenza strains useful in the e or immunogenic ition of the present
invention can be any strain or isolate. Representative strains e Equi—2/Ohio/03, deposited
as ATCC Accession NO: PTA—9522, Equi—2/Kentucky/95, deposited as ATCC Accession NO:
PTA—9523, and Equi—2/New Market/2/93, deposited as ATCC Accession NO: PTA—9524.
Representative strains ATCC Accession Nos. PTA—9522, PTA—9523, and PTA—9524 were each
deposited with the ATCC at 10801 University ard, Manassas, VA, 20110—2209 on
September 23, 2008, under the provisions of the Budapest Treaty.
Equine Herpes Virus (“EHV”) strains useful in the vaccine or immunogenic
composition of the present invention can be any strain or isolate. Representative strains e
EHV Subtype l, deposited as ATCC Accession NO: PTA—9525, and EHV Subtype 4, deposited
as ATCC Accession NO: PTA—9526. Representative strains ATCC Accession Nos. PTA—9525
and PTA—9526 were each deposited with the ATCC at 10801 University Boulevard, Manassas,
VA, 20110—2209 on ber 23, 2008, under the provisions of the Budapest Treaty.
n Equine Encephalomyelitis strains useful in the vaccine or immunogenic
composition of the present invention can be any strain or isolate. A entative strain includes
the Fleming Strain, deposited with the ATCC (ATCC Accession NO: PTA—9410), d at
10801 University Boulevard, Manassas, VA, 20110—2209, on August 14, 2008, under the
provisions of the Budapest Treaty.
Venezuelan Equine Encephalomyelitis strains useful in the e or immunogenic
composition of the present invention can be any strain or isolate. A entative strain includes
the TC—83 , deposited with the ATCC (ATCC Accession NO: 11), located at 10801
University Boulevard, Manassas, VA, 20110—2209, on August 14, 2008, under the provisions of
the Budapest Treaty.
Eastern Equine Encephalomyelitis strains useful in the vaccine or immunogenic
composition of the present invention can be any strain or isolate. A representative strain includes
the NJO strain, deposited with the ATCC (ATCC Accession NO: PTA-9412), located at 10801
University Boulevard, Manassas, VA, 20110-2209, on August 14, 2008, under the provisions of
the Budapest Treaty.
Tetanus toxoid strains useful in the vaccine or immunogenic composition of the
present ion can be any strain or isolate. A representative strain is that taken from a master
seed of Clostridium tetani from The Massachusetts ment of Public Health Institute of
Laboratories in Boston, Massachusetts.
The vaccine or immunogenic composition as disclosed herein is safe for
administration in ERAV or ERBV susceptible species, particularly equidae, at any age. In a
preferred embodiment, the present invention is safe for administration to foals 12 months of age
or older, more preferably, it is safe for administration to foals 10 months of age or older, more
ably, it is safe for administration to foals 8 months or older, more preferably, it is safe for
administration to foals 6 months of age or older, more preferably, is safe for administration to
foals 4 months of age or older, more preferably, it is safe for administration to foals 2 months of
age or older, more preferably, it is safe for administration to foals 1 month of age or older, even
more preferably, it is safe for administration to foals between 1 day and 1 month of age, and,
most ably, it is safe for administration to foals 1 day of age or older.
The compositions as disclosed herein can be administered in any conventional
manner. Examples of administration methods include any that afford access by cells of the
immune system to the immunogenic ition including oral, transdermal/intradermal,
intravenous, subcutaneous, intramuscular, intraocular, intraperitoneal, ectal, intravaginal,
intranasal, astrical, racheal, ulmonarial, or any combination thereof. In a
preferred embodiment, the vaccine is administered parenterally, preferably intranasally,
subcutaneously, or intramuscularly, and in the most preferred embodiment the vaccine is
administered intramuscularly.
In one embodiment, provided is a method for preparing and immunogenic
composition comprising an ERAV and/or ERAB as disclosed herein. In one embodiment, the
method comprises:
a) infecting a susceptible cell line with ERAV or ERBV;
b) g the infected cell line in growth media until a cytopathic effect (CPE) is attained;
c) harvesting the media;
d) filtering the media to yield a filtered media; and
e) contacting the filtered media with an inactivating agent to obtain the inactivated ERAV or
ERBV.
In one embodiment, the method comprises providing strain ERAV/ON/OS or a
ERBV strain having ATCC Accession NO: PTA—11829. These strains are used to infect a
susceptible cell line having advantageous growth and secretion properties useful for vaccine
preparation. A preferred susceptible cell line is a Vero cell line such as a Vero76 or an E-Vero
cell line.
Suitable growth media e E199. This media may be supplemented with L—
glutamine solution and an antibiotic such as gentamicin sulfate solution. In some embodiments
the growth media is E199 supplemented with L—glutamine solution (up to 2 mM), and
gentamicin sulfate solution (up to 30 ug/mL). In some ments, viral fluids are harvested
when the thic effect CPE reaches 75% or r. The harvested media are pooled and
filtered such as through 5.0 micron pore—size rated opylene filter cartridges. The strains
are inactivated chemically such as by treatment with 01—02% formaldehyde solution over a
suitable period of time, for example 48 hours to 72 hours and the resulting fluids are
concentrated. In some embodiments, preservatives and adjuvants are next added. Suitable
preservatives include one or more of ericin B, gentamicin sulfate, and formaldehyde. In
other embodiments the adjuvant is HRA—S. In still other embodiments the adjuvant is HRA—3
with cottonseed oil (C80).
In one embodiment and in accordance with the methods disclosed herein, provided
is an immunogenic composition comprising ERAV/ON/05 and/or a ERBV strain having ATCC
Accession NO: 829 and Amphotericin B, gentamicin e, formaldehyde, and HRA—S
prepared according to the methods disclosed herein.
Examples
The following examples are set forth below to illustrate specific embodiments of
the present ion. These examples are merely illustrative and are understood not to limit the
scope or the ying principles of the present invention.
Example 1
This example illustrates one embodiment of a Equine Rhinitis A Virus composition
in accordance with the present invention.
Materials and Methods
Equine Rhinitis A Virus strain ERAV/ON/05 (ATCC Accession No. PTA-11828)
was recovered from Rabbit-kidney-l3 ) cell e from a nasal swab from a horse in
Ontario Canada. The virus was passaged once on E-Vero cells to produce a high pre-titered
master stock, and was then diluted with cell culture media to produce the Master Seed Virus.
Master Cell Stock is an E—Vero cell line grown and maintained using E199 mented with L—
Glutamine solution (up to 2 mM) and Gentamicin sulfate solution (up to 30 ug/mL). Inactivated
ERAV/ON/05 was produced according to the following l procedure.
Frozen Master Cell Stock is thawed at room temperature °C) and used to
inoculate a range of pre—sterilized T—25 cm2 up to T—150 cm2 flasks or pre—sterilized 850 cm2 or
1050 cm2 PETG roller bottles. Thawed cells are suspended in growth medium at the rate of 0.15
to 0.40 mL per cmz. Cells are incubated at 36—38°C for up to seven days. Cultures planted from
frozen stock may be re—fed with medium to remove residual Dimethyl Sulfoxide (DMSO), to
remove excessive debris, to stimulate the growth of cultures which have not reached confluency,
or to maintain viability of nt cultures. Cells are passaged by decanting the spent medium
and adding 1—10 mL (depending on the size of the vessel), of 25% trypsin—EDTA solution to
each vessel. The vessels are agitated gently until the cells slough from the surface. The cells are
removed from the vessels by rinsing with growth medium and pooled er. The range of cell
culture passages is one to .
Prior to inoculation, cell growth medium is decanted from cells that are at least 90%
confluent. The cell sheet is rinsed with 20-50 mL of virus infection media (E199 supplemented
with L-Glutamine solution (up to 2 mM) and Gentamicin sulfate solution (up to 30 , then
re—fed with virus infection media at the rate of 0.15 to 0.40 mL/cmz. Vessels are then ated
at a Multiplicity of Infection (MOI) of 0.0005 to 0.005. Roller bottle cultures are incubated at
36—38°C for two to five days at 0.2—0.4 rpm.
During the growth period, cultures are checked for CPE microscopically and for
gross contamination macroscopically. Unsuitable cultures are discarded after sterilization.
Virus fluids are harvested when CPE reaches 75% or greater. Roller s are
swirled to remove loose cells, and fluids are pooled into sterile 2—20 L glass, plastic, or PETG
bottles, 20 L sterile polypropylene containers or 2—200 L sterile stainless steel tanks appropriate
for clarification. Pooled fluids may be held for up to seven days at 2-80C prior to clarification.
Only fluids from monolayer es showing evidence of viral ion are
harvested. Bottles ting contamination are discarded. A sample of pooled, clarified fluids
is collected before inactivation for titration by TCID50. Fluids with a titer of 106'2 TCIDso/mL or
greater may be used in the preparation of final product. Multiple lots can be blended to achieve
the minimum titers.
Harvested lots are ied by filtration using 5.0 micron pore—size rated
polypropylene filter cartridges. Post—clarified harvest lots may be stored for up to seven days at
2—8°C. Clarified fluids are then inactivated with formaldehyde solution, USP, 01—02% by
volume, transferred to a secondary ner, and held at room temperature (18—26°C) with
agitation for a minimum of 48 to 72 hours. A sample of inactivated fluids is taken for
inactivation nce testing prior to concentration. Inactivated lot material is held at 2—8°C
prior to concentration. Clarified, inactivated virus fluids are concentrated by a factor of 5X to
50X using tangential flow ultra—filtration membrane cartridges with molecular weight cut—off
ratings of not more than 10,000 Dalton MW.
A number of suitable adjuvants may be added to the vaccine formulation, most
preferably HRA—5. Other adjuvants include HRA—3 with cottonseed oil (CSO). Typical
processing steps may be employed such as mixing, blending, microfluidization, and
emulsification, of the adjuvant and/or the harvested virus antigens with other ingredients.
The product is then assembled to final formulation. In a batching method in one
exemplary ment, the required amounts of adjuvant and MEME Diluent are combined in a
sterile container and the pH is adjusted to approximately 7 with Sodium Hydroxide.
ERAV, gentamicin sulfate, formaldehyde, and Amphotericin B are added one at a time during
constant mixing. The pH is ed to 6.8—7.0 with sodium hydroxide or hydrochloric acid and
the serial is mixed for a minimum of 18 hours at 2—8°C. The completed bulk serial is then
transferred to a suitable storage container and stored at 2—8°C. Amphotericin B may be added at
a concentration of up to 2.5 ug/mL of the diluent volume as a preservative. Gentamicin sulfate is
added at a concentration of up to 30 ug/mL of the diluent volume as a preservative
dehyde is added at a concentration of 0.1% of the diluent volume as a preservative. An
adjuvant such as HRA-S is added at a concentration of 10% v/v of the final serial volume.
The vaccine is given by typical hypodermic injection, with booster vaccinations if
desired.
This investigation was carried out to obtain an cy evaluation of a Equine
Rhinitis A Virus vaccine to protect horses from challenge With Equine Rhinitis A Virus.
Materials and Methods
A high dose A—9 (107-5 TCID50/mL) and low dose A—10 (107-0 TCID50/mL) ERAV
vaccine were prepared according to Example 1.
Table l: A—9 e formulation (1 mL):
N/OS 107- TCIDso/mL
HRA-S 100 uL
t, MEM-E+ containing Gentamicin, q.s.
ug/mL of diluent volume and
Formaldehyde, 0.1% of diluent volume
Table 2: A—10 1 vaccine formulation (1 mL):
ERAV/ON/OS 107“O TCIDSO/mL
HRA-5 100 uL
Diluent, MEM-E+ containing Gentamicin q..
ug/mL of diluent volume and
Formaldehyde, 0.1% of diluent volume
A V—05 placebo 1 mL formulation was prepared as in the A—9 and A—lO vaccines
but without the ERAV/ON/05 antigen.
A total of 44 horses were randomly divided into one of three treatment groups
ting of a 15 horse V-05 placebo control group, a 14 horse A—10 se group, and a 15
horse A—9 high-dose group. Horses were vaccinated with a 1 mL dose product adjuvanted with
HRA-5 for three total doses, with a 21 day interval in between doses. Horses were subsequently
challenged 21 days after the third vaccination by intranasal aerosolization with a 107‘0
TCID50/mL nebulized Rhinitis A dose over a four minute period. Horses were evaluated for
clinical signs of signs of ature, nasal exudate, ocular discharge daily. Blood for serum
neutralization (SN) was taken weekly.
Challenge Virus
The challenge virus was produced in tissue culture on E—Vero cells. The titer of the
challenge virus was determined to be 1 x 106'9 TCIDso/mL on the day of challenge. Challenge
virus was diluted on the morning of challenge 1: 10 with tissue culture media to effect a titer of l
x 105-9 TCID50/mL.
Intranasal Challenge Method
Sedivet® (romifidine hydrochloride), a sedative and analgesic, was administered
intravenously to each horse prior to challenge at a dosage of 50 [Lg/kg of body . Each
horse was then challenged with imately 106‘2 TCID50 of equine is A virus. The
challenge virus was administered intranasally as an aerosol produced by a nebulizer into an
Equine AeroMask (Trudell Medical ational, Ontario, Canada) by the following method.
Four milliliters of 105‘9 /mL challenge virus were placed into the nebulizer
cup in the AeroMask . A pressure hose was fitted from an air compressor to the inlet port
of the nebulizer. The outlet tube was then inserted into the Aero Mask attached to the head of the
horse being challenged and approximately 10 psi of air re was applied to the inlet port for
three minutes. During this time approximately two milliliters of challenge Virus fluid was
aerosolized directly into the nostrils of the horse being challenged.
Serum Neutralization
A standard microtiter serum neutralization test was employed in this study. A
standard microtiter serum neutralization test was employed in this study. All sera were tested in
sterile flat bottom microtiter plates using five wells per dilution and an 8 well dilution series for
each of the 5 test wells. Each of the 5 test wells contained 25 ul of serum dilution mixed with 25
pl of the indicator virus and 150 pl of a freshly planted eVero cell suspension containing
approximately 5 X 104 cells. The test indicator virus used was either Equine Rhinitis Virus Type
I. Serum neutralizing antibody titers are expressed as Reed—Muench ID50 titers.
For performance of the test, two—fold dilutions of each test serum was made in a
sterile flat bottom microtiter plate using five replicate wells per test serum and an 8 well dilution
series. Dilutions were made with an able volume single or multi—channel pipeting
instrument using e microtiter tips. The volume of serum added each of 5 wells of the first
row was 50 Ml. All other wells contained 25 ul of DMEM (no FBS). ing serial dilution
down the plate, 25 ml was ded from the last row. 25 pl of a pre—determined dilution of the
indicator Virus was added to each test well. Plates were then mixed and incubated for one hour
at 37°C in 5% C02. On conclusion of the incubation period, 150 ul of a suspension containing 4
x 106 /mL eVero cells was added to each test and cell control well. The plates were incubated at
37° C in a C02 tor for 5 days, at which time plates were microscopically examined for
CPE typical of equine rhinitis virus.
Nasal Exudate Evaluation
All nasal e observations were made prior to collection of nasopharyngeal
swabs. On the Day of Challenge and for 10 days hallenge, the nasal passages and muzzle
of each of the 44 vaccinated and control horses were ed and graded using the grading and
scoring description listed below.
The scoring grades of 0 through 6 were assigned on the basis of the severity of the
disease indicated by each of the following classification:
Table 3: Scoring Grades
Score Descri tion of s mtoms
Essentially normal indicates the horse was clean and ially
free of nasal exudate
Slight clear serous discharge that may be frequently observed in
both diseased and normal horses
Very slight mucopurulent discharge indicates that mucus was
definitely present in small s in either one or both nostrils
Moderate clear serous discharge is indicative of a definite
increase in volume over that normally observed
Slightly mucopurulent is a discharge easily observed in one or
both nostrils
Copious clear serous discharge that is generally observed only in
diseased horses
Moderately mucopurulent indicates that mucoid discharges were
present in large quantities in both nostrils
Heavy mucopurulent indicates that copious amounts of a mucoid
rge filled both nostrils
Ocular tion
Ocular discharge was evaluated daily at the time of nasal exudate tion.
Ocular discharge scores were recorded as 0=normal; l=mild to moderate ocular discharge, and
2=severe ocular discharge.
Nasopharyngeal Viral Isolation
On each observation test day each nasal passage of each vaccinated and control
horse was swabbed deeply by means of a sterile WECK-CELTM surgical spear (Edward Weck
and Company, Inc., Research Triangle Park, NC. 27709) attached to an ll—inch long e
c pipette. On collection, each of two surgical spears was immediately placed in a single
tube containing 4 mL of chilled transport medium (E—l99 supplemented with gentamicin, L—
glutamine, 2X Pen/Strep, 2X Amphotericin B).
For isolation of virus, the tubes were mixed, the swabs aseptically removed, and the
medium centrifuged at 1500 rpm for 10 to 15 minutes to remove particulates. Medium was
ed through a 0.2 ML syringe filter prior to inoculation on tissue culture cells. After filtration,
4—6% of e 85% sucrose solution was added to each sample for freezing at —80°C in order for
all samples to be tested concurrently.
For ion of virus, the tubes were mixed, the swabs aseptically removed, and the
medium centrifuged at 1500 rpm for 10 minutes to remove particulates. Medium was filtered
through a 0.2 ML syringe filter prior to inoculation on tissue culture cells. One mL of the clarified
transport medium was used to inoculate a 2 cm2 two day old monolayer of E—Vero cells grown in
a 24 well tissue culture plate from which the growth medium had been aseptically removed.
Following ation, the inoculum was allowed to adsorb on the cell monolayer for one hour at
37°C in a humidified tor containing a 5% C02 atmosphere. After the adsorption period, an
additional 1 mL of re—feed medium (E—199 containing 7% fetal bovine serum (FBS), 2mM L—
glutamine, Gentamicin 2X Pen—Strep and 2X Amphotericin B) was added to each well.
Following addition of re—feed media the plates were then incubated at 37°C in a C02 incubator.
Each test and l tissue culture well was examined microscopically for 7 days for signs of
cytopathic effect (CPE) typical of the ERAV challenge virus. Wells that were negative at the end
of the 7 day observation period were subcultured onto fresh cells and observed for an additional
7 days.
STATISTICAL EVALUATION METHODS
Data from all horses vaccinated with either A—9 or A—10 were combined for
tical evaluation. The influence of vaccination on the duration of disease (number of days
with nasal scores> 0) was evaluated using the Kruskal-Wallis and Hodges—Lehmann test (the
NPARlWAY procedure in SAS, SAS Institute, Cary NC). ty of disease was ted by
comparing the maximum disease status between the vaccinated horses and the control horses.
Nasal scores were dichotomized to g 1.5 and> 1.5 based on the distribution of outcomes. The
prevented fraction (PF) and 95% confidence als (CI) were estimated. Ocular scores were
evaluated as present or absent and the prevented fraction and 95% confidence intervals were
estimated (the FREQ procedure in SAS). Repeated es analysis appropriate for continuous
data was used to assess the effect of vaccination on body temperature and serum neutralization
titers (the MIXED procedure in SAS). The proportion of horses which were virus positive over
time and buffy coat positive over time was evaluated using Fisher's exact test at each time point
(the Freq procedure). Nasal and ocular scores were ed by Wilcoxon's rank sum test at each
time point (the NPARlWAY procedure).
Results and Conclusions
VIRUS ISOLATION FROM NASAL SWABS (Virus Shedding) and BUFFY COATS
(Viremia)
The proportion of animals which were virus positive was significantly lower in the
vaccinated groups on days 2 through 7 (Table 4 below and Figure 1) as compared to control
group (P<0.05).
Table 4. Proportion of nasal swab virus positive over time (* P<0.05 versus control, Fisher’s
Exact test on each day)
Day Control A—9 A—10 A-9 + A-lO
0 0 0 0 0
1 25 7.1 7.7 7.4
2 100 20* 231* 21.4*
3 100 467* 57.1* 51.7*
4 100 60* 57.1* 58.6*
93.3 53.3* 35.7* 448*
6 60 40 0* 20.7*
7 100 46.7* 78.6 62.1*
8 26.7 13.3 0 13.8
9 0 6.7 0 3.5
0 6.7 0 3.5
11 0 0 0 0
12 0 0 0 0
13 0 0 0 0
14 0 0 0 0
Buffy coat positive animals were less frequent in the ated group on days 4—7
as compared to the l group (Table 5 below and Figure 2).
Table 5: Proportion of Buffy Coat positive over time (* P<0.05 versus control, Fisher’s Exact
test on each day)
4 73.3 35*
80 39*
6 8O 35*
7 33.3 0*
8 o 3.5
9 o 0
1o 0 0
11 o o
12 o o
13 o o
14 o 3-5
Serum Neutralization
Table 6: Summary of body temperature and serum neutralization
P-Values
——-E-Vaccine * Da
Temoerature 0.9269 < 0.0001 0.0255
SN titer In transformed < 0.0001 < 00001 < 0.0001
Mean body temperature values (rectal temperature measured with ated GSA
Electronics meter probe) on each challenge day were always within normal body
temperature parameters. Large increases in SN titers resulting from vaccination were found (see
also Fig. 3) following challenge.
Nasal And Ocular Evaluation
Mean ranks for nasal scores were lower on days 4 though 10 and days 12—13 in the
vaccinated group compared to the l group (Table 7 below and Figure 4). The mean ranks
for ocular scores were lower on day 7 in the vaccinated group as compared to the control group
(see also Figure 5).
Table 7: Mean rank for nasal and ocular score across time (*P<0.05 versus control; Wilcoxon’s
rank sum test on each day, A-9 and A-lO combined).
__A-9+A-10 A-9+A-10
Disease Duration: Nasal Exudate Evaluation
Table 8: Summary of the effect of vaccination on the duration of disease (Number of days with
nasal score > 0)
Group Minimum 25th quantile 50Lh quantile 75th quantile Maximum
Control 8 9 10 l l l 3
Vaccinated 0 1 3 9 l 3
Table 9: Effect of ation on the duration of disease (nasal scores; >“significantly lower than
control group by l—Wallis test P<0.05)
Control Vaccinate Shift in days 95% confidence interval
Duration 10 3 7* 3, 8 days
Long duration of nasal rge in controls was found following challenge (Table
8, see also Figure 4). Vaccinated group showed a significant reduction in duration of nasal
discharge. Controls experienced a minimum of 8 days of nasal discharge vs 11 vaccinates (38%)
with 1 day or less. Two thirds of vaccinates had r duration of nasal discharge than the
minimum of 8 days in the control group. Duration was from first to last abnormal observation,
even if horse had normal days in between. The number of days animals were sick with al
signs of atory disease (nasal score > 0) was significantly shorter (shift of 7 days) in the
vaccinated group ed to the control group.
Table 10: Maximum Nasal Scores —Signif1cant difference between the two distributions of
scores (Kruskal—Wallis test, P = 0.0157).
Grouo Maximum Nasal Score
_I-I-Imn
13 10
Vaccinated 4 14% 2 7% 45% 34%
Table 11: Nasal scores (3 1.5 and > 1.5)
Group % with score P-value Prevented Fraction 95% confidence
interval
Control 66.7% < 0.0588 0.48 0.042
Vaccinate 34.5% 0.72
Vaccination also reduced severity of nasal discharge (maximum score on any day
post—challenge). Maximum nasal scores were compared n groups (Table 10). The
m nasal score for horses in the control group was 1.5. Results were thus dichotomized to
scores 3 1.5 and > 1.5 for the evaluation of disease severity (Table 11). The prevented on
was 48% with a lower confidence limit greater than 0. The overall bution of maximum
nasal scores was significantly reduced by vaccination al—Wallis test, P=0.0157).
Ocular Evaluation
Table 12: Ocular scores (present or absent)
Group % with score P—value Prevented Fraction 95% confidence
interval
Control 66.7% < 0.0001 0.897 0.587
Vaccinate 6.9% 0.9741
Since only two values were reported for ocular scores (0 or 2), results were
dichotomized to present or absent within an individual. The prevented fraction was then used to
evaluate the effect of vaccination on the presence of ocular signs. The vaccine significantly
d the severity of ocular discharge resulting from infection with ERAV. Mean ocular
scores over time are also shown in Figure 5.
Data from this study demonstrate that administration of intramuscular doses of the
inactivated Virus is capable of immunizing an animal to high levels of antibody detection which
prevent ocular disease and reduce severity and duration of nasal discharge. Vaccine was highly
effective in preventing any ocular discharge following ERAV challenge. Nasal discharge
persisted for a relatively long period hallenge, while ocular rge peaked and abated
quickly. Hence the vaccine showed a significant improvement in nasal discharge for a prolonged
period (9 of 10 consecutive days), whereas vaccine significantly reduced ocular discharge for 1
day during which ocular signs were most severe. In addition, vaccination significantly reduced
nasal virus shedding throughout the successive six days of peak viral shedding, and viremia also
was significantly reduced during the four day of peak viremia within the challenge period.
No unacceptable adverse reactions either at the injection sites or by manifestation of
signs of ic illness were observed. The vaccine is safe and well tolerated for stration
in Equine rhinitis A susceptible species, particularly equidae. This study thus demonstrates that
3 x 1 mL intramuscular ions of the ERAV compositions of the example significantly
reduced severity and duration of atory disease caused by ERAV virulent challenge.
Example 3
This example illustrates sequencing and analytical studies carried out on an Equine
is A Virus strain as disclosed herein.
Cells And Virus
Rabbit—kidney—l3 (RK—l3) cells (passages 100—160) were grown in Dulbbeco’s
modified eagles medium nutrient mixture F12 HAM (DMEM F12) (Sigma—Aldrich Canada Ltd.
Oakville, Ontario) with 2—5% fetal bovine serum (FBS) (Sigma). Cell growth and viral
propagation were performed in a C02 (5%) incubator at 37 0C. The ERAV isolate N/OS
was propagated in RK—l3 cells and aliquots were stored at —70 0C for later work. RK—l3
yers were inoculated at 90% confluence and RNA was ted before cytopathic effects
(CPE) was observed.
Virus Titration And Plague Purification
RK—l3 cells were grown on 3 cm round dishes, using DMEM F12 with 2% fetal
calf serum. Cells were infected at 90% confluence and plates were ted at 37 0C for 72
hours. After 24 hours, the medium was replaced and a 0.7 % agarose layer was added. Plaques
were counted and recorded every 24 hours. At 72 hours the agarose layer was removed and
plaques were d with crystal violet and counted.
For plaque purification RK—l3 cells were infected with ERAV/ON/OS, adsorption
was allowed for 45 minutes and the inoculum was removed and replaced with a 0.7 % agarose
layer. Plates were checked every 12 hours and plaques were classified as small, medium and
large. Five s of each size were selected, picked into 300 uL of DMEM F12, and frozen at
-70 OC. Viruses from each plaque size were ated in RK-13 cells and RNA was extracted
from the small and large plaques for genome sequencing of the 5’ UTR.
Viral Growth Kinetics
To study the growth characteristics of this strain, RK—l3 cells were infected with
ERAV/ON/OS and supernatant samples were collected at s times for titration. RK—l3 cells
were grown on 3 cm individual round plates and infected at 90% confluence. Plates were
incubated at 37 OC and atant samples were taken every 4 hours starting at 0 hours for a
period of 28 hours. All samples were titrated using the plaque forming unit (PFU) que as
previously described here.
Immunofluorescence
RK—l3 cells were grown on glass tissue culture chamber/slides (Miles Scientific,
Inc., Naperville, Illinois), and inoculated with ERAV/ON/05. Twenty eight hours post—infection,
the cell culture medium was removed and cells were fixed in acetone. The slides were kept at 4
0C until processing. Sera from experimentally infected horses were used as a source of ERAV
antibodies.
Rna Extraction And Sequencing
RNA was extracted from infected cell yers. Cells were treated with 1 mL of
TRIzol (Invitrogen) 18-20 hours post-infection and extraction was performed according to
manufacture’s endations. RNA pellets were eluted in 30 uL of RNAse free water and
kept at —70 0C for later use. First strand cDNA was synthesized using superscript lI (Invitrogen)
following manufacturer’s recommendations. A SOuL PCR reaction was carried out using a set of
sense and antisense primers. For genome sequencing, the primer walking approach was used,
and primers were designed based on eight ERAV sequences available on GenBank. PCR
conditions were: 4 minutes at 94 OC, followed by 30 cycles of 30 s at 94 0C, 30 seconds at
55 OC and 30 seconds at 72 0C with a final ion at 72 0C for l0 s.
Sequencing of the 5’ and 3’ ends were ted with the 5’ RACE and 3’ RACE
kits (Invitrogen) as recommended by the manufacturer. Several nested PCRs were required to
amplify the 5’ UTR end.
Seguence Analysis
The preliminary identification of the virus was completed by partial sequencing of
the structural protein VPl using primers designed based on other sequences available on
GenBank.
Table 13: Primers used to amplify some of the ERAV s.
NAME PRIMER SEQUENCE SEQ ID NO: GENOMIC SITE
foerP1 last 5’ to aataoocaa o onccttt 3’ 3087
revVP1 last 5’ acctttaaaa act ocaca 3’ 3671
foerC112 5’ gtcagtaaaacgcaacaaccat 3’ 1 12
foerC805 5’ tgtgaagaatgtcctgaaggca 3’ 805
749 5’ accatccacctaaaccao am a 3’ 1749
foerC5217 5’ atto ooocttttca ooottt aa 3’
revPC5952 5’ gtttctaactttgggacccgaa 3’ 10 5952
foerC6915 5’ tggatttgagattggttctgca 3’ 1 1 6915
revPC7511 5’ gcgaacgaaactgaggattg 3’ 12 7511
All primers were designed on Gene Runner version 3.05 (Hastings Software Inc.).
Sequencing reactions were set and run by the Laboratory Services Division at the sity of
Guelph.
All sequences were assembled and edited with EditSeq and SeqMan DNASTAR
Lasergene 8 (DNASTAR Inc., Madison, WI, USA). Sequencing results were entered into the
BLAST software [National Center for Biotechnology Information, Bethesda, MD (NCBI)] and
compared to similar entries on GenBank. ClustalW2 [European Bioinformatics ute, Dublin,
Ireland (EBI)] was used for le sequence alignment and preliminary construction of the
phylogenetic tree. The final phylogenetic tree was d on MEGA 4.0 by using the Maximum
Composite Likelihood method and the reliability was evaluated by bootstrapping with 1000
replications. Analysis of the nucleotide sequences were d on t n 3.5.1
(Baltimore, MD, USA). In order to investigate the possibility of viral recombination between
ERAV isolates, we completed a Bootscan analysis on SimPlot (Version 3.5.1) comparing the
genomic sequences of all reported ERAV available on GenBank. Polyprotein cleavage sites
were predicted based on sequences reported on GenBank with accession numbers: DQ272578
and NC003982.
Results
Initial Characterization
The viral protein (VPl) of the virus was amplified, partially sequenced and
compared to sequences available on GenBank sion numbers: NC003982, DQ272577,
DQ272128, DQ272127, DQ268580, DQ272578, ). Results from this initial comparison
demonstrated a maximum identity of 95% to Equine rhinitis A Virus VPl.
Virus Titration
The ERAV isolate was initially propagated in cell e and ed by the plaque
g unit method. The stock virus titre obtained was 5X107 PFU on the initial titration.
uent experiments showed no dramatic s in viral titre after 3 years of initial
freezing. For animal experiments the stock virus with the initial titre was employed.
GROWTH KINETICS
All supernatant samples were titrated using the PFU technique and results were
entered on a spread sheet to construct a growth curve. As seen in other picornaviruses, the
Ontario isolate showed an increased titre at 4 hours post—infection, reaching a plateau by 12
hours post—infection.
Immunofluorescence
Infected RK-13 cells were visualised under the immunofluorescence microscope.
Bright green fluorescence signals were detected in the cytoplasm of ERAV infected cells
compared to negative signals on mock infected cells.
Plague Purification
Sequencing of a 426 tide fragment in the 5’ UTR on the small and large
plaques showed no difference n plaque sizes at the nucleotide level. However,
morphological characteristics were evidently different on RK—13 cell cultures.
Full Genome Seguencing
Genome sequencing of the ERAV isolate resulted in 7839 nucleotides in length
with a GC content of 47% including the poly (A) tail. Four cal repeats
(CTGTAGCGTCAGTAAAACGC SEQ ID NO: 13) separated by 18, 21 and 18 nucleotides
were identified on the 5’ UTR. The ERAV 5’ UTR was composed of 940 nucleotide with a
54% GC content. A single polyprotein with 6747 nucleotides (2248 amino acids) composes the
viral genome with a 46.8% GC content. The protein starting sis was detected on
nucleotide 940 with the AUG start codon and the ending on nucleotide 7686 with the UAA stop
codon. Of great interest, a second AUG sequence was identified following the initiation codon.
A subsequent AUGAUG sequence was also identified 58—nucleotides downstream from the
polyprotein start codon. Analysis with Blastx (NCBI) of the polyprotein on this isolate showed a
96% nucleotide identity with respect to other ERAV reported, however when the full—length
genome sequence of the Ontario isolate was aligned and compared to others using ClustalW2
(EBI) and BlastX (NCBI), only a maximum identity of 80 % was observed. The amino acid
composition showed an identical protein (structural and non structural) organization and length
along the entire genome. These comparisons were made with PERV—l and PERV reported
genome sequences (accession s DQ272578, and NC003982).
The 3’ UTR was composed of 110—nucleotides with a 24.3 % GC content, and a
poly—A tail. Alignments of the 5’ UTR of all ERAV available demonstrated a lower identity
percentage, g from 73% to 81%. Similarly, the 3’ UTR was analysed by the same method
and the ty percentage ranged from 75% to 81%. Interestingly, various ions (1-
tide, 2—nucleotides, and l3—nucleotides) and two small deletions (2—nucleotides, and 3—
nucleotides) in the 5’ UTR were identified (Fig. 4). No other major s were observed
throughout the entire genome.
Simplot Genome Analysis
t analysis showed a comparable similarity (percentage) among all ERAV
isolates when ed to ERAV/ON/OS. However, the mayor disparities were fied at
nucleotide 1500 (59% similarity) and nucleotide 4700 (65% similarity). Nevertheless, this
analysis showed that the similarity along the genome was between 70% and 82%. To further
investigate the major divergence in the genomes, a scan (Bootscan) to identify possible
ination sites was performed. These analyses demonstrated that the Ontario isolate has not
had predicted recombination sites with other ERAV isolates. heless, when the Ontario
isolate was removed from the analysis, possible recombination between other ERAV isolates
may have happened in the pass.
Discussion
ERAV is not routinely sought and recovered from clinical cases during equine
respiratory outbreaks. Therefore ERAV isolation from clinical cases has been incidental and in
most cases a challenge. For these reasons the recovery and sequencing rate of these viruses may
be small.
During previous years, equine rhinitis viruses were classified within the
Picornaviridae family, but were not clearly assigned to a ic genus. In 1996 Li and
coworkers (Li F, Browning GF, Studdert MJ, and Crabb BS. Equine irus l is more closely
related to foot—and—mouth disease virus than to other picornaviruses. Proc Natl Acad Sci U S A.
1996 6; 93:990—995) demonstrated that ERAV was closely related to foot and mouth disease
virus (FMDV) based on the phylogenetic characteristics and nucleotide sequencing. In
agreement with their findings and others (Wutz G, Auer H, Nowotny N, Grosse B, Skern T and
er E. Equine rhinovirus serotypes 1 and 2: relationship to each other and to
aphthoviruses and cardioviruses. J Gen Virol 1996, 77:1719-1730) the ERAV e has been
found to be closely related to es L43052, DQ272578, and NC003982.
The ERAV/ON/05 isolate resulted in 7839 nucleotides including the 5’ UTR, the
polyprotein, 3’ UTR and the poly—A tail. In comparison to previously reported ERAV isolates,
the ERAV/ON/05 is one of the most complete ERAV sequences ed to date. Most of the
other ces lack some information either from the 5’ UTR or are partial sequences of
individual viral proteins. Data from the 5’ UTR revealed the presence of 3 repeats that have
been previously reported in other ERAV and commonly found on the FMDV. It has been
suggested that these repeats may be required in the formation of the ary structures found
in the 5’ UTR, the internal ribosome entry site (IRES). The ty is showed that the
ERAV/ON/05 isolate’s polyprotein bears a highly conserved nucleotide sequence. As an RNA
virus, the ERAV is prone to constant mutations due to the lack of proofreading by the
polymerase. This may indicate, that even though this RNA virus has been under natural
evolution and constant replication no significant genomic changes have been introduced since its
first genomic sequence was reported. It is evident that the structural and non structural ns,
which are encoded within the polyprotein, represent the most conserved regions in the genome.
Interestingly, the viral ation rate in cell culture was rapid and efficient. A
complete viral replication cycle was detected in less than 4 hours, reaching a plateau in 12 hours.
These characteristics are typical of picornaviruses and may reflect the viral activity in viva. Such
features might explain the severity and speed of clinical signs in some equine respiratory viral
infections. As observed in other viruses, such as irus and FMDV, the presence of small
deletions and/or insertions in the 5’UTR have been associated with differences in plaque size in
cell culture, and excel virulence in vivo. We found that the ERAV/ON/05 isolate generates
different plaque sizes when infecting RK—l3 cells. To investigate and correlate the presence of
these insertions and deletions in the 5’ UTR in the ERAV/ON/05 e, we sequenced this
region from plaque purified viruses from different plaque sizes, and found no discrepancy at the
nucleotide level. This finding may indicate that the plaque size difference may be due to a
growth and replication characteristic of the RK—l3 cells and perhaps not associated with the
ce or absence of the ces we found in this region.
Example 4
This e shows results of a study designed to develop a reliable ERAV
infection model for investigating the clinical characteristics of N/OS.
Materials and Methods
On the first phase a pony foal was infected with ERAV/ON/05 to adjust the
infectious dose and sampling collection techniques. A second pilot study was designed to
compare infected and control animals, and to master sampling techniques. The main infection
study was conducted in two phases due to animal ng and time sampling constraints. One
year after the first infection, four previously infected ponies were selected for a re—infection
study based on their titre to ERAV. Animals with an intermediate and a high titre to ERAV were
selected to be re-exposed to the Ontario isolate.
Experimental Animals
A total of 12 pregnant pony mares were selected and their foals were kept for the
experimental ERAV infection. All mares and foals were kept in a separate group away from the
main barn and biosecurity measurements were put into place to prevent Viral respiratory
infection. Blood samples from all foals were taken regularly and titers to ERAV were checked
ically. Foals were kept until they reached 12 months of age. These animals were not
vaccinated against any respiratory s during this period and general practices were
ined to ensure healthy living conditions. All animals were de—wormed according to the
herd management protocol. Animal ization and handling was performed regularly. Ponies
were trained for pulmonary function test (PFT). Once the animals were conditioned for the
experiments, they were transported in groups to the isolation unit and acclimatized for at least
one week prior to the Viral infection.
Isolation unit
All ion trials were conducted at the animal isolation unit in the Department of
Pathobiology, at the University of Guelph. This isolation unit contains dual stalls that are
equipped with controlled ature, ty, airflow, and lighting. Access to the stalls was
restricted to the researchers and care personnel.
Selection criteria
All foals were handled frequently, and health status was checked periodically.
Based on health status and serological parameters, animals to be included in these experiments
were chosen. At that time, all ponies remained seronegative to equine rhinitis A Virus ,
equine rhinitis B virus (ERBV), equine virus 1 and 4 (EHVl/4), and equine influenza 2
Virus (AE2). Even thought AE2 antibody titers were detected at birth, a steady decreased was
observed during the first 5 months and were not able by the single radial haemolysis test
(SRH) at six months of age. For the ERAV experimental infection trial, one pony was selected
to be used. Subsequently, two other ponies were selected for a second pilot study, and a group of
8 ponies (four infected and four controls) were selected for the main infection study. After a
year from the first infection trial, 4 ponies with intermediate and high titers to ERAV were
chosen for a re-infection trial.
ERAV isolate (ERAV/ON/05) recovered from a horse during an equine viral
respiratory outbreak in o 2005 was propagated in rabbit kidney—l3 cells (RK—l3) and
aliquots were stored at —70 0C for viral characterization and animal viral infection experiments.
, for inoculum preparation, the isolate was propagated in RK—l3 cells. 30
mL round dishes containing 90% confluent yers were infected with 500 uL of
ERAV/ON/05 and incubated in the presence of C02 (5%) at 37 0C for 24—36 hours. All dishes
were removed from the incubator and freeze/thawed four times to provoke cell rupture and viral
release from intact cells. Supematants from all dishes were pooled into one flask and centrifuged
at 6000 RPMS for 15 minutes to clarify and discard cell debris. The clarified supernatant was
tted in 10 mL vials to be used as an inoculum in the animal viral infection experiments.
Additionally, small 1 mL—aliquots were separated and kept for viral titration. The virus was
ed using the plaque forming unit method (PFU).
Animal model
Ponies were chosen as an animal model due to the nature of the experimental agent
(ERAV), animal size, availability and handling.
Infection protocol
Ponies between 8 and 12 months of age were selected, trained and used in the
infection experiments. Due to the large number of samples to be taken, these experiments were
divided in five sections (two pilot studies, two main infection experiments, and one re—infection
experiment). During the pilot studies, equipment, animal handling, inoculum dose, route of
stration, and sample collection were optimized. The re-infection study was conducted one
year after the initial infection trial. Ponies in the re—infected group were exposed to the same
viral strain at the same dose used during the first infection. Only clinical examination, blood
sampling for titers assessment and nasopharyngeal swabs for Virus isolation were collected from
this group.
Face mask and nebulization
For viral infection, a small size Equine AeroMaskTM was fitted with a rubber seal on
the nostril ending. Size was adjusted depending on the pony’s head and the breathing windows
were not modified. The mask was fitted with an inhaler connector and a one way “T” valve for
virus nebulization. Conventional 6 mL nebulizer cups were ed to deliver the inoculum.
Nebulization was performed using a PM14 compressor (Precision Medical Inc. Northampton,
PA) with a gas flow of 9 LPM (liters per minute). This flow rate and delivery cups allow for
consistent delivery of breathable particles of more or less 5 microns. Each pony was nebulized
for 45 min (taking a 5 minute break every 15 minutes) with 15 mL (total volume) of either
inoculum or o. A nasopharyngeal swab per pony was collected nfection to ensure
viability of the inoculum when delivered. Ponies that were re—infected a year latter were exposed
to the virus by the same protocol.
al examination
All ponies were clinically evaluated on a regular basis from birth. Prior to the pilot
and infection studies, all ponies were evaluated daily and during trial ments twice daily for
the first 10 days and once daily from day 11 up to day 21 nfection. Clinical examination
included: Body temperature (temp) (Celsius degrees), heart rate (hr), respiratory rate (rr),
capillary refill (ref), gastrointestinal ty (gi), lung sounds (ls), nasal discharge (nd), ocular
rge (od) [presence or absence and characteristics], lymph nodes (In) [size and
teristics], tion, and general physical condition. Physical examination was
performed at around the same times on each pony every day, commencing with the control
animals and moving onto the infected group. Approximately 10 minutes were spent on each
animal examination every time and all individual data were recorded on a daily check up form.
Pulmonary function test (PFT)
The PFT was carried out as usly described by Hare and coworkers (Hare JE,
Viel L. Pulmonary eosinophilia associated with sed airway responsiveness in young racing
horses. J Vet Intern Med 1998;12(3):163—?0). The test was performed on all control and infected
ponies prior to infection (day 0) and on days 1, 7, 14, and 21 post-infection. , on testing
day, ponies were off feed in the morning and were mildly sedated as previously described here
for endoscopy procedures. A rubber face mask was fashioned to snugly fit the ponies’ .
A pneumotachograp # 4 (Gould Electronics, Biltholven, The Netherlands) was attached to the
face mask, and connected to a set of transducers that t the flow and pressure signals into
breath loops that are recorded on a computer (Pulmonary Mechanics Analyzer, Buxco
onics Inc, Sharon, CT, USA). Flow was measure at the pneumotachograp level and the
pleural pressure was assessed by an esophageal balloon (10cm long) that was placed in the mid
thorax Via esophageal tubing. A total volume of 3ml of air were introduced into the balloon.
The pressure difference between the pleural pressure and the atmospheric pressure (measured at
the nostril level) was considered as the transpulmonary pressure (APpl).
Bronchoprovocation g
Bronchoprovocation challenge was carried out as part of the PFT testing. To
determine the hyperresponsiveness of the airways post ERAV/ON/OS infection, control and
infected animals were exposed to increasing histamine doses (doubling dose) by nebulization
with a PMl4 compressor with a gas flow of 9 LPM (Precision Medical Inc. Northampton, PA).
Pulmonary physiological parameters were assessed initially by administering 0.9% physiological
saline solution (base line), followed by increased histamine doses. After each administration (2
minutes) data was recorded for 3 s and respiratory physiology was later analyzed.
ine doses were started at 0.5 mg/ml and were increased gradually to a maximum of 32
mg/ml. Dynamic compliance (Cdyn) and APpl were used as parameters to discontinue ine
nebulization. When Cdy11 was decreased by two thirds or APpl was d during histamine
administration, nebulization was suspended. Histamine triggering dose was later plotted and
calculated. All ponies were mildly sedated and physically restrained during these procedures.
Sampling technigues
Blood collection
Blood samples were collected from either the right or left jugular vein.
Approximately 10 ml of blood were collected on a red top tube (serum) from each pony
according to the sample collection schedule. onally, 3 to 5 ml of blood were also collected
for CBC (complete blood count) and profile. All samples were collected in the morning hours
and processed within the same day.
Blood samples for serum separation were kept at room temperature for at least 30
minutes and then centrifuged at 3000 rpm on a table centrifuge. Serum was separated within 6
hours from the tion time and aliquots were labelled and frozen at —700 C for later analysis
(antibodies to ERAV, ERBV, AE2, and EHVl/4). Blood samples for CBC and profile were
sed within the same day.
Nasopharyngeal swabbing
Nasopharyngeal swabs were collected for virus ion on days previous to the
infection trial and on days 0, l, 3, 5, 7, 10, 12, l4, l7 and 21. Each pony was ined with a
muzzle twitch and a 30 cm long swab (Kalayjian Industries, Inc. Signal Hill, California) was
passed into either the right or left nostril until it reached the pharynx. Swabbing was performed
by ng the swab for about 5 to 10 seconds. The swab was removed carefully, and the tips
were cut off into a vial containing 3ml of virus transport medium (VTM). The vials containing
the swabs were shaken and kept on ice until processing. To release the viral les and cells
attached to the swabs, vials were vortexed for about 20 seconds and the medium was transfer to a
1.5 mL Eppendorf tube and frozen at -?0 0C for later analysis.
Urine and fecal sampling
Virus isolation was attempted on urine and fecal samples pre and post-infection
with ERAV/ON/OS. Urine was collected in the morning after al examination and/or stall
cleaning by holding a collection cup while the animals were urinating. When the sample could
not be collected by hand, the animal was fitted with a plastic collection bag around the genitals.
This bag was removed after the animal urinated and a 10 mL aliquot was saved for virus
isolation. Fecal samples were hand collected from fresh manure on the stall’s floor. About 5 mL
of manure were collected into a collection cup and 10 mL of e saline were added to ve
the sample. Urine and fecal samples were kept on ice until sed.
Upper and lower endoscopy
Bronchoscopy and BAL were performed as previously described (Hare et al.,
1998). A sterile flexible fiberoptic endoscope, 140 cm length with a 0.8 mm OD (Olympus,
Corp., Tokyo, Japan) was advance through the right or left nostril into the nasal cavity to the
larynx level. At this point the upper s conformation was evaluated. Followed, the
bronchoscope was advance into the trachea and the presence or absence of inflammation and/or
mucus and its teristics were recorded. Data were recorded on the daily evaluation sheet
and all the endoscopies were video recorded for later analysis.
Pharyngeal and al brush biopsies
In order to assess viral replication in the upper and lower airways, a brush biopsy
was taken from the pharynx, mid trachea, and the carina of infected and control animals on days
0, l, 3, 5, 7, 10, 14, and 21. During endoscopy examination, a 200 cm guarded (protective
sleeve) cytology brush (Hobbs l Inc. Connecticut) was e through the biopsy
channel at the predetermined sample location and a sample was collected. Brushes were
retracted into the protective sleeve and removed from the bronchoscope. To remove the sampled
tissue from the brush, this was put into 600 uL of VTM and vortexed for l0 to 20 seconds. All
samples were kept on ice and transported to the laboratory for further analysis (virus isolation).
Bronchoalveolar lavage [BAL]
Briefly, all ponies were mildly d with Romifidine (0.04 mg/kg, IV) and a
sterile 0.8 mm OD bronchoscope us, Corp., Tokyo, Japan) was advance through the
right or left nostril into the trachea to the carina level. As the bronchoscope was advanced, a
0.2% warmed lidocaine solution was administered to reduce cough and distress. Once the cough
reflex was reduced the bronchoscope was advanced and wedged into a proximal terminal
bronchus. A total of 250 mL of warmed sterile saline solution was administered h the
biopsy channel divided in two aliquots. BAL fluid was retrieved by manual suction with a 60 cc
syringe through the biopsy channel and placed on ice. The fluid was filtered and aliquots for
virus isolation, cell count, and cytospin slides were made.
Clinical samples culturing
Collected samples were transported on ice and frozen at —70 0C for later inoculation
on cell cultures.
RK-13 cells (passages 100-160) were grown in Dulbbeco’s modified eagles
medium nutrient mixture F12 HAM (DMEM F12) (Sigma—Aldrich Canada Ltd. le,
Ontario) with 2—5% fetal calf serum (Sigma). Cell growth and isolation were med in a C02
(5%) incubator at 37 OC. RK—l3 cells monolayers were grown on 6 well plates to a 90 %
confluence and infected with the clinical samples ted from the infection trial. In brief, 90%
of the growing medium was removed from each of the wells and 200 uL of the specimen to be
tested were added to the yer. Plates were put on the rocker platform for one hour and 3
mL of medium were added after the time elapsed. Plates were incubated and checked every 24
hours for cytopathogenic effects (CPE). If CPE was detected, the supernatant was removed from
the well and frozen for later analysis. Results from the virus isolation test were recorded on a
spread sheet. Plates were checked for up to 7 days and if CPE was not developed, a second
e was attempted using 200 uL of supernatant from the first passage. After a second
passage if CPE was not detected the sample was classified as negative. atant from
positive and negative samples was saved to be confirmed by reverse transcriptase polymerase
chain on RT—PCR).
tical analysis
Results from virus isolation and all clinical scores (Table 7) were entered on a
spread sheet.
Table 14. Scoring system for experimental infection with ERAV/ONOS.
Clinical sign Degree Score
Cough None 0
Intermittent l
Frequent 2
Mucus membranes Pink 0
Pale 1
Gastro intestinal Normal 0
auscultation
Abnormal 1
Feces/Urine Normal 0
Abnormal 1
Lung Sounds Normal 0
Slightly Increased 1
Marked Increased throughout 2
chest
Crackles and wheezes 3
Nasal Discharge None 0
Moderate/severe serous 1
Mucopurulent 2
Ocular Discharge None 0
Serous 1
purulent 2
Adenitis not palpable 0
le (<lcm) 1
Enlarged (>1 cm) 2
Anorexia None 0
Mild to te 1
Severe 2
Temperament Bright, alert and responsive 0
Dull (head down, 1
disinterested)
Perfusion Time Normal (2s) 0
3-4s 1
5s 2
Virus isolation results were categorized as positive or negative and results were
compared between groups. To determine if there was a statistical difference between locations
on virus isolation (in the infected group) an exact conditional logistic regression was used at each
day and site. The same test was used to determine if there was a statistical difference between
groups depending on the ion day. Clinical scores were summarized and the totals were
analysed and compared between .
A generalized linear mixed—model was employed to analyze all clinical parameters.
Factors included in the model were: pony, ent, and time as well as their interactions. Since
animals were measured over time, the AKAIKE information criterion (AIC) was used to
determine an error structure for the auto-regression. The assumptions of the ANOVA were
assessed by comprehensive residual analyses. A Shapro—Wilk test, a orov—Smirnov test,
a Cramer—von Mises test, and an Anderson—Darling test were ted to assess overall
normality. Residuals were plotted against predicted values and explanatory les (pony,
ent and time) to look for patterns that suggested outliers, l variance or other
problems. If residual analyses suggested a need for data transformation or data was presented as
a percent, analyses were done on a logit or log scale. If the overall f test was significant, a
Dunnetts test going back to baseline within a ent or a tukey test between treatments and
sites at each time was applied.
gical response was defined as a four fold increase in antibody levels from
baseline (day 0) to any of the time points in sampling collection (days 7, 14, or 21).
Statistical analysis was carried out on SAS 9.1.3 (SAS institute Inc., 2004, Cary, NC). Statistical
significance was set at P < 0.05.
Results
This study was designed to consistently reproduce ERAV clinical disease in ponies
and to study its in viva characteristics. Pilot studies demonstrated that nebulized ERAV/ON/OS
was able to cause clinical respiratory disease in healthy ponies (age 10—12 months). Mild
immunosuppression was induced in all ponies except in the ected animals to mimic natural
conditions under stressful events (e.g. movement for sales, field relocation, vaccination
programs, etc.). Results from the main infection study confirmed the results observed during the
pilot studies. Ponies in the ed group (n=4) developed respiratory clinical disease that
consisted with increased body temperature, lymphadenopathy, increased lung sounds, increased
tracheal mucus, and increased nasal discharge (Fig. 7—8). None of these clinical signs were
significantly extreme to require additional animal care or supportive treatment. Neither
respiratory rate, nor heart rate was significantly different between groups. None of the al
signs developed by the infected group were observed on the control s (n24), which
remained healthy throughout the extent of these trials. The etiological agent (ERAV) was only
recovered from ponies in the infected group for up to seven days (Table 8). Ponies in the re—
infected group (n=4) did not developed clinical respiratory signs and remained healthy
throughout the experiments. The statistical analysis of the data collected during these trials
demonstrated a significant difference between infected and control animals.
Table 15. Equine rhinitis A Virus (ERAV) shedding summary. Results of Virus isolation from
samples ted during the ERAV/ON/OS experimental infection.
Sample collection day
Sample location
x brush
biopsy
Mid trachea brush
biopsy
Carina brush biopsy
Plasma
Urine
+ Virus was red from clinical sample on cell culture (RK—l3 cells)
— Virus was not recovered from al sample
BAL Bronchoalveolar lavage
Neither depression, nor appetite lost was recorded in either group. As well
hydration, urination, defecation, and gastrointestinal movements remained unchanged on all
groups during the infection trials. There was no difference between re-infected and control
animals on the clinical scores and Virus isolation test, since no al disease was observed on
the re—infected animals and the Virus could not be recovered from this group.
Clinical findings
All ponies were considered to be y prior to these experiments. ERAV/ON/OS
exposure induced clinical respiratory e in infected animals compared to controls and re—
infected animals. The main clinical signs able by physical examination were pyrexia, nasal
discharge, and lymphadenopathy. opic examination also revealed the presence of large
volumes of mucus and emia in the mid a and lower airways of the infected animals.
Rectal temperature
No significant differences in daily rectal ature were found between groups
prior to Viral or placebo exposure. A significant treatment effect was identified when infected
animals were compared to controls and re—infected (p = 0.002). When the body temperature
from the three groups was compared at different times, the infected group was significantly
different compared to controls and re—infected animals ([9 = 0.028). Increased body temperature
was detected 24 hours post—infection only in the infected animals and was significantly different
from day 2.5 to day 6 when compared to control animals at the same time points ([9 2 <0.005).
The body temperature increase picked on day 4 with a mean body temperature of 38.450C
) (p = 0.001) and persisted for two more consecutive days (Fig. 8). No statistical
difference was found when body temperatures from control and re—infected groups were
compared at different times. Animals in the l and re—infected groups did not have a
significant change in their body’s temperature when comparing baseline to individual points in
time within the groups (days 1, 7, l4 and 21).
Lymph nodes
Submandibular and retropharyngeal lymph nodes were examined daily and
classified as non palpable, palpable and enlarge. Palpability or enlargement of the lymph nodes
was only recorded on the infected and re-infected animals. In all infected , the
submandibular area became sensitive to palpation on day two and in most cases persisted for up
to two weeks. The submandibular lymph nodes size in the infected animals varied from 3 to 5
cm in length by 2 to 3 cm in ess, and the analysis of the total scores demonstrated a
statistical ence between groups (p = <.0001) (Fig.7). Interestingly, the retropharyngeal
lymph nodes were not consistently palpable in all infected animals, but a significant change in
size was recorded in one pony. This lymphadenopathy did not appear to interfere with food or
water consumption and the sensitivity to palpation became less pronounce as the days
progressed. Submandibular lymph nodes were palpable in three animals from the re—infected
animals with an average size of less than one cm in length and 0.5 cm in thickness
approximately. Control s had no detectable lymph nodes changes at palpation throughout
the ion experiments.
Heart and atory rate
Respiratory rate (RR) and heart rate (HR) means were not significantly different
between treatment groups (P = 0.1) at any time points. In general RR and HR were within the
normal physiological parameters and small changes were only associated with handling and
sample collection. The highest RR mean among all groups was fied on day 0 and the
lowest mean from all the groups was recorded on day 21.
Endoscopic examination
On the endoscopic examination, infected animals had an increase amount of
tracheal mucus detectable on day one that persisted up to day 21. Neither the control nor the re—
infected animals had mucus secretions detectable at endoscopic examination throughout these
experiments.
Characteristics of the mucus varied from clear and serous on day one to mucoid on
days 7—21. Mucus patches were consistently distributed from the upper trachea to the bifurcation
of the carina. Localized tracheal hyperaemia was observed in all ed and in some control
animals throughout these experiments. The carina on all infected animals was blunted and in
some cases emic starting on day three. Sensitivity to endoscopic ation was
noticeably increased by day seven on infected animals and bronchoconstriction was observed
during BAL. Nasal discharge varied from mild to moderate in all infected ponies and was not
present in the control and re—infected . Serous nasal discharge was ed during
clinical examination for about 8 days on the ed animals starting n 36 and 48 hours
post—infection. However this discharge was not a reflection of the mucus (characteristics and
volume) observed during endoscopic ation. Mild ocular rge was observed
inconsistently in the infected animals.
Serology
A total of 12 ponies (age 10 to 12 months) were infected with ERAV/ON/OS or
placebo by nebulization. All ponies were serologically negative to ERAV, ERBV, AE2, and
EHV1/4 and in a healthy condition prior to the infection experiments. Following exposure to
ERAV/ON/OS all infected animals (100%) seroconverted (four fold increase) to ERAV
determined by the virus neutralization test (VN) (Fig. 9). A significant treatment by day
interaction was observed in infected animals (P = <0.0001). A statistical difference between
infected and re—infected animals was found on baseline and day 7 (P 2 <0.001). In the re—
infected group no statistical differences were found when titers to ERAV on days 7, 14, and 21
were compared back to baseline.
Antibody titers against ERAV were significantly elevated in infected animals from
day 7 and in most cases peaked by day 14 and maintained to day 21 (P 2 <0.001). In st,
all control animals remained seronegative to ERAV and no detectable changes were identified by
the VN test. s in all groups did not show an se in antibody levels or serological
conversion to any other atory viruses (ERBV, AE2, and EHV1/4) during these ments
(Fig. 9). Animals in the re—infected group (n=4) did not have a significant difference in antibody
titers to ERAV between baseline and day 21 post—infection. However, a small change in
antibody levels to ERAV was detected in 3 ponies and a four fold increase in one pony from the
same group (Fig. 9).
Virus Isolation
aryngeal swabbing, laryngeal brushing, tracheal brushing, BAL, fecal and
urine samples were negative for virus isolation (equine respiratory viruses) on all ponies prior to
infection (Table 8). Swabs obtained from the nasopharynx from infected and l animals
after completing nebulization were cultured on RK—13 cells and ERAV was recovered on a first
passage from all infected animals only. RT—PCR using primers that targeted the VP1 gene
confirmed the positive and negative diagnoses from both groups.
Virus isolation results from the infection and re—infection trials are summarized on
Table 8. A significant difference between infected, l and re—infected animals was
fied when comparing virus isolation between groups (P = < 0.05). ERAV was only
recovered from animals in the infected group on specific days and specific areas of the
respiratory tract (Table 8). No other viruses were recovered from samples collected during
theses experiments. All ponies in the control group were negative in the virus ion tests
throughout the study. A treatment by day interaction on infected animals was first detected on
day 7 and persisted on days 14 and 21 (P = < 0.05).
on for virus recovery varied from the lower airways on days 1, 3, and 5 to
mid and upper airways on days 1, 3, 5, and 7. On day one ERAV was isolated from the pharynx
and carina from all the ponies in the infected group and the mid trachea and BAL from 3 ponies
from the same group. All attempts for virus recovery from feces in all groups were unsuccessful.
Virus isolation from urine and plasma was achieved only in rare occasions (Table 8). Virus
ry was gradually decreased from day 1 up to day 7 when ERAV was consistently
red from al samples. This last viral recovery was associated with an increase in
antibody titre to ERAV and a decrease in the clinical signs scoring (Figs. 7 and 9).
Pulmonary function testing [PFT]
Hyperactivity of the airways was assessed based on the physiological and clinical
response to histamine provocation. Data from infected and control s were plotted and
triggering histamine doses were calculated. Interestingly, ponies from both groups (infected and
control) responded on day 0 to a low dose of histamine (<6 mg of histamine). Overall, the
triggering histamine doses did not go beyond 13 mg. The clinical histamine reaction (dose—
dependant) was ed as hyperventilation associated with abdominal lift and breathing
difficulty. The physiological reaction was detected in the PFT by a 35% drop in lung c
ance (Cdyn) or a doubling in the transpulmonary pressure (APpl) when comparing saline
and histamine administration. Ponies in the infected group showed a small reduction to the
histamine triggering dose from day 0 to day 1. However, this was not significantly different
n groups. A significant difference between infected and controls was detected on day 21
(P = 0.02).
BAL fluid differential cell counts
Differential cell counts were carried out on the cytospin slides prepared from BAL
fluid aliquots. No significant differences in the cell counts were found among horses in the
different treatment groups prior to the infection trial. No treatment by day effect was detected on
the macrophage and epithelial cells percentages throughout the experiments. A significant
increase in the number of neutrophils was observed on day 7 post-infection in the infected group
(P = <0.05). These numbers were not significantly different on the control or ected animals
when comparing base line to days 7‘, 14, and 21. The mean tages of lymphocytes,
eosinophils and mast cells were proportionally decreased on day 7 nfection in the infected
animals and a statistical difference was detected (P 2 <0.05). Ciliated epithelial cells were
ly observed on the slides from infected and control animals, however, no significant
differences were detected, except on one of the infected s that had a high count on day 7.
In general, a non—septic suppurative inflammation with the presence of epithelial cells and
ic giant cells was detected in the infected ponies. Interestingly, no major s in the
cytological examination were observed on the samples from the re—infected animals.
This study demonstrates that N/05 d clinical respiratory disease in
infected ponies. Serology demonstrated that no other respiratory viruses were present during
these trials. The disease is characterized by pyrexia, nasal discharge, increased lung sounds, and
increased submandibular lymph nodes size. Additionally, large volumes of mucus were
opically detected in the lower airways that persisted up to day 21. The virus was isolated
from the lower and upper airways up to day 7 corresponding with the ance of detectable
equine rhinitis A virus (ERAV) antibodies. None of the re—infected animals developed clinical
disease and only one pony from this group had a four fold increase in the antibody titers to
ERAV. Ponies with pre-existing ERAV antibodies did not develop clinical disease when
exposed to the virus.
Example 5
This example rates one embodiment of a Equine is B Virus composition
in accordance with the present invention.
Materials and Methods
Equine Rhinitis B Virus strain 07-10342 (ATCC Accession NoPTA—11829) was
red from Rabbit—kidney-l3 ) cell culture from a nasal swab from a horse in Ontario
Canada. Inactivated 07-10342 was produced following the general procedure described in
Example 1 for ERAV/ON/OS.
The following compositions containing ERBV alone or in combination with ERAV
were prepared.
Table 16. Vaccine Groups
Vaccine Group Vaccine Titers A fB Adjuvant Volume
1 (N=8) Monovalent B - High 7.5 HRA-S 200 mL
2 (N=8) lent B - High 7.5 HRA-3 with CS0 100 mL
3 (N=8) Monovalent B - Low 7.0 HRA-S 200 mL
4 Bivalent A and B - High 8.0 i 7.5 HRA-S 200 mL
Bivalent A and B — High 8.0 / 7.5 HRA-3 with C50 100 mL
Eight horses from each of vaccine groups 1, 2, and 3, were challenged along with
eight l horses with a 106‘6 TCID50 challenge dose. Disease status based on nasal discharge
and conjunctivitis scores as indicated in Table 10. Effect of vaccination on duration, severity,
and incidence of disease is shown in Tables 17—22.
Table 17. Disease status scoring
‘ Disease Status ‘ Nasal Score Conjunctivitis Score ‘
Normal (0) O or 1 0 or 1
Vaccinated group showed a icant reduction (Table 18) in duration of nasal
discharge including in some cases no signs of mild respiratory disease.
Table 18. Number of days with mild, moderate, or severe respiratory disease
Vaccine Group Minimum 25th quantile 50th quantile 75th quantile
Control (N:8) 1 ‘9Maximum
The number of days animals were sick with clinical signs of respiratory disease
(nasal score > 0) was significantly r in the ated group ed to the control group.
Table 19. Effect of vaccination on duration of disease
Control Vaccinate Shift in days 95% confidence interval
Duration vs Group 1 ‘ 8 ‘ 1* ‘ 1, 8 days
Duration vs Group 2 ‘ 8 ‘ 1* ‘ 0, 8 days
on vs Group 3 1, 7 days
*Significantly lower than the control group by Kruskal—Wallis test (P<0.05)
Immunization with ERBV also lessened the severity of the disease with a lower
percentage of vaccinates than controls demonstrating mild and moderate clinical signs of
respiratory disease throughout the study (Table 20).
Table 20. Summary of the severity of disease based on the m respiratory score
Vaccine Group ‘ Normal Mild ‘ Moderate
Control (N=8) ‘ 0% (0/8) 87.5% (7/8) t 12.5% (1/8)
1 (N=8) 37.5% (318) 50.0% (48) 12.5% (1/8)
2 (N=8) 25.0% (2I8) 75.0% (6.8) 0.0% (0/8)
3 (N=8) 12.5% (1i8) 87.5% (778) 0.0 % (0/8)
Immunization with ERBV was found to icantly reduce the incidence of
disease, by 37.5%, 25%, and 12.5% in vaccinated groups 1, 2, and 3, respectively (Tables 21 and
22).
Table 21. Effect of vaccination on incidence of disease (disease statuses of mild and moderate
were pooled for the purposes of this evaluation)
Control Group Prevented 95% confidence interval
(n=8) (n=8) fraction
Control vs. Group 1 1 62.5% 0.3?5 —0.069, 0.6346
Control vs. Group 2 —0.119, 0.4973
Control vs. Group 3 0.125 —0.137, 0.3266
Vaccination also reduced the shedding of virus from the nares indicating lesser
clinical disease in the vaccinated horses as well as demonstrating the effectiveness of the vaccine
in preventing spread of the infectious disease to other ially susceptible horses (Table 22).
Table 22. Incidence of Virus positive over time
Day Control | Group 1 Group 2 Group 3
0 0.250 0.25 0.000 0
7 0.125 0.00 0.125 0
Results and Discussion
Inactivated ERBV vaccines were found to be capable of immunizing an animal to
high levels of antibody detection. The vaccines reduced the duration, severity, and incidence of
disease in immunized animals challenged with ERBV. Vaccination also d the shedding of
infectious virus from ill . No unacceptable adverse ons either at the injection sites or
by manifestation of signs of systemic illness were observed. The vaccines are safe and well
tolerated for administration in Equine rhinitis B tible species, particularly equidae.
Example 6
This example illustrates a guinea pig model for use in a release y assay.
e 5 (A/B—l) and Vaccine 6 (A/B—2) were each administered to guinea pigs
(five guinea pigs per vaccine, 0.5 mL per intramuscular vaccination). A booster vaccination shot
was administered three weeks later. After 19 days, the pigs were bled and blood was analyzed
using serum neutralization tests for ERAV and ERBV.
Table 23. Vaccine 5 (A/B-l) d with 108-0 A/107-5 B, with HRA—S adjuvant
Guinea Pig ERVA Titer ERVB Titer
>1414
2 1300 180
3 448 | 120
4 1123 360
1120
Table 24. Vaccine 6 (A/B-2) Batched with 103~0 14/107“5 B, with HRA-3 + cottonseed oil
adjuvant
ERVA Titer ERVB Titer
1 194 220
2 326 | 280
194 560
No Sample No Sample
Back titer 191 | 260
Example 7
This example illustrates a challenge evaluation of Rhinitis Virus A after
vaccineation with a 2 dose equine Rhinitis A/Rhinopneumonitis/Influenza Killed Virus e
and protention against Equine Rhinitis A respiratory infection after vaccination with the Rhinitis
A/Rhinopneumonitis/Influenza Killed Virus e.
Objective
The objective of this vaccination—challenge study was to demonstrate efficacy of
Equine Rhinitis A (ATCC Accession No. PTA—11828) for Equine Rhinitis
A/Rhinopneumonitis/Influenza Killed Virus Vaccine. The primary outcome variable used to
evaluate the efficacy of vaccination was reduction of respiratory disease caused by Equine
Rhinitis A Virus.
Material and Methods
The e used in this study is an Equine Rhinitis A/Rhinopneumonitis/ za
e of the present invention, Killed Virus vaccine.
A. EQUINE RHINITIS A VIRUS
The original Equine Rhinitis Virus A Strain (ERhA V) was obtained from
University of Guelph, Animal Health Laboratory, as Isolate number 04—54188, and was received
on September 9, 2008 under Import Permit No. 106930. The virus was passed once on E—Vero
cells to produce a high titered pre-master stock and was then diluted with cell culture media to
produce the Master Seed Virus (MSV). The MSV is designated as ERhA V (04-54188), MSV,
Lot 091508A-diluted, 24Sept08, and was approved for use for Establishment 597 by USDA on
June 18, 2010.
The Equine Rhinitis A Viral antigen used in vaccines evaluated in this study was a
MSV+5 virus produced on the twentieth passage of APHIS ed E—Vero cells. Following
, viral fluids were filtered, in inactivated, and concentrated in accordance with the
Outline of Production for Product Code A522.20. The inactivated viral fluids were tested for
residual live virus after inactivation. The s were satisfactory. Inactivated viral fluids were
used to formulate e at an antigen inclusion level of 107'5 TCIDso/mL.
1. Experimental Vaccine Rhinitis Combo Lot 122110
Experimental vaccine Rhinitis Combo Lot 122110 was formulated based on pre—
inactivation titers.
The final formulated vaccine ned the following ingredients per 1 mL dose:
Equine Rhinitis A 107-5 TCID50/mL
EHV—l 107-0 TCID50/mL
EHV-4 106-5 TCIDso/mL
Influenza A2/Ohio/03 107-0 TCIDso/mL
Influenza 95 107-0 /mL
Influenza A2/NewMarket/2/93 107-O TCIDso/mL
Adjuvant (MVP Laboratories, SO. #25) 100 uL
Diluent, MEM-E containing q.s.
Gentamicin, 30 ug/mL of diluent volume
Formaldehyde, 0.1% of t volume
Amphotericin B, 2.5 ug/mL
B. mental Horses
1. Description of Experimental Horses
Forty (40), six to eight—month old, draft—cross horses purchased from Steve
Waagen, Bottineau, North Dakota were microchipped upon arrival at Equine Resources, LLC,
Butler, Mo. and were assigned to either IVP (Investigational Veterinary Product) or Control
Product (CP) based on random number generator after being pre-screened for rhinitis A titers of
1:4.
During the entire study, horses were quartered in a single large paddock with
common feed bunks, waterers and hay racks. Upon challenge, each animal was assigned a 2
digit “barn code” by laboratory nel that was attached to a halter worn throughout the post—
nge time period and used to identify horses when clinical signs and samples were taken
each day. During each observation day, horses were corralled into holding pens and worked
randomly h individual restraining .
Table 25 summarizes the study design:
Table 25: Study Design
1 ‘ 20 ‘IVP 2x1mL IM D46
2 ‘20 ‘CP 2x1mL IM D46
2. Vaccination /Challenge and Sampling Schedule
On January 28, 2011 and February 18, 2011, experimental vaccine Rhinitis Combo
Lot 122110 was administered intramuscularly in a 1 mL dose volume to each of 20 horses
(vaccinate group, IVP). Twenty horses (control group, CP) received a 1 mL dose of adjuvanted
MEM-E (Experimental product 005) containing the excipients used in the Lot 122110 vaccine
(adjuvant, gentamicin, amphotericin B, and formaldehyde) but no antigens. All horses were
challenged by intranasal aerosolization of nt Equine Rhinitis A virus at Study Day 46 (25
days post—booster vaccination) on March 15, 2011. Table 26 shows the schedule of events.
Table 26: Schedule of Events
Jan 28,2011 Randomize horses to groups
Collected serum samples all horses
IVP administered to Group 1
CP administered to Group 2
February 18, 2011 ted serum samples all horses
IVP administered to Group 1
CP administered to Group 2
March 15, 2011 Challenge Groups 1 and 2
Body Temperatures
Whole blood samples (virus isolation)
Nasal Swabs (virus ng)
Clinical observations
March 16-21, Body Temperatures
2011 Whole blood samples (virus isolation)
Nasal Swabs (virus shedding)
Clinical observations
March 22, 2011 Serum samples
Body Temperatures
Whole blood samples (virus isolation)
Nasal Swabs (virus shedding)
Clinical observations
March 23-28, Body atures
201 1 Whole blood samples (virus isolation)
Nasal Swabs (virus ng)
Clinical observations
March 29, 2011 Serum samples
Body Temperatures
Whole blood samples (Virus isolation)
Nasal Swabs (virus shedding)
Clinical observations
March 30-April 4, 61-66 Body Temperatures
2011 Whole blood samples (virus isolation)
Nasal Swabs (virus shedding)
Clinical observations
April 5 , 201 1 67 Serum s
Body atures
Whole blood samples (virus isolation)
Nasal Swabs (virus shedding)
Clinical observations
End of Study
3. Intranasal Challenge Inoculation of Horses
a. Challenge Virus
The challenge virus Equine Rhinitis A lot 112108A was produced in tissue culture
on E—Vero cells. The titer of the challenge virus was determined to be 1 X 107‘3 TCID50/mL on
the day of challenge.
b. Intranasal Challenge Method
Sedivet® (romifidine hydrochloride), a sedative and analgesic, was administered
intravenously to each horse prior to nge at a dosage of 50 ug/kg of body weight. The
challenge virus was stered asally as an aerosol produced by a nebulizer into an
Equine AeroMask (Trudell Medical International, Ontario, Canada) by the ing method:
Four milliliters of 107‘3 TCID50/mL challenge virus were placed into the nebulizer cup in the
AeroMask device. A pressure hose was fitted from an air compressor to the inlet port of the
nebulizer. The outlet tube was then ed into the AeroMask attached to the head of the horse
being challenged and approximately 10 psi of air pressure was applied to the inlet port for three
minutes. During this time approximately two milliliters of challenge Virus fluid was lized
directly into the nostrils of the horse being challenged. Challenge Virus was administered to
horses undiluted, effecting a Challenge amount of 1 x 107'6 TCID50 in a 2 mL dose.
C. PRE AND POST CHALLENGE EVALUATION PARAMETERS
l. Nasal Exudate Evaluation
All nasal exudate observations were made prior to collection of nasopharyngeal
swabs. On the Day of Challenge (D46) and for 21 days post challenge, the nasal passages and
muzzle of each of the 40 vaccinate and control horses were examined and graded using the
grading and scoring ption listed below.
The scoring grades of 0 through 6 were assigned on the basis of the severity of the disease
indicated by each of the following classification:
Essentlally normal 1nd1cates the horse was clean and
essentially free of nasal exudate
Slight clear serous rge that may be frequently
observed in both ed and normal horses
Very slight mucopurulent discharge indicates that mucus
was definitely present in small amounts in either one or
both nostrils
Moderate clear serous discharge is tive of a definite
increase in volume over that ly observed/slightly
mucopurulent is a discharge easily observed in one or
both nostrils
Copious clear serous discharge that is generally ed
only in diseased horses
Moderately mucopurulent indicates that mucoid
discharges were present in large quantities in both nostrils
Heavy mucopurulent indicates that copious amounts of a
HM 6
mucoid discharge filled both nostrils
2. Ocular Discharge
Ocular rge was evaluated daily at the time of nasal exudate tion.
Ocular discharge scores were recorded as 0 = normal;
1: mild to moderate ocular discharge and 2 2 severe ocular discharge.
3. Temperature
Daily rectal temperatures were recorded for each of the 40 vaccinate and l
horses on Day of Challenge and for 21 days post challenge by means of a calibrated, electronic
thermometer (GSA onics) probe. The daily rectal atures were recorded in degrees
Fahrenheit (OF).
4. Nasopharyngeal Viral Isolation
On each observation test day each nasal passage of each vaccinated and control
horse was swabbed deeply by means of a e WECK—CEL® surgical spear (Edward Weck
and Company, Inc., Research Triangle Park, NC. 27709) attached to an ll—inch long e
plastic pipette. On collection, each of two surgical spears was immediately placed in a single
tube containing 4 mL of chilled transport medium (E—l99 supplemented with gentamicin, L—
glutamine, 2X Pen/Strep, 2X Amphotericin B).
For isolation of virus, the tubes were mixed, the swabs aseptically removed, and the
medium centrifuged at 1500 rpm for 10 to 15 minutes to remove particulates. Medium was
ed through a 0.2 u syringe filter prior to inoculation on tissue culture cells. After filtration,
4—6% of sterile 85% sucrose solution was added to each sample for freezing at —80°C in order for
all samples to be tested rently.
On the day of testing, one mL of the thawed, clarified transport medium was used
to inoculate a 2 cm2 two day old monolayer of E—Vero cells grown in a 24 well tissue culture
plate from which the growth medium had been aseptically removed. Following inoculation, the
inoculum was allowed to adsorb on the cell yer for at least one hour at 37°C in a
humidified incubator containing a 5% C02 atmosphere. After the adsorption period, an
additional 1 mL of re-feed medium (E-199 containing 2 mM L-glutamine, Gentamicin 2X Pen-
Strep and 2X Amphotericin B) was added to each well. Following addition of re—feed media the
plates were then incubated at 37°C in a C02 incubator. Each test and control tissue culture well
was examined microscopically for 7 days for signs of cytopathic effect (CPE) typical of the
Equine Rhinitis A nge virus. Wells that were negative at the end of the 7 day observation
period were subcultured onto fresh cells and observed for an additional 7 days.
Statistical tion Methods
Horses were classified to a range of respiratory disease status, on a daily basis. The
fication to disease status included combining the nasal and ocular tions. The
algorithm used is detailed below:
33211 Score
Normal (0)
Mild (1) ‘ 0 or 1
Mild (1) ‘ 1.5
Moderate (2) ‘ 2 or 3
Severe (3)
The influence of vaccination on the duration of disease (number of days with at
least moderate disease) was evaluated using the Hodges—Lehman (exact) estimate (the
NPARlWAY procedure in SAS, SAS Institute, Cary NC).
Severity of e was evaluated by comparing the maximum disease status
between the vaccinated horses and the placebo horses. The mitigated fraction and 95%
confidence intervals (CI, asymmetric standard error) were calculated (the FREQ procedure in
SAS).
Rectal temperature and serum neutralization titers were analyzed by repeated
measures analysis appropriate for continuous data (temperature and log ormed SN titers;
ANOVA). SN titers were assumed to be 0 if the titer was reported as < 4 and 709 if the titer was
reported as > 709. SN titers were log transformed prior to the analysis. Buffy coat and nasal
swab results on each day were ed using Fisher’s exact test.
Results
One horse, #39 (IVP group) died on Day 62 of the study. Upon necropsy at
University of Missouri College of nary Medicine, the diagnosis was made of chronic—
active, diffuse, severe izing and emphysematous submucosal esophagitis, gastritis, and
pharyngitis with intralesional coccobacilli bacterial colonies and plant material, as well as a
diffuse severe fibrinosuppurative pleuropneumonia of the lung. The most likely explanation of
this death suggests a previous mucosal breach, such as a mucosal ulcer in the cardia of the
stomach which allowed seeding of plant material in the associated connective s (pathology
report attached).
A. DURATION
The bution of the duration of disease (number of days with moderate or severe
respiratory disease) in days is ized in Table 27. The median number of days animals in
the placebo group were observed with disease was 14. In the vaccinated group, the median
number of days with disease was 1. The duration of disease was significantly lower in the
vaccinated animals as compared to the ls (Table 28; P < 0.0001).
Table 27: Summary of the effect of ation on the duration of disease (Number of days with
moderate or severe respiratory disease)
Control
(N = 20)
Vaccinated
(N = 20)
Table 28: Effect of ation on the duration of disease (Number of days with moderate or
severe respiratory disease)
Duratlon
14 1 1 1
(median days)
Severity
The distribution of the severity of disease is summarized in Table 29. The severity
of disease was significantly lower in the vaccinated horses as compared to the placebo horses
(Table 30; mitigated on 2 0.7550, 95% CI = 0.5518, 0.9582). Individual outcomes are
provided in Table 31.
In Table 31 the values for horse #39 which died on Day 62 of the study are reported
as 0’s from Day 62 through 67, but in the analysis only values > 1 are considered, therefore not
affecting the outcome. Duration is 1 day for this horse and the max score is 3.
Table 29: Summary of the severity of disease based on the maximum nasal rge score
Control 0% 5% 20% 75%
(N = 20) (0/20) ( 1/20) (4/20) )
Vaccinated 5% 35% 55% 5%
(N = 20) (1/20) (7/20) (11/20) (1/20)
Table 30: Effect of ation on the severity of disease
Severity
28.05 1295* 0.7550 0.5518, 0.9582
(mean rank)
*Significantly lower than the placebo group by Wilcoxon’s rank sum test (P < 0.05).
o o o o o o o o o H H o o o o o o
o o o H o o o o o o o o o o o o o
o o o o o o o OH o o o o. o o o o o
o o o o o o o
.88ch H o o o o
H o
82,8 o o
H o
830on o H
o o
Ho o o
8333 o o
H o
:06 o o H o o o o o
o o H o o H o o o o o H o o o o o
:2on o o H o o o o o o o o o o o o o
H5923 o H o o H o H o H o o H H o o o o o o o
o o o o o o o o o o o o o o o H o o o o
me8qu o o o o o o o o H o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o
1.5339: o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o
89¢ 06—800 06—800 0:809 U 09:00 0:800 09:50 onEoU onEoU onEoU onEoU onEoU 09:50 09:50 03:50 09:50 09:50 09:50 09:50 09:50
£30m
”Hm mwmovmwmv Nwmomwmv finchmwmv Nwmoowmv HmoHowNw Nooobwmw omowgmv Emowwmv mmoowwmv omwoowmv meHmmv ammommon mmOnmmon wwNHomon Nmmmomon mwmoomon on thNHmon mBOmHmon ooommmon
.88me
89,8
BSovoS
832%
:06
32on
8923
22:5“.
E5339:
£53m OOOO
BREE 88E 80an Boos—m 882m 30an 8035 Boos—m 383m O
noon—n— 882m 30an 30an 0982; 23an 80an 80an 80an 882; 882m
“@025qu fi
owomoowfi Mama? macaw? 2 2
Gwmv mewmowmw @853? mw $33? 8ng cowvbwmv 38%? 309me mmmmmwmv wwmmwwmv 550%? 32%? 008%? :3?on 303on £23on
B. RECTAL TEMPERATURE
The results of the statistical analysis are summarized in Table 32. The vaccine by
day interaction was statistically significant. Within day analyses are provided in Table 33
(appendix). On Days 3, 4, and 5, horses in the vaccinated group had statistically significantly
lower temperatures than those in the placebo group. On Day 20, horses in the vaccinated group
had significantly higher temperatures than those in the placebo group. However, on all days any
differences between treatment groups were not clinically meaningful and only one horse (#39)
had a rectal temperature greater than 102°F (39°C) on any challenge study day.
Table 32: y of the effect of ation on rectal ature and serum neutralization
titers
0.5754 < 0.0001 0.0006
< 0.0001 < 0.0001 < 0.0001
1. Serum Neutralization Titers
The results of the statistical analysis are summarized in Table 32. On Days 46 and
53, horses in the vaccinated group had significantly higher titers than those in the placebo group.
On Day 67, horses in the vaccinated group had significantly lower than those in the o
group.
Discussion
This study was conducted to demonstrate efficacy of the Equine Rhinitis A virus
component of an inactivated Equine Rhinitis A virus vaccine in ation with inactivated
Equine Herpesvirus types 1 and 4 and Equine Influenza Viruses. Vaccination was given in a 2—
dose format, and challenge of virulent Equine Rhinitis A virus was performed 25 days post-
booster vaccination. Vaccinated and placebo treated control horses were evaluated to assess
effect of vaccination on reduction of severity and duration of clinical respiratory disease.
al signs, nasal swabs and buffy coats were evaluated daily for evidence of Equine Rhinitis
A e and presence of the virus in the challenged horses.
Results from this challenge study show a statistically significant and clinically
important reduction of both the ty and of the duration of respiratory disease in vaccinates
following challenge. As med by mitigated fraction analysis of respiratory disease scores in
horses vaccinated with the IVP as compared to horses vaccinated with the control product,
moderate/severe signs of respiratory disease were reduced 75.5% (95% ence interval 96%
to 55%). Duration of moderate/severe disease was also significantly reduced by 11 days in
vaccinated horses as compared to l horses (95% confidence interval 14 days to 8 days
shorter disease duration). In addition, vaccination significantly reduced nasal virus shedding
throughout the successive 5 days of peak viral shedding, and viremia also was significantly
reduced during the 4 days of peak viremia within the challenge period. Importantly, virus was
recovered from buffy coat samples of l horses a total of 54 times over 5 study days in
ison to only 8 total days of viremia over 4 study days in vaccinated horses.
Conclusions
Data from this study clearly demonstrate that 2 X 1 mL uscular doses of
Equine Rhinitis A/Rhinopneumonitis/Influenza Killed Virus Vaccine ct Code TBD,
unlicensed), administered at 21 day intervals between doses to , significantly reduced
ty and duration of respiratory disease caused by Equine Rhinitis A virulent challenge.
The study results illustrate the use of this vaccine for the immunization of horses six
months of age or older against respiratory disease caused by Equine Rhinitis A virus. These data
also establish Vaccine Lot 122110 as an acceptable nce vaccine for potency testing of
subsequent serials of Equine Rhinitis A/Rhinopneumonitis/ Influenza Vaccine, Killed Virus and
of Equine Rhinitis A Vaccine, Killed Virus (Product Code 1522.21, unlicensed).
Claims (24)
1. An immunogenic composition comprising one or more strains of inactivated Equine is B Virus (ERBV).
2. The immunogenic composition according to claim 1, wherein the ERBV strain grows in cell culture to 106 /mL or higher, or, when used as a vaccine in s at a dose of 106 TCID50 or higher results in a serum titer of 1:112 to 1:1000.
3. The genic composition according to claim 1 or claim 2, wherein the immunogenic composition further comprises one or more strains of inactivated Equine Rhinitis A Virus (ERAV).
4. The immunogenic composition according to claim 3, wherein the ERAV strain comprises a genomic ce whose reverse transcript has greater than 95% identity to SEQ ID NO: 2 or encodes a polyprotein with an amino acid sequence with greater than 95% identity to SEQ ID NO: 3, wherein said ERAV strain, prior to inactivation or attenuation, is active to infect and replicate in host cells.
5. The immunogenic composition according to any one of claims 1 to 4, wherein the ERBV strain comprises a genomic sequence whose reverse transcript has r than 95% identity to the reverse transcript of the genomic sequence of the ERBV strain having ATCC Accession no. PTA-11829 or encodes a otein with an amino acid sequence with greater than 95% identity to the polyprotein encoded by the genome of the ERBV strain having ATCC ion no. PTA-11829, wherein said ERBV strain, prior to inactivation or attenuation, is active to infect and replicate in host cells.
6. The immunogenic composition according to any one of claims 1 to 5 in which the strain of ERBV is strain 07-103042 (ATCC Accession PTA-11829).
7. The immunogenic composition according to any one of claims 1 to 6, wherein said genic composition comprises antigens or an inactivated or live, attenuated strain of Equine Herpes Virus. 11178739_1:JJP
8. The immunogenic composition according to any one of claims 1 to 7, wherein said immunogenic composition comprises antigens or an vated or live, attenuated strain of Equine Influenza Virus.
9. The immunogenic composition according to any one of claims 1 to 8, wherein said immunogenic ition further comprises antigens of one or more strains selected from the group ting of West Nile Virus, Eastern Equine Encephalomyelitis Virus, Western Equine Encephalomyelitis Virus, and Venezuelan Equine Encephalomyelitis Virus, or antigens of Tetanus Toxoid, or combinations thereof.
10. Use of an immunogenic composition according to any one of claims 1 to 9 for the manufacture of a medicament for reducing the incidence or lessening the severity of clinical symptoms associated with or caused by ERBV in an animal or a herd of animals.
11. Use of an immunogenic composition according to any one of claims 3 to 9 for the manufacture of a medicament for reducing the incidence or lessening the severity of clinical symptoms associated with or caused by ERAV in an animal or a herd of animals.
12. Use of an immunogenic composition according to any one of claims 7 to 9 for the manufacture of a medicament for ng the incidence or lessening the severity of clinical ms associated with or caused by ERBV and one or more of the pathogens selected from the group ting of: West Nile Virus, Eastern Equine Encephalomyelitis Virus, Western Equine Encephalomyelitis Virus, Venezuelan Equine Encephalomyelitis Virus, Equine Herpes Virus, Equine Influenza Virus, and Clostridium tetani in an animal or a herd of animals.
13. The use ing to any one of claims 10 to 12, wherein the incidence of clinical symptoms caused by one or more of said ens in a herd of animals is reduced as compared to a herd not receiving said genic composition.
14. The use according to any one of claims 10 to 13, wherein the administration of one dose or two doses of said immunogenic composition provides a on of immunity of at least 12 months against one or more of said pathogens.
15. The use according to any one of claims 10 to 14, wherein said immunogenic composition is safe for use in foals or horses 4 months of age or older. 11178739_1:JJP
16. The immunogenic ition according to any one of claims 1 to 9 for use as a ment.
17. A method for reducing the incidence or lessening the ty of clinical symptoms associated with or caused by ERBV in an animal or a herd of animals, said method comprising the step of administering an immunogenic composition according to any one of claims 1 to 9 to an animal in need thereof, wherein the animal is a non-human animal.
18. A method for reducing the incidence or ing the ty of clinical symptoms associated with or caused by ERAV in an animal or a herd of animals, said method comprising the step of administering an immunogenic composition according to any one of claims 3 to 9 to an animal in need thereof, wherein the animal is a non-human animal.
19. A method for ng the incidence or lessening the severity of clinical symptoms associated with or caused by ERBV and one or more of the pathogens selected from the group consisting of: West Nile Virus, n Equine Encephalomyelitis Virus, Western Equine Encephalomyelitis Virus, Venezuelan Equine alomyelitis Virus, Equine Herpes Virus, Equine Influenza Virus, and Clostridium tetani in an animal or a herd of animals, said method comprising the step of administering an immunogenic composition according to any one of claims 7 to 9 to an animal in need thereof, wherein the animal is a non-human animal.
20. The method according to any one of claims 17 to 19, wherein the incidence of clinical symptoms caused by one or more of said pathogens in a herd of animals is reduced as compared to a herd not receiving said immunogenic composition.
21. The method according to any one of claims 17 to 20, wherein the administration of one dose or two doses of said immunogenic composition provides a duration of immunity of at least 12 months against one or more of said pathogens.
22. The method of any one of claims 17 to 21, wherein said immunogenic composition is safe for use in foals or horses 4 months of age or older.
23. A method for producing an immunogenic ition comprising one or more s of inactivated ERBV, the method comprising: a) infecting a susceptible cell line with ERBV; 11178739_1:JJP b) growing the infected cell line in growth media until a cytopathic effect (CPE) is attained; c) harvesting the media; d) filtering the media to yield a filtered media; and e) contacting the ed media with an inactivating agent to obtain the inactivated ERBV.
24. The method of claim 23 wherein the ERBV is strain 07-103042C ATCC Accession NO: PTA-11829. Boehringer Ingelheim Vetmedica, Inc. By the Attorneys for the Applicant
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161452390P | 2011-03-14 | 2011-03-14 | |
US61/452,390 | 2011-03-14 | ||
US201161510226P | 2011-07-21 | 2011-07-21 | |
US61/510,226 | 2011-07-21 | ||
NZ614147A NZ614147A (en) | 2011-03-14 | 2012-03-12 | Equine rhinitis vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ708320A NZ708320A (en) | 2016-08-26 |
NZ708320B2 true NZ708320B2 (en) | 2016-11-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017201526C1 (en) | Equine Rhinitis vaccine | |
BRPI0618593A2 (en) | vaccine combination comprising an attenuated bovine viral diarrhea virus | |
US9962435B2 (en) | West Nile Virus vaccine | |
KR20130109220A (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
US20140363466A1 (en) | Method of treating pregnant cows and/or heifers | |
TWI306404B (en) | Method of vaccination against testicular bvdv infection | |
TW201731526A (en) | Hybrid core feline vaccines | |
NZ708320B2 (en) | Equine Rhinitis vaccine | |
US20240285752A1 (en) | Attenuated Porcine Epidemic Diarrhea Virus | |
KR101191518B1 (en) | Vaccine composition for korean porcine reproductive and respiratory syndrome virus | |
Abousenna | Studies on inactivated vaccine of Foot and Mouth Disease virus |